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ABSTRACT 
 
JULIE CLARKE WILLIAMS:  Regulation of Innate Immune responses by Mertk  
(Under the direction of Glenn K. Matsushima) 
 
 The Tyro3/Axl/Mertk(TAM) family of receptors is important for phagocytosis of 
apoptotic cells, cytokine regulation, and suppression of autoimmune disease.  Mice 
lacking Mertk present with a Systemic Lupus Erythematosus-like syndrome; however, 
the etiology of the autoimmune phenotype in the mertk-/- mice is unknown.  As such, our 
hypothesis is that Mertk is regulating innate immune responses that prevent the initiation 
of autoimmune disease.  This dissertation examines the role of the TAM family of 
receptors in 1) the clearance and killing of bacteria, 2) the regulation of immune cells in 
the peritoneal cavity and 3) the regulation of cytoplasmic dsDNA-induced cell death 
through the regulation of p202.  Chapter 2 shows the TAM receptors are dispensable for 
phagocytosis and killing of bacteria.  Chapter 3 shows, Mertk regulates the immigration 
and the number of immune cells in the peritoneal cavity, particularly the T cells and B 
cells.  In addition, this increase in peritoneal cells correlates to autoantibody formation 
found only in mertk-/- mice and not axl-/- or tyro3-/-.  Finally, Chapter 4 shows that Mertk 
suppresses expression of the lupus susceptibility factor, p202, and that p202 may rescue 
macrophages from cytoplasmic dsDNA-induced cell death.  These studies have clarified 
the literature with regards to TAM receptor family and bacteria clearance, have provided 
new insights to the autoimmune phenotype associated with the under studied peritoneal 
cavity, and have established a novel mechanism by which Mertk regulates death of APCs 
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which may be critical in preventing the development of autoimmune disease.  
 
 
iv
  
TABLE OF CONTENTS 
 
LIST OF TABLES ............................................................................................................. vii 
 
LIST OF FIGURES .......................................................................................................... viii 
 
LIST OF ABBREVIATIONS ............................................................................................ xi 
 
CHAPTER 1. INTRODUCTION................................................................................1 
1.1 The Tyro3/Axl/Mertk Family ....................................................2 
1.1a Ligands for the TAM family .....................................2 
1.1b Mertk Expression......................................................3 
1.1c Mertk: down stream signaling...................................4 
1.1d mertk-/- mouse ...........................................................7 
1.1 e Axl expression and function.....................................8 
1.1f Tyro3 expression and function ................................10 
1.2 Responses to Infections............................................................11 
1.2a Toll-like Receptor signaling in response to 
infections.........................................................................12 
 
1.2b Phagocytosis of Bacteria.........................................13 
1.2c Phagocytosis of Bacteria and Apoptotic Cells ........15 
1.2d Phagocytosis of Apoptotic Cells.............................16 
1.2e Regulation of Cytokine signaling by Apoptotic  
Cells ................................................................................16 
 
1.3       Systemic Lupus Erythematosus ..............................................18 
 
 
v
1.3a Antigen Presenting Cells and SLE..........................20 
1.3b TLR signaling in SLE .............................................21 
1.3c Cytokines involved in SLE .....................................22 
1.3d Chemokines involved in SLE .................................27 
1.3e Involvement of Peritoneal cells in SLE ..................29 
1.3f TAM and SLE .........................................................30 
1.4      HIN-200 Family- SLE susceptibility genes..............................33 
1.4a AIM2 expression and function................................34 
1.4b p202 expression and function .................................36 
CHAPTER 2. TAM RECEPTORS ARE DISPENSIBLE IN THE 
PHAGOCYTOSIS OF BACTERIA................................................40 
 
2.1 Abstract ....................................................................................41 
2.2 Introduction..............................................................................42 
2.3 Materials and Methods.............................................................46 
2.4 Results......................................................................................51 
2.5 Discussion................................................................................55 
CHAPTER 3. INCREASED CELLS IN THE MERTK-/- PERITONEAL 
CAVITY: A RESULT OF AUGMENTED MIGRATION ............68 
 
3.1 Abstract ....................................................................................69 
3.2 Introduction..............................................................................70 
3.3 Materials and Methods.............................................................74 
3.4 Results......................................................................................79 
3.5 Discussion................................................................................87 
CHAPTER 4. MERTK ON MACROPHAGES IS A CRITICAL REGULATOR 
OF P202 AND DNA INDUCED CELL DEATH ...........................107 
 
 
vi
 
4.1 Abstract ..................................................................................108 
4.2 Introduction............................................................................109 
4.3 Materials and Methods...........................................................113 
4.4 Results....................................................................................116 
4.5 Discussion..............................................................................121 
CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS.................................137 
REFERENCES..................................................................................................................152 
 
 
vii
LIST OF TABLES 
 
Table 1.1 Cytokines dysregulated in SLE............................................................27 
 
Table 1.2 Chemokines and their receptors dysregulated in SLE .........................29 
 
 
viii
LIST OF FIGURES 
 
Figure 2.1 TAM receptors are not required for the phagocytosis of E. coli 
O111:B4 GFP by macrophages ...........................................................62 
 
Figure 2.2 Phagocytosis of E. coli O111:B4 is time dependent and Mertk 
independent in thioglycollate-elicited and bone marrow-derived 
macrophages ........................................................................................63 
 
Figure 2.3 Phagocytosis of E. coli O111:B4 is similar in thioglycollate and 
resident peritoneal macrophages..........................................................64 
 
Figure 2.4 In-vitro phagocytosis assay by flow cytometry ...................................65 
 
Figure 2.5 Lack of affect in mertk-/- macrophages is not dependent on Gram 
status ..................................................................................................66 
 
Figure 2.6 Killing and replication of bacteria are not Mertk dependent ...............67 
 
Figure 3.1 Increase in peritoneal cellular populations in the mertk-/- mouse ........98 
 
Figure 3.2 Increase in DC, pDC, and T cells by subset in mertk-/- peritoneal 
cavity …...............................................................................................99 
 
Figure 3.3 Increase in B1 cell populations and lower B cell maturation status in 
mertk-/- peritoneal cavity. …. .............................................................100 
 
Figure 3.4 Increase in cells is not due to proliferation ........................................101 
 
Figure 3.5 Increase in cells is not due to cell death.............................................102 
 
Figure 3.6 Enhanced migration to mertk-/- peritoneal cavity...............................103 
 
Figure 3.7 Both hematopoietic and non-hematopoietic sources are required for 
cellular increase in mertk-/- peritoneal cavity.....................................104 
 
Figure 3.8 Expression of chemokines, cytokines, and migration receptors in 
PEC ....................................................................................................105 
 
Figure 3.9 Increase in peritoneal cells and autoantibody production is due to 
Mertk and not Axl or Tyro3...............................................................106 
 
Figure 4.1 Macrophages lacking Mertk are less susceptible to cytoplasmic DNA 
induced cell death ..............................................................................129 
 
Figure 4.2 Mertk negatively regulates ifi-202 expression...................................130 
 
 
ix
 
Figure 4.3 Mertk negatively regulates ifi-202 mRNA and p202 protein 
expression in response to a variety of stimulants...............................131 
 
Figure 4.4 Axl and Tyro3 do not negatively regulated ifi-202 mRNA and p202 
protein expression ..............................................................................132 
 
Figure 4.5 Mertk regulates ifi-202 mRNA and p202 protein expression in bone 
marrow-derived DC. ..........................................................................133 
 
Figure 4.6 Mertk suppresses IFN stimulated Stat3 phosphorylation. .................134 
 
Figure 4.7 IFN stimulation increases p202 expression and decreases response to 
cytoplasmic DNA in mertk-/- cells .....................................................135 
 
Figure 4.8 Schematic of AIM2 and p202 function in the context of Mertk........136
 
 
x
LIST OF ABBREVIATIONS 
 
AIM2   Absent in Melanoma 2 
 
APC   Antigen Presenting Cell 
 
ASC   Apoptosis Spec associated protein containing a CARD domain 
 
AT   poly dA:dT 
BAFF   B cell activating factor 
BMMФ  Bone marrow derived macrophage 
BrdU   5-bromo-2’-deoxyuridine 
CRP   C reactive protien 
CT   Calf Thymus DNA 
CTL   Cytotoxic T lymphocyte 
DC   Dendritic Cell 
dsDNA  double stranded DNA 
EBV   Epstein Barr Viruse 
GAP   GTPase activating proteins 
Gas6   Growth arrest specific factor 6 
GDI   Guanine nucleotide dissociation inhibitor 
GEF   Guanine nucleotide exchange factor 
GFP   Green fluorescent protein 
FAK   Focal adhesion kinase 
IFN   Interferon 
IFNR   Interferon receptor 
IKK   Iκβ kinase 
 
 
xi
IL   Interleukin 
IRAK   IL-1R associated kinase  
IRF3   Interferon regulatory factor 3 
LBP   Lipopolysaccharide binding protein 
LPS   Lipopolysaccharide 
MФ   Macrophage 
MFG-E8  Milk fat globule E8 
MHC   Major histocompatability complex 
MNDA  myeloid nuclear differentiation antigen 
MyD88  myeloid differentiation primary-response factor 88 
Nba2   New Zealand Black Autoimmunity 2 
NF-κB   Nuclear Factor kappa B 
NOD   Nonobese diabetic 
PAMP   Pathogen associated molecular pattern 
PEC   Peritoneal Exudate Cells 
PGE2   Prostaglandin E2 
PLCγ   Phospholipase Cγ 
RILP   rab-7 interacting lysosomal protein 
SAP   Serum ameloid protein 
SLE   Systemic Lupus Erythematosus 
Sm   Smith antigen 
SOCS   Suppressor of cytokine signaling 
STAT   Signal transducer and transactivator 
 
 
xii
SR-A   Scavenger receptor A 
TAB   TAK 1 binding protein  
TAK   Transforming growth factor β activated kinase  
TAM   Tyro3/Axl/Mertk family 
TBK   TRAF-family member associated NF-κB actvator binding kinase 
TGF-β   Transforming growth factor beta 
Th   T helper 
Thio-PEC  Thioglycollate elicited peritoneal exudate cells(macrophage) 
TIR   Toll and IL-1 receptor  
TLR   Toll like receptor 
TNFα   Tumor necrosis factor alpha 
TRAF   tumor necrosis factor receptor associated factor 6 
TRAM   TRIF-related adaptor molecule 
Treg   T regulatory cell 
TRIF   TIR-domain-containing adaptor protein inducing IFN-β 
UV   Ultraviolet  
WT   Wild-type 
 
 
 
 
 
 
 
 
xiii
  
Chapter 1: 
 
Introduction 
1.1 The Tyro3/Axl/Mertk family 
 The Tyro3/Axl/Mertk(TAM) family of receptor tyrosine kinases is one of the last 
families of receptors to be described and functionally delineated.  These cell surface 
receptors are expressed in many different cell types, including neural, reproductive, 
vascular smooth muscle, cancer, osteoclast, and hematopoietic cells (1-6).   The work 
presented in this dissertation focuses on the function of these receptors by hematopoietic-
derived cells, macrophages (MΦ) and dendritic cells (DC).  This family of receptors is 
characterized by two extracellular immunoglobulin(IgG)-like domains, two extracellular 
fibronectin three-like domains, and an intracellular kinase domain containing a 
KWIAIES motif (7, 8).  Tyro3 is an 880 amino acid long protein that is derived from a 
2643 base pair processed sequence found on chromosome 2 in mice.  While Axl is 
similar in length to Tryo3 at 888 amino acids and 2667 base pair sequence, the gene is 
located on chromosome 7 in mice.  Mertk is larger than Axl and Tyro3 and consists of 
994 amino acids from 2985 base pairs, but is found on chromosome 2 along with Tyro3 
(NCBI database).  The amino acid sequence homology between Mertk and Axl is 45.1%, 
comparing Mertk with Tyro3 is about 42.9%, and between Axl and Tyro 3 is 44.7%.  In 
addition, in the cytoplasmic region, most of the 15 tyrosine residues are conserved with 
the exception of two fewer in Axl and three less in Tyro3.  This difference in homology 
suggests that their may be functional differences regarding interactions with potential 
ligands, interactions with other receptors and in the signaling capacity of the three family 
members.       
1.1a Ligands for TAM family 
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One of the ligands for the TAM receptor family is growth arrest specific factor 
6(Gas6)(9).  Gas6 is a serum protein produced by several cell types and is primarily 
involved in amplifying platelet aggregation (10).  More recently, Gas6 is thought to act as 
a bridging molecule between a receptor and phosphatidylserine present on apoptotic cells 
(11-14). This ligand causes phosphorylation of all three TAM family members (9, 15-17).  
Gas6 is expressed  by MΦ and is also found pre-bound to apoptotic thymocytes (18, 19).  
Gas6 has a relative binding affinity of Axl>Tyro3>>Mertk (20).  The binding of Gas6 to 
the TAM receptor family members and subsequent phosphorylation is thought to activate 
phagocytosis of the apoptotic cell (11, 12) .   
 Protein S is another ligand for the TAM family members.  Protein S and Gas6 
share 40% sequence homology and are thought to function similarly with regard to 
binding of apoptotic cells and bridging to the TAM receptors to trigger phagocytosis (10). 
In addition Protein S and Gas6 are both vitamin K dependent proteins found in plasma 
but Gas6 lacks a critical loop and does not have the anti-coagulation properties of Protein 
S (10).  However, while MΦ express Gas6, both MΦ and DC can express Protein S (18).  
Protein S appears to be the more important ligand for phagocytosis of rod outer segments 
in the eye by retinal pigment epithelial cells, which express Mertk (21).  Early studies on 
binding of Protein S to TAM family members remains unclear but favors Protein S 
binding preferentially to Tyro3 but not Axl or Mertk.  A recent report suggests that 
Protein S can bind Mertk only after oxidation and this may be critical for bridging 
phosphatidylserine on apoptotic cells to Mertk (22). 
 
1.1b Mertk expression 
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 Mertk is a receptor tyrosine kinase that is in the TAM family.  Mertk is an 
acronym for monocyte, epithelial cells and reproductive tissue which express high levels 
of mRNA and it has tyrosine kinase activity.  Northern analysis of mouse tissue revealed 
expression of Mertk in the heart, brain, spleen, lung, liver, muscle, kidney and testis (7).  
Mertk is expressed on MΦ, DC, NK, and NKT cells, but not neutrophils (23).  Mertk is 
also not expressed on normal T and B cells, though it is found on some lymphocytic 
cancer cell lines (7).  In concordance with this, overexpression of Mertk in NIH 3T3 cells 
causes transformation (24).  Mertk is also expressed in the murine monocytic cell lines, 
RAW 264.7 and J774.1 (7, 25).     
 
1.1c Mertk: downstream signaling 
 In earlier reports when a ligand for Mertk had not yet been identified, many of the 
original Mertk signaling studies performed used chimeric proteins that dimerized without 
stimulation.  Nonetheless, these studies identify the autophosphorylation sites in the 
Mertk intracellular domain.  These sites are found to be tyrosine 749,753, and 754 in the 
human protein which correspond to 744, 748, and 749 of the murine protein (26).  The 
use of chimeric proteins identify the ATP-binding site at lysine 614 which is critical for 
kinase activity (27).  In addition, overexpression of chimeric Mertk proteins identifies a 
number of downstream signaling pathways that are activated by Mertk including 
signaling through PI3K, Shc, Grb2, Raf-1, MAPK, Phospholipase Cγ(PLCγ), and NF-κB 
(24, 27).  While some of these signaling intermediates are confirmed using appropriate 
ligands, others are may be the result of over expression or the particular cell type.   
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 Previously published data from our lab also implicates Mertk as a receptor 
involved in the clearance of apoptotic cells (28).  MΦ lacking Mertk have the ability to 
bind, but not ingest apoptotic cells (28).  In contrast, DC lacking Mertk phagocytize AC 
similarly to wild-type, where as DC lacking Axl and Tyro3 have a decreased ability to 
clear apoptotic cells (18, 23, 29).  Signaling by Mertk after activation with Gas6 activates 
the Guanine Nucleotide Exchange Factor(GEF) Vav1 (12).   Upon stimulation of cells 
with Gas6, Mertk is phosphorylated and subsequently phosphorylates Vav, leading to its 
activation (12).  Vav is a GEF for the Rho family GTPases, and in human monoctyes.  
Gas6 activates, Rac, Rho, and Cdc42 to become GTP bound, resting monocytes show no 
active Rac, Rho, or Cdc42 (12).  This is somewhat curious, because Vav is not a GEF for 
Cdc42 (30).  Therefore, there must be another signal stimulated via Gas6 that activates 
this Rho family GTPase.   
A second mechanism by which Mertk activates phagocytosis of apoptotic cells is 
through cooperation with scavenger receptor A(SR-A) or integrin αvβ5 (31, 32).  SR-A 
and Mertk are phosphorylated and associate in a time-dependent manner upon 
stimulation with apoptotic cells (25, 31).  Anti-SR-A antibodies inhibit apoptotic cell-
induced phosphorylation of Mertk and the activation of PLCγ2(31).  Inhibition of PLCγ2 
blocks phagocytosis of apoptotic cells (25).   Thus, the SR-A dependent phosphorylation 
of Mertk and subsequent activation of PLCγ2 is a signaling pathway critical for 
phagocytosis of apoptotic cells.  
Integrin αvβ5 associates with Mertk and facilitates the phagocytosis of apoptotic 
cells.  αvβ5 activity is triggered by the binding of its ligand, Milk Fat Globule EGF factor 
8(MFG-E8)(33).  When both αvβ5 and Mertk are present, there is a synergistic activation 
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for the phagocytosis of apoptotic cells (32).  The engagement of Mertk results in the 
autophosphorylation of tyrosine 867 which subsequently phosphorylates focal adhesion 
kinase(FAK) in a Src kinase-dependent manner.  Phosphorylation of FAK allows it to 
interact with αvβ5 (32).  This integrin αvβ5 and FAK complex then recruits 
p130/CrkII/Dock180 complex which in turn activates Rac, one of the Rho family 
GTPases discussed previously.  Finally, tyrosine 867 found on the intracellular domain of 
Mertk is implicated in this pathway and virtually all of the signaling pathways discussed 
in this section (34).   
One last function of Mertk is that it acts in the negative regulation of 
lipopolysaccharide (LPS) signaling and cytokine expression.  An in depth discussion of 
LPS/Toll-like receptor can be found in section 1.2a.  Early work suggests Mertk is 
important for inhibiting the production of Tumor Necrosis Factor α(TNFα) by LPS-
stimulated MФs (35).  Evidence from work completed in DC shows that Mertk is 
necessary for the inhibition of LPS-mediated signaling by apoptotic cells (36).  The 
interaction of Mertk and PI3K as well as Src kinase upon ligand-binding has been 
established, and both are important in down-regulating nuclear factor-κB (NF-κB) 
signaling and subsequent Interleukin-12 (IL-12) production.  However only PI3K is 
implicated in modulating NF-κB signaling and subsequent TNFα production (36).  
Similarly, another TNF family cytokine, B cell activating factor (BAFF), appears to be 
regulated by Mertk.  Mice deficient in Mertk have excessive levels of BAFF in their 
spleens and DC.  High levels of this cytokine is implicated in autoimmune disease such 
as systemic lupus erythematosus(SLE) (discussed in more in 1.3c); however, the BAFF 
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produced by DCs from mertk-/- mice does not provide any survival advantage to B cells 
suggesting other mechanisms are likely contributing to B cell autoimmunity (37). 
 
1.1d mertk-/- mouse  
Our lab has previously generated a mouse in which the kinase domain of Mertk is 
replaced with a neomycin cassette previously termed merkd or mertkkd now known as 
mertk-/-(35).  Although this mouse was predicted to express a signaling dead Mertk 
protein, no protein is detectible by Western blot of MФ whole cell lysates (unpublished 
data Matsushima Lab,(38)).  However, experiments on the mertk-/- mouse provide one of 
the first physiologic functions for Mertk, the negative regulation of the LPS response and 
the control of pro-inflammatory cytokines.  MФ from mertk-/- mice show extended 
nuclear NF-κB binding to the cis-acting site of the TNFα promoter during stimulation 
with LPS (35).  In addition, upon LPS challenge, mertk-/- mice are susceptible to 
endotoxic shock and death.  Serum TNFα levels are markedly increased and mertk-/-  
mice show increased intestinal inflammation as compared to wild type (35).  The 
pretreatment of mertk-/- mice with anti-TNFα antibody significantly reduces lethal 
endotoxic shock.  These data suggest that Mertk is a negative regulator of LPS signaling. 
Mice lacking Mertk have enlarged spleens which contain apoptotic cell fragments 
(35, 37).  Spleens of TAM family triple knock-out mice are larger than their mertk-/- 
counterparts on a mixed genetic background (39).  This notion is challenged in recent 
studies included in Chapter 3 in which backcrossed mice from our colony now show 
similar splenic weights in mertk-/- and TAM-/- mice.   However, axl-/- and tyro3-/- mice 
have splenic weights which are similar to wild-type mice.  Although mertk-/- mice have 
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greater splenic weight, this increase can not be attributed to an increase in hematopoietic 
cells as similar numbers of nucleated cells are found in both mertk-/- and wild-type mice 
(37).  The only cell type elevated are DCs, which comprise on average less that 3% of the 
total splenic cellular population (37).  Data from the Lemke lab also indicates increased 
splenic DC populations in their TAM-/- mice (40).  It is plausible that the increase in 
splenic weight is primarily attributable to the red blood cell population. 
In addition, a mutation in Mertk is implicated in vision loss of the Royal College 
of Surgeons (RCS) rat, a model of retinitis pigmentosa.  In these rats, loss of vision is due 
the failure of retinal pigment epithelial cells to clear outer segments shed by the 
photoreceptor cells (41).  Similar to the RCS rats, mertk-/- mice are also blind, however 
mice lacking the family members Axl and Tyro3 are not(18).  This has important 
implications for Mertk as a critical regulator of photoreceptor homeostasis and mertk-/- 
mice are a model to study this mechanism of blindness which has been reported in 
humans (41).  
 Correlating to a defect in apoptotic cell clearance, mertk-/- mice develop 
autoantibodies with age and present with a SLE-like syndrome. This syndrome is marked 
in humans as well as mice by development of autoantibodies to chromatin, single and 
double-stranded DNA(dsDNA) among other antigens (29, 42).  Although an earlier 
report describes individual TAM family members as contributing to autoantibody 
production, our data in Chapter 3 suggests only Mertk is critical for autoantibody 
formation and not Axl or Tyro3 (43).  A more detailed description of the SLE like 
syndrome is found in section 1.3f.   
1.1e Axl expression and function 
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 The TAM family member Axl is expressed on a variety of cell types.  Northern 
blot analysis shows expression in breast, tail, uterus, ovary, heart, lung, bone, kidney, and 
brain(44).  Important to this work, Axl is also expressed on MФ and DC (18).  In addition 
to expression in normal tissue, Axl also has transforming qualities when over-expressed 
in cell lines (45).  Concurrently, Axl is highly expressed in many different human cancers 
including but not limited to leukemia, Gastric, colon, prostate, lung, breast, liver, 
melanoma, and glioblastoma (46).  Axl also has a role in erythropoiesis (47).   
 Interestingly, Axl expression is inducible on human DC by type I Interferon 
(IFN).  This expression can be suppressed by TLR stimulation and the suppression is 
dependent on proteolytic cleavage of Axl by the metalloproteinase ADAM10 (48, 49).  
This proteolytic cleavage results in soluble Axl which can be found bound to Gas6 in 
mouse serum (48).  In addition, human DC are rescued from growth factor deprivation-
induced cell death by Gas6 stimulation (49).   Axl associates with IL-15 receptor to 
protect cells from TNFα-stimulated cell death (50).   
 While Axl associates with two membrane-bound receptors, IL-15R and Interferon 
receptor 1 (IFNR1), there are a number of intracellular signaling molecules that can also 
associate with Axl (40, 50).  These intracellular signaling components include, PI3K, 
Grb2, SHP2, PLCγ, (Suppressor of cytokine signaling 1) SOCS1, HCK2, RanBPM, and 
C1-TEN (51).  With so many possible binding partners, the intracellular signaling options 
are almost limitless.  It is possible that ligand binding to receptors, receptor-receptor 
interactions, or cell type determine the functional consequences of signaling downstream 
of Axl.   
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 While the axl-/- mice are viable, there are few studies involving the axl-/- singly.  
Our lab shows that unlike mice lacking Mertk, axl-/- mice do not have retinal 
degeneration, however, MФ lacking Axl are defective in phagocytosis of apoptotic cells, 
though not to the extent of cells lacking Mertk.  DC however appear to be more reliant on 
Axl than MФ for the phagocytosis of apoptotic cells (18).  Another study finds slightly 
elevated autoantibody production in the axl-/- mice however unlike the mertk-/- or TAM-/- 
mice, these mice do not have increase splenic weights (43).  Taken together these data 
suggest that Axl plays a less prominent role in autoimmunity than Mertk.   
 
1.1f Tyro3 expression and Function 
 The TAM family member Tyro3 is most highly expressed in the brain (52).  
However it is also expressed on epithelium, kidney, reproductive tissues and most 
important to this work, MФ (53, 54).  Low levels of Tyro3 are also detected on bone 
marrow-derived DC (18).  Tyro3 is expressed in cancer, including myeloid leukemia and 
multiple myeloma (46). 
 Studies involving the signaling via Tyro3 are much more limited than that of the 
other TAM family members.  Tyro3 is important for the binding of the ligand Protein S 
and subsequent activation of Mertk in retinal pigmented epithelial cells (21).  Tyro3 
associates with PI3K, Src, and RanBPM; however, no downstream signaling events have 
been specifically linked to Tyro3 (51). 
 Mice lacking Tyro3 (tyro3-/-) are also viable, though similar to Axl, studies 
investigating this single knock out are few.  Our lab shows that similar to axl-/- and unlike 
mertk-/- mice, tyro3-/- are not blind and do not have retinal degeneration (18).  Again, 
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similar to axl-/-, tyro3-/- MФ have a decreased ability to phagocytize apoptotic cells 
though again not as dramatically as mertk-/-.  DC lacking Tyro3 also behave like axl-/- DC 
and show less phagocytosis of apoptotic cells (18).  One other group shows slightly 
elevated autoantibody production and normal splenic weights in the tyro3-/- mice (43).  
Overall, it appears that mice lacking Tyro3 have similar experimental outcomes as those 
lacking Axl.     
 
1.2 Responses to Infection 
During a typical course of infection, both bacteria and apoptotic cells are present 
(55).  First, bacteria interact with resident macrophages that detect the pathogen through 
cell surface receptors including Toll-like receptors (TLRs), complement receptors and 
scavenger receptors.  Engagement of these receptors initiates signaling cascades that 
leads to phagocytosis and activation of several transcription factors including NF-κB.  
Transcription resulting from NF-κB activation includes the pro-inflammatory cytokines 
TNFα and IL-1 among others (56).  These cytokines in combination with chemokines act 
to call in “help” to combat the infection.  In most cases, depending on location of the 
infection, the “help” is in the form of neutrophils and macrophages.  The first wave of 
responders is the neutrophils partly due to their large percentage of the white blood cells 
in blood (>45%), which migrate into the area of infection in the first 24 hours.  After 
these neutrophils engulf bacteria, they begin to die by apoptosis.  About 48 hours after 
the initial exposure to bacteria, macrophages become more prominent in the infected 
area, where they interact with bacteria as well as dead and dying neutrophils.  It is 
believed that the macrophage is a key modulator in resolving inflammation. 
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 1.2a Toll-like receptor signaling in response to infections 
 One important family of pattern recognition receptors are the TLRs.  To date, 
there are 10 human TLRs and 13 murine TLRs.  Each TLR whose function is known 
recognizes a different subset of pathogen associated molecular patterns (PAMPs) (57).  In 
general, TLR2 will recognize peptidoglycan of Gram-positive bacteria, TLR4 will bind 
Lipopolysaccharide (LPS) of Gram-negative bacteria, TLR5 recognizes flagellin, TLR7 
can bind double-stranded RNA, and TLR9 will sense CpG DNA.  TLR2, TLR4 and 
TLR5 will sense PAMPs in extracellular compartments while TLR7 and TLR9 are found 
in endosomes and sense nucleic acids from pathogens captured in phagosomes (57).   
TLR4 binds LPS in a complex with MD-2, CD14, and lipopolysaccharide-binding 
protein (LBP), all which enhance TLR4 signal transduction (58).  Upon binding of LPS 
to TLR4, there are two pathways that become activated, these are termed myeloid 
differentiation primary-response factor 88 (MyD88)- dependent and MyD88-independent 
pathways (57).  For the MyD88-dependent pathway, MyD88 interacts with the TLR 
through their Toll/Il-1R (TIR) domains.  MyD88 subsequently recruits IL-1R associated 
kinase 4 (IRAK4) which interacts with IRAK1 (57).  Upon MyD88/IRAK4/IRAK1 
complex formation, IRAK1 becomes hyperphosphorylated and this phosphorylation 
engages the binding of tumor necrosis factor receptor associated factor 6 (TRAF6).  
Binding of TRAF6 to IRAK1 allows these two molecules to dissociate from the receptor 
complex and bind to transforming growth factor β activated kinase 1(TAK1), TAK 1 
binding protein 1(TAB1), and TAB2(57).  At this point IRAK1 is degraded and the 
TRAF6/TAK1/TAB1/TAB2 complex moves into the cytosol.  Translocation to the 
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cytosol allows the complex to associate with ubiquitin ligases that ubiquitinate TRAF6 
(57).  Ubiquitination of TRAF6 activates TAK1 and TAK1 can now phosphorylate the 
IκB kinase (IKK) complex.  The IKK complex then phosphorylates the inhibition of 
nuclear factor κB (IκB).  Phosphorylation of IκB causes its dissociation from NF-κB, 
allowing NF-κB to translocate to the nucleus and upregulate gene expression (57).  Genes 
regulated by NF-κB in this context are typically pro-inflammatory cytokines such as 
TNFα and IL-1β.   
 For the MyD88-independent signal transduction, ligand binding recruits the 
adaptor molecule TIR-domain-containing adaptor protein inducing IFN-β (TRIF) via 
TRIF-related adaptor molecule (TRAM) to the TLR (57).  Once recruited to the receptor, 
TRIF activates IKKε and TRAF- family member associated NF-κB actvator-binding 
kinase (TBK1) which subsequently phosphorylate the interferon regulatory factor 
3(IRF3).  IRF3 then moves to the nucleus and binds to the interferon regulatory elements 
of certain genes.  These genes include the IFN-β and other IFN regulatory genes (57).   
Not mentioned previously, TLR3 recognizes dsRNA typically found in some 
viruses.  TLR3 is found in endosomal compartments and upon binding of dsRNA, an 
adaptor molecule, TRIF, will activate TBK-1 and IKKe (57).  TLR3 is the only TLR 
which exclusively uses the My-D88-independent signaling pathway.  In addition, dsRNA 
can be recognized in the cytosol by RIG-I, which through its CARD domain, can activate 
TBK-1 and IKKe.  In both pathways, TBK-1 and IKKe activate IRF-3 which facilitates 
transcription of type I interferons (59).  
 
1.2b Phagocytosis of Bacteria   
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During the course of an infection, the macrophage first senses pathogen-
associated molecular pattern of bacteria through many different receptors including Toll-
like receptors(TLR), mannose receptors, scavenger receptors, CD36 as well as Fc and 
complement mediated interactions (60, 61).  Upon recognition, these receptors signal for 
phagocytosis by the myosin contraction and rearrangement of the actin cytoskeleton; 
however, each receptor-mediated pathway may track through different subcellular 
mechanisms (62).  This actin rearrangement is mediated by the Rho family of GTPases, 
Rac, Rho, and Cdc42 (63).  The activation status of this family of molecules cycles from 
“on”, GTP bound, to “off”, GDP bound.  The GTPases are regulated by GTPase 
activating proteins (GAPs) and GEFs(63).  The GAPs stimulate intrinsic GTPase activity 
thus pushing the Rho GTPases to the off state.  In contrast, the GEFs assist the exchange 
of GDP to GTP and thereby activate the Rho GTPases.  One important GEF for the Rho 
family GTPases are the Vav proteins (64, 65).  Vav proteins are themselves regulated by 
their phosphorylation status.  This phosphorylation status of Vav is controlled by  binding 
to phosphorylated cell surface receptors (65).  Thus, upon activation, Vav is 
phosphorylated and acts as a GEF for Rho and Rac, but not the structurally similar Cdc42 
(30).  Rho and Rac are now in their active form and cause the cytoskeleton rearrangement 
necessary for phagocytosis.  Also, TLR activation of macrophages can lead to Vav 
phosphorylation (66, 67), providing a further link between TLRs and phagocytic 
machinery.   
  Once the phagosome is formed around the bacteria, it begins to mature by fission 
and fusion events with lysosomes and late endosomes (61).  Although protein markers of 
phagolysosome maturation such as LAMP 1 and 2 are identified, the regulation of this 
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vesicle fusion event is poorly understood (61).  Currently the small GTPases rab-5 and 
rab-7  as well as rab-7 interacting lysosomal protein(RILP) are implicated as factors 
regulating phagosome-lysosome fusion (68, 69).  The TLRs are also implicated as 
modulators of phagosome maturation, and this maturation is dependent on p38 mitogen- 
activated protein kinase (70).  With the addition of this recent evidence, Colin Watts 
proposes that the p38 regulated protein, guanine nucleotide dissociation inhibitor (GDI), 
a rab affecter, could be the link between TLR signals and phagosome maturation (71).  
The penultimate consequence of phagocytosis and phagosome maturation is for the break 
down of antigens.  The presentation of antigens by major histocompatability complex 
(MHC) is ultimately critical for the induction of adaptive immunity which further 
facilitates removal of pathogens by ushering antibody-mediated phagocytosis and the 
provision of cytokines such as IFNγ to increase phagocyte killing.  
 
1.2c Phagocytosis of Bacteria and Apoptotic cells 
 One important role for the TAM receptors is phagocytosis(18, 28). This process is 
critical to resolving an infection, both by phagocytosis of bacteria and of infected dead 
cells.  Phagocytosis is mediated by a combination of interactions with cell surface 
receptors and ligands expressed on the surface of the phagocytic particle.  Interestingly, 
many of the receptors involved in phagocytosis recognize foreign or non-self molecules 
of bacteria and apoptotic cells.  These include SR-A, CD14, integrins, complement 
receptors and Fc receptors (72-75).  In addition to cell surface proteins, intracellular 
machinery used for phagocytosis of bacteria and apoptotic cells also overlaps.   
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1.2d Phagocytosis of apoptotic cells 
 As stated previously, many receptors used for phagocytosis of bacteria are also 
engaged for phagocytosis of apoptotic cells (75).  Once an apoptotic cell is targeted for 
phagocytosis, the intracellular phagocytic machinery used for bacteria is employed.  
Similarly to bacteria, apoptotic cells are engulfed via activation of the Rho GTPases.   
Phagosome maturation proceeds similarly to that of a phagosome containing bacteria 
with one important distinction (76, 77).  This distinction is with regard to the MHC 
molecules that fuse with the maturing phagosome.   Maturation of the phago-lyso-
endosome is critical for antigen presentation of particles from phagosomes that contain 
bacteria.  However, importantly the lack of MHC fusion to phago-lyso-endosomes 
containing apoptotic cells prevents antigen presentation of self antigens found in the 
apoptotic cell (76).  Improper presentation of self-antigens could potentially lead to 
autoimmune disease.   
 
1.2e Regulation of Cytokine Signaling by Apoptotic cells 
 Phagocytosis of apoptotic cells regulates the production of a number of cytokines 
and chemokines.  Some of these cytokines are upregulated directly by apoptotic cells, and 
some are downregulated after or with an inflammatory stimulation such as LPS.  For 
example, macrophages given apoptotic cells alone will upregulate the anti-inflammatory 
factors transforming growth factor-β (TGF-β) and Prostaglandin E2(PGE2)(78).  In 
addition, the same group shows that macrophages given apoptotic cells and LPS together 
have decreased levels of IL-1β, TNFα, and IL-10 when compared to cells exposed to LPS 
alone (78).  Therefore, the downregulation of pro-inflammatory cytokines is attributed to 
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a feedback loop mediated by apoptotic cell-induced production of TGF-β and PGE2 (78).  
In addition, another group found that apoptotic cells inhibit TNFα and IL-6 production by 
macrophages (79).  Moreover, apoptotic cells also suppress LPS or IFN stimulation of the 
chemokines CXCL9 and CXCL10 (79).  In addition, a negative feedback pathway is 
activated by the transcription of the SOCS1 and SOCS3 genes which are increased upon 
apoptotic cell stimulation (79).  These SOCS proteins are known to inhibit both the TLR-
signaling pathway as well as the Jak/Stat signaling intermediates (80, 81).   
 The SOCS proteins are directly implicated in TAM receptor-mediated inhibition 
of TLR-signaling components (40, 82, 83) .  Recently it has been shown that a ligand of 
the TAM receptors, Gas6, stimulates SOCS1 and SOCS3 upregulation (40).  It is 
believed that this upregulation of SOCS interferes with TLR or type I interferon receptor 
signaling (IFNR) (40).  SOCS1 can inhibit TLR signaling by binding MAL to mediate 
polyubiquitination; IRAK which inhibits phosphorylation of IKKα; the p65 subunit of the 
NF-κB complex in the MyD88-dependent signaling.  Alternatively, SOCS1 can bind 
Tyk2 within the IFNR complex of the MyD88-independent pathway to prevent 
phosphorylation of Stat1(82).  SOCS proteins can also compete for Signal transducer and 
activator of transcription 1 (STAT1) binding to the IFNR and thus preventing 
phosphorylation and activation of STATs.  It is believed that inhibition is partly 
accomplished by SOCS3 binding STAT3 binding sites on cytokine receptors, thereby 
uncoupling STAT3 and preventing its phosphorylation (84, 85).  In addition, SOCS3 may 
bind TRAF6 in the MyD88-dependent pathway and TRAF3 in the MyD88-independent 
pathway thereby inhibiting NF-κB and IRF3 respectively (83).  Correspondingly, TAM-/- 
DC produce greater amounts of TNFα and IL-6 in response to TLR stimulation.  
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Consistent with these findings, Gas6 stimulation also reduces DC responses to TLR 
ligands and IFN stimulation (40).   
A brief discussion of cytokines regulated by Mertk is found in section 1.1c.  
Relevant to this discussion, it has been found by our lab and others that Mertk is 
important for the ability of the apoptotic cell to regulate production of the cytokines 
TNFα, IL-1β, and IL-12 (19, 35, 36)(unpublished data, Matsushima Lab).  LPS and 
apoptotic cell-stimulated DCs lacking Mertk on the NOD background have similar 
production of TNFα and IL-12 when compared to stimulated DCs that did not receive 
apoptotic cells (19, 36).  Where as LPS and apoptotic cell-stimulated wild-type NOD DC 
have lower TNFα and IL-12 when compared to cells stimulated with LPS alone.  This 
exposure to apoptotic cells and subsequent DC inhibition induces Mertk PI3K/Akt 
signaling and more recently recruitment of Src to Mertk leading to Stat3 activation (36, 
86).  Thus, Mertk is critical for apoptotic cell induced down regulation of TNFα and IL-
12 by DC.   
 
1.3 Systemic Lupus Erythematosus  
 SLE is an autoimmune disease of unknown etiology with both genetic and 
environmental contributions (42).  Because this disease has a wide range of symptoms, 
the American college of rheumatology identifies 11 criteria for diagnosis of SLE (42).  
These criteria include Malar rash, Discoid rash, photosensitivity, oral ulcers, arthritis, 
serositis, renal disorder, hematologic disorder, immunologic disorder (anti-dsDNA, anti-
Sm) and anti-nuclear antibody production.  At least 4 of these criteria must be present in 
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order for the patient to be diagnosed with SLE.  However, antibodies to dsDNA and Sm 
antigen are present in greater than 95% of patients (42).   
A role for genetic contributions to SLE is evident in skewing of disease variance 
by sex as well as familial associations.  SLE is more common in women than men, 9:1, 
and also more common and severe in African Americans (42).   Certain HLA alleles are 
linked to a prevalence of SLE and genetic alterations in the complement components and 
Fc receptors are also linked to SLE.  More monozygotic twins both have SLE than 
dizygotic twins.  Family members of SLE patients are more likely to be diagnosed with 
SLE, although 20% of family members of SLE patients have increased autoantibody 
titers but do not progress to full blown disease (42).  This is one clear indication that 
genetics is not the only factor contributing to the onset of SLE.  
Many environmental factors are correlated with SLE.  Ultraviolet(UV) light 
causes disease associated flares in 70% of patients (87).  UV light has the potential to 
induce apoptosis, thus providing increased availability of autoantigens.  Oral hormone 
ingestion is also associated with SLE as women taking oral contraceptives or hormone 
replacement are twice as likely to be diagnosed (87).  In addition, a role for infection in 
SLE etiology has been proposed.  SLE patients are more likely to be infected with 
Epstein-Barr Virus(EBV) than age-matched controls, and interestingly they also have 
higher viral titers (87, 88).  Another piece of evidence that points to EBV as a potential 
factor contributing to SLE is that EBV Nuclear antigen-1 is a known molecular mimic to 
self antigens and is capable of inducing cross-reactive antibodies to Sm and Ro (89).  
Given that SLE patients also tend to have elevated circulating type I IFN, a cytokine 
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known to induce anti-viral host mechanisms, EBV seems a likely candidate for 
involvement in SLE pathology and etiology.   
 
1.3a Antigen presenting cells in SLE 
 Antigen-presenting cells (APC) including MФ and DC have been shown to play a 
variety of roles in the pathogenesis of SLE including phagocytosis of apoptotic and 
necrotic cells, antigen presentation to T and B cells, maintenance of tolerance, and 
modulation of cytokine and chemokine production.  The role of the APC varies as 
interactions between APC and lymphocytes occur under non-autoimmune scenarios as 
well.  Impairment in clearance of apoptotic and necrotic cell material is seen in both 
murine models of SLE and human SLE.  In fact, one study found increased apoptotic 
cells in lymphnodes of SLE patients (90).  Defects in the complement-mediated 
phagocytosis components are also strongly correlated with SLE, as 93% of patients with 
complete C1q deficiency develop SLE early in life (91).  However, most defects 
associated with C1q and SLE are due to autoantibody production and hypercatabolism 
(92, 93).  The dysfunction of DNase I is also associated with SLE in humans.  DNase I is 
necessary for the digestion of chromatin in apoptotic and necrotic cells as well as removal 
of DNA from interstitial compartments. DNase I activity is lower in SLE patients and this 
correlates with increased disease severity(94).  Another human genetic polymorphism 
associated with SLE and clearance of self materials is in C-reactive protein (CRP).  Two 
polymorphisms found in the CRP and Serum ameloid protein(SAP) loci are associated 
with low levels of these proteins and SLE (95).  Clearly the disposal of self material plays 
a role in SLE pathogenesis.  
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Deficiencies in clearance of dying cells are found in mouse models of SLE as 
well.  Confirming the previously described human genetic predispositions, mice lacking 
C1q, DNase I, and SAP, all have SLE like phenotypes including autoantibody production 
and glomular nephritis (96).  In addition, mice lacking secreted IgM show delayed debris 
clearance and manifest disease in the form of antinuclear antibodies and deposition of 
complement and renal IgG (97).  Mice lacking phosphatidylserine receptor are neonatal 
lethal; characterized by accumulation of apoptotic cells in the brain and lung (98).  MFG-
E8 knock out mice show impaired uptake of apoptotic B cells resulting in antinuclear 
antibodies, anti-dsDNA antibodies and glomular nephritis (99).  Lastly and most 
important to this work, mice lacking Mertk also show defects in apoptotic cell clearance 
and produce anti-nuclear and anti-dsDNA antibodies (28, 29, 37).   
 
1.3b TLR signaling and SLE 
 Shown recently, signaling by TLR3, 7, 9 contributes to the progression of SLE.  
These TLRs reside in the endosomal compartments of the cell and recognize single-
stranded and double-stranded nucleic acids.  As discussed earlier, TLR3 recognizes 
double-stranded RNA and uses the MyD88-independent TRIF adaptor molecule to 
upregulate type I IFN (57).  TLR7 recognizes single-stranded RNA and uses the MyD88 
adaptor for down-stream signaling.  TLR9 recognizes CpG-rich double-stranded DNA 
and also uses the MyD88 adaptor for down-stream signaling.  These receptors are 
normally thought of as viral pathogen-sensing receptors.  Due to the restricted endosomal 
localization of these nucleic acid-sensing TLRs, they do not normally engage self nucleic 
acid.   
 21
One hallmark of SLE is the deposition antibody-nucleic acid complexes.  In B 
cells, upon engagement of the BCR, the antibody-nucleic acid complexes found are 
internalized and TLR7, and 9 are present to engage the nucleic acid and transmit 
downstream signaling (100, 101).  As such, these complexes may increase the production 
of autoantibody.  
In DC, these antibody-nucleic acid complexes can be recognized by both Fc 
receptors and TLRs (102).  DC can be activated by anti-nucleosome and chromatin 
complex as well as anti-DNA complexes to produce IFNα (103, 104).  However, similar 
to the BCR-TLR dual engagement, the Fc receptor-TLR dual engagement is necessary 
for activating plasmacytoid dendritic cells (pDC) as Fc crosslinking with out TLR 
engagement will not activate pDC (105).  Discussed in more detail below, the activation 
of pDC is a critical step for the production of IFNα.  Dual activation of TLR and Fc 
receptor or BCR can lead to aberrant cytokine production and autoantibody producing 
cell activation.   
 
1.3c Cytokines involved in SLE 
 A variety of cytokines play a role or are elevated in both murine and human SLE.  
An overview of these cytokines can be found in Table 1.  To introduce the potential roles 
for these cytokines, it is necessary to first introduce the concept of T helper (Th) subsets, 
Th1 and Th2.  Th0 cells are driven by APCs to become Th1 cells that produce IFN-γ as 
well as TNFα.  Th1 cells then proliferate in the presence of IL-2 and perpetuate their own 
phenotype by producing IFN-γ.   In contrast Th1, Th0 cells can be driven by APCs to 
become Th2 which primarily produce IL-4.  Th2 cells perpetuate their phenotype by 
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producing IL-4, IL-5, and IL-10.  Interestingly, IFNγ produced by Th1 cells actually 
inhibits Th2 cell differentiation, and IL-4 produced by Th2 cells inhibits Th1 cell 
differentiation (56).  Th1 cells activate the cell-mediated immune response to kill 
pathogens by secreting IFNγ which promotes killing of phagocytized bacteria in 
macrophages or by helping in the induction of cytotoxic T lymphocytes (CTL) (56).  In 
contrast, Th2 cells are thought to combat pathogens by activating the humoral immune 
response to produce antibody to these pathogens.  These antibodies mediate complement-
dependent killing or opsonize pathogens which target them for phagocytosis.  SLE was 
once thought to be a Th2-mediated disease, however, an increased expression of Th1 
cytokines IFNγ and TNFα are higher in SLE patients than controls (106, 107).  Similarly, 
in mouse models, both Th1 and Th2 cytokines are involved as, SLE prone MRL/lpr mice 
lacking IFNγ and IL-4 separately, have less disease than mice with intact cytokines (108) 
 The Th1-related cytokines, IFNγ, TNFα, IL-2, IL-12, and IL-18 are dysregulated 
in murine or human SLE.  IFN-γ was discussed previously, however more evidence for 
involvement of this cytokine is that SLE patients with high IFNγ also have greater 
disease(109).  In addition, NZB/W F1 mice receiving IFNγ had increased disease 
incidence and NZB/W F1 mice lacking IFNγ show reduction in disease (110, 111).  
Paralleling these studies, TNFα levels are elevated in the kidneys of SLE patients, and 
TNFα administration to lupus-prone NZB/W F1 mice increases disease severity and 
mortality (112, 113).  Interestingly, T cells from both murine and human SLE produce 
less IL-2, and consequently are less proliferative (114-116).  IL-12 has been found to be 
increased in serum from SLE patients (117).  In addition, DC from MRL/lpr mice have 
higher expression of IL-12 and consistent with these findings, disease-associated 
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pathology is increased in lupus-prone mice injected with IL-12 (118, 119).   
Correspondingly, MRL/lpr mice lacking IL-12 have reduced disease (120).  In both 
murine models of IL-12 dysregulation, modulation of IFNγ is also observed.  Lastly, IL-
18 is known to act synergistically with IL-12.  As such, MRL/lpr mice injected with IL-
18 have increased disease pathology (121).  In humans, an increased level of IL-18 
correlates with increases in active SLE (122).  Taken together, this data suggests Th1-
associated cytokines are dysregulated in SLE and appear to exacerbate pathology. 
 The Th2-associated cytokine IL-10 is involved in SLE.  Normally IL-10 acts to 
inhibit Th1 cytokines, promotes humoral responses and is produced by a variety of cells 
including APC and lymphocytes.  Evidence to support the involvement of IL-10 in SLE 
is shown in studies using anti-IL-10 antibody treatment which delays the onset of disease 
in lupus-prone mice.  These mice have lower anti-dsDNA antibody titers and increased 
survival (123).  In addition, reports show correlation between increased IL-10 in lupus 
patients and disease severity as well as dsDNA antibody titers in a mouse model (124, 
125).  The Th2 cytokine IL-4 is also elevated in SLE patients (126).     
 Another set of cytokines involved in SLE are the Th17-associated cytokines, IL-6, 
IL-17 and TGF-β.  Th17 cells are distinct from Th1 and Th2 and are characterized by the 
production of IL-17 as well as IL-1 and IL-6.  Both IL-6 and TGF-β produced by APC 
are involved in Th17 differentiation (107).  IL-17 is elevated in serum from SLE patients 
(127).  The murine model of lupus, BXD2 mice, also has elevated levels of serum IL-
17(128).  In addition to IL-17, the cytokine IL-6, which supports Th17 cells, is also 
elevated in SLE patients and murine models of SLE (129-132).  In addition, NZB/W F1 
mice treated with IL-6 show increases in disease severity (133).  In accordance, NZB/W 
 24
F1 mice treated with anti-IL-6 antibody show reduction in disease and increased survival 
(134, 135).  In addition, since IL-6 inhibits T regulatory cells (Treg), it is possible that an 
increase in IL-6 activity correlates to a decrease Treg activity whereby leading to 
dysregulation of autoimmune T cells and a break in tolerance.   
 Two other cytokines are of importance to the discussion on SLE and Mertk.  
Those cytokines are BAFF and the type I IFN, IFNα.  Evidence for the involvement of 
BAFF (also known as BLyS, TALL-1, THANK, and zTNF4) in SLE is found in studies 
where BAFF is elevated in some SLE patients and overexpression of BAFF in transgenic 
mice results in autoimmune disease similar to SLE (136-138).  In addition, blockade of 
BAFF signaling using antibodies to its receptors shows a decline in mortality of lupus-
prone NZB/W F1 mice (139).  Of importance to the work presented in this manuscript, 
our lab also observes an increase in splenic BAFF mRNA from mice lacking Mertk, 
another murine model of SLE described previously (37).  An increase in BAFF mRNA 
expression is also found in spleens of TAM-/- mice (40).  A similar increase in BAFF 
production is found in mertk-/- DC, however this does not correlate to a increase in B cell 
survival when co-cultured with DC lacking Mertk(37).  It is plausible that marginal zone 
B cells which are dependent on BAFF may have increased survival by mertk-/- DCs. 
 The type I IFNs were first identified as anti-viral mechanism produced by infected 
cells.  However, there is mounting evidence for involvement of IFNα in SLE.  A number 
of studies have shown patients undergoing IFN treatment have an increased risk of 
developing autoantibodies (140, 141) and multiple studies have identified increase levels 
of IFNα in serum of SLE patients (142-144).  Serum IFNα levels in SLE patients also 
correlate with antibody production (145).  IFNα may be regulating SLE directly or 
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indirectly through the upregulation of IFN responsive proteins.  TLR7 and TLR9 are 
expressed in peripheral blood monoctyes and are upregulated in response to IFN, thus 
may increase the sensitivity and response to nucleic acids by B cells or dendritic cells 
(146, 147).  Another IFN-responsive protein family is the HIN-200 proteins.  This family 
is known to be located within a lupus susceptibility region in both mice and humans 
(148).  An in depth discussion of this family is found in 1.4.   
The most active IFNα-producing cell is the pDC.  pDC can be activated to secrete 
IFNα by a variety of insults(149).  Interestingly and important for the involvement in 
SLE, pDC can produce IFNα in response to immune complexes (150).  Immune 
complexes are formed by antibody and self proteins or nucleic acids and are found often 
in both murine and human SLE.  Also important for the work discussed in this 
manuscript, TAM-/- and mertk-/- mice have elevated splenic DC (37, 40).  While neither 
group determined if these DC were plasmacytoid, our studies find CD11b+ DC to be 
significantly elevated while CD8+ DC are not (37).  A synopsis of cytokines involved in 
SLE can be found in Table1.  
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Table 1. Cytokines dysregulated in SLE 
Cytokine Human Mouse Cell 
IFN-γ increased KO NZB/W F1 less disease Th1 
TNF-α increased administration leads to increased disease Th1 
IL-2 decreased decreased Th1 
IL-12 increased 
administration leads to increased disease; KO 
MRL/lpr less disease Th1 
IL-18 increased administration leads to increased disease Th1 
IL-10 increased anti-IL-10 delays disease Th2 
IL-4 increased KO MRL/lpr less disease Th2 
IL-17 increased increased in BXD2 lupus mice Th17 
IL-6 increased 
administration leads to increased disease; 
anti-IL-6 decreases disease Th17 
BAFF increased 
overexpression leads to disease in non lupus 
prone mice; anti-BAFF decreases disease in 
NZB/W F1 B cell 
IFN-α increased 
KO NZB/W F1 for receptor leads to 
decreased disease;KO MRL/lpr has increased 
disease  
DC and 
others? 
 
1.3d Chemokines involved in SLE 
 A wide variety of chemokines and their receptors are implicated in SLE 
pathogenesis.  Expression of CXCL10, a chemokine that targets activated T cells and 
binds to the CXCR3 receptor, correlates with SLE and disease severity by multiple 
groups (56, 151, 152).  Another chemokine which binds CXCR3, CXCL9 is also elevated 
in serum of SLE patients(152).  Serum concentrations of CXCL13, which acts on naïve B 
cells and activated CD4 T cells, correlates with disease index, and anti-dsDNA titers 
(153).  CXCL13 is recognized by CXCR5 and is also critical for B-1 cell migration to the 
peritoneal cavity (154).     
Another study investigates the association of serum MIP-1α, MIP-1β, and 
RANTES with SLE.  MIP-1α (CCL3), MIP-1β (CCL4), and RANTES (CCL5) all target 
a variety of cells expressing CCR1 and CCR5 including MФ, T cells, NK cells and 
immature DC (56).  The study observes that SLE patients have higher concentrations of 
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all three chemokines(155).  Another study finds RANTES promoter polymorphisms that 
correlate to SLE patients in Chinese children(156).  Thus, these studies indicate that 
elevated chemokines and their receptors may be controlling a greater migration or 
abnormal accumulation of key immune cells at sites that may be conducive for 
autoimmunity.  
Levels of a chemokine, CCL17 that binds CCR4 and acts on T cells, immature 
DC and NK cells, are significantly different in untreated and treated SLE patients.  Those 
SLE patients that are treated with immunosuppressive therapy have significantly lower 
plasma levels of CCL17 than  patients who are not treated (157).  This study also 
examines MCP-1(CCL2) and finds no correlation between CCL17 and CCL2 levels.  
However, CCL2, which binds CCR2 on T cells and monoctyes (56), is investigated by a 
number of groups in relation to SLE.  Two different groups associate CCL2 secreted in 
urine of SLE patients with disease severity (158, 159).  One of these groups suggests that  
CCL-2 secretion could be used as a biomarker for future disease flare (158).  In addition 
promoter polymorphisms of CCL2 are evident in a Spanish cohort with SLE (160).  A 
synopsis of chemokines involved in SLE can be found in Table 2.  
Several chemokine receptors are also associated with SLE.  First, CCR4, the 
receptor for CCL22 and CCL17 (56), has increased expression on peripheral blood T 
cells from SLE patients compared to healthy controls (161).  This expression correlates 
with disease index and could be reduced with corticosteroid therapy(161).  Another study 
examines CCR1, CCR2, CCR5, CXCR3, CXCR4, and CXC3R1 for differences in whole 
blood samples (162).  This study concludes that CCR2 and CXCR3 positive T cells were 
lower in blood of patients with active disease flares and the authors suggest that low 
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levels of circulating CCR2 and CXCR3 positive T cells can be used as a biomarker for 
SLE flare (162).  CCR2 is found on T cells and monoctyes and is the receptor for MCP1-
4 or (CCL2, 8, 7, 13)(56).  CXCR3 is found on T cells, B cells and pDC and is the 
receptor for CXCL9, 10, and 11 (56, 163-165).  In support of the involvement of CXCR3 
in SLE, MRL/lpr mice lacking CXCR3 also have decreased kidney disease (166).  A 
synopsis of chemokine receptors involved in SLE can be found in Table 3.  Taken 
together, these data show that many chemokines and their receptors are markers for SLE 
disease.    
Table 2: Chemokines and their receptors dysregulated in SLE 
Chemokine Human Target cell Receptor 
CXCL10 increased T  CXCR3 
CXCL9 increased T CXCR3 
CXCL13 increased B, B1, T CXCR5 
CCL2(MCP-1) increased MФ ,T  CCR2 
CCL3(MIP1-α) increased MФ, DC, T, NK CCR1,5 
CCL4(MIP1-β) increased MФ, DC, T, NK CCR1,5 
CCL5(RANTES) increased MФ, DC, T, NK CCR1,5 
CCL17(TARC) increased T, NK, DC CCR4 
    
Receptor Human Found on Chemokine ligand 
CCR4 increased on T T, NK, DC CCL17, 22 
CCR2 decreased MФ,T cell CCL2, 8, 7, 13 
CXCR3 decreased DC, T, B  CXCL9,10,11 
 
1.3e Involvement of Peritoneal cells in SLE 
 Many types of cells are found in the peritoneal cavity including DC, MФ, T cells, 
B cells, NK cells, and Mast cells.  However, little is known of the regulation of the 
peritoneal environment in the pathogenesis of SLE.  Since the majority of low affinity 
autoantibody producing B-1 cells found in the body are found in this location (167), the 
peritoneal cavity is an attractive location for the initiation of autoantibody production.   
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B-1 cells are known to produce antibodies to PAMPs that can cross react with self-
antigens and these cells do not require T cell help for this process (167).  However, T cell 
help promotes class switching of B-1 cell antibody production.  In addition, B-1 cells are 
known to contribute virtually all circulating IgM.  These cells are generally characterized 
by the following expression pattern CD19+, B220low, IgMhi, CD23-, CD43+, and IgDlow.  
In addition the T cell activation marker CD5 can be found on B-1 cells as well.  These 
cells are termed B1a, and CD5- cells are termed B1b (167).   
The contribution of B-1 cells to the development of autoimmunity is 
controversial.  One study shows through hypotonic ablation, that B-1 cells contribute to 
disease in the lupus-prone NZB and NZB/W F1 mice (168).  In addition, another group 
shows that NZB/W F1 xid mice, which have and X-linked mutation that results in no B-1 
cells, had lower antibody production (169).  More recent data has proven that high 
affinity autoantibody to DNA is produced exclusively by conventional B2 cells (170).  
However as discussed above, B-1 cells make low affinity autoantibody and there is 
potential for a break in tolerance at this level resulting in B-1 cell response to T cell help 
and subsequent class switching to high affinity IgG molecules(167).  Whether the 
autoantibody production in the found the mertk-/- mice is due to the contribution of B-1 
cells remains to be investigated.  Although all the immune components necessary for a 
functional innate and adaptive immune response are found in this location, the 
relationship between autoimmune disease and other cells found in the peritoneal cavity is 
not clear.    
 
1.3f TAM involvement in SLE 
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 Previously published data establishes that mice lacking Mertk as well as mice 
lacking all three TAM receptors have autoimmune like syndromes.  Data from the Lemke 
lab has shown the propensity for the TAM-/- mice to develop a variety of autoimmune 
symptoms similar to those found in the human diseases Rheumatoid Arthritis, Pemphigus 
vulgarus and SLE(43).  This study shows increased splenic weight from TAM-/- mice, 
AM-/-, and TM-/- as well as mice that were null for Tyro3 and Mertk and heterozygote for 
Axl.  In addition, they show increases in peripheral lymphocyte populations, as well as 
lymph invasion of liver and kidney among other organs.  Not only were the lymphocyte 
populations increased, they also have higher expression of activation markers.  These 
TAM-/- mice also have the ability to induce division of adoptively-transferred WT 
lymphocytes, suggesting these mice provide a hyper-proliferative environment.  Most 
relevant to the discussion on SLE, autoantibody production to dsDNA, collagen, 
cardiolipin, and phophatidylinositol are all increased in TAM-/- mice.  Mice lacking other 
family members also show autoantibody production in this study, though not to the extent 
of the TAM-/- mice (43).   
 While the TAM-/- mice have a variety of autoimmune syndrome symptoms, the 
mertk-/- mice manifest symptoms similar only to that of SLE.  Three different studies 
show autoantibody production in these mice.  The first documentation of autoantibody 
production to dsDNA is by our lab in 2001.  We show that over 50% of mertk-/- mice 
tested are sera positive for anti-DNA antibodies(28).  In 2002, another group published 
that there are statistically significant increases in the amount of anti-chromatin antibodies 
found the serum of mice lacking Mertk (29).  The same study finds mertk-/- mice positive 
for antibodies to Rheumatoid factor and ssDNA as well as mild renal pathology.  Lastly, 
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the third study from our lab documented elevated anti-nucleosome antibody in the serum 
of mertk-/- mice in addition to anti-dsDNA antibodies (37).  While SLE in humans has a 
wider variety of symptom indicators, the lack of Mertk is only sufficient to display 
autoantibody production and mild kidney pathology.       
 Three other studies of mice lacking Mertk are relevant to the discussion of 
autoimmunity.  While one study shows Mertk expression on B cells in a model of chronic 
graft-versus-host disease is critical for direct maintenance of B cell tolerance (171).  Two 
other studies focus on the ability of mice lacking Mertk to contribute to autoimmunity 
through the APC-mediated activation of lymphocytes.  In this chronic graft-versus-host 
disease model, wild-type B cells upregulate Mertk upon activation.  Surprisingly, this 
leads to autoantibody production and higher expression of activation markers.  Contrary 
to other studies, this study is also remarkable in that a lack of Mertk was protective from 
autoimmune chronic graft-versus-host disease (171).  
A second study from the Clarke lab showed that 2-12H transgenic mice which 
constitutively express anti-Sm antibody that were also lacking Mertk have greater anti-
Sm antibody levels in the serum when compared to 2-12H transgenic animals with intact 
Mertk (172).  In fact, a few mertk-/- mice that were not expressing the 2-12H transgene 
show elevated serum anti-Sm antibodies (172).  2-12H mice lacking Mertk also have 
elevated numbers of antibody-secreting B cells in the bone marrow, spleen, mesenteric 
lymph node and lamina propria (172).  This study provides direct evidence that the defect 
in clearance of apoptotic cells contributes to the autoimmune potential of the mertk-/- 
mice.   
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 The third study is from the Tisch lab showing that Mertk on APC is important for 
the maintenance of T cell tolerance (19).  In this study, nonobese diabetic (NOD) mice, a 
model of autoimmune induced diabetes, which lack Mertk have exacerbated disease 
when injected with T cells specific for β cell antigens (19).  In addition, T cell 
proliferation in response to induction of β cell apoptosis in NOD mice lacking Mertk was 
also elevated.  This study also shows DC lacking Mertk have increased production of T 
cell stimulatory cell surface receptors and cytokines (19).  Taken together, these last two 
studies show the potential for the APC to be involved in maintenance of tolerance 
towards self antigen.   
 
1.4 HIN-200 family- SLE susceptibility genes 
 The HIN-200 proteins are termed HIN-200 for the hematopoietic expression, 
interferon induction, and nuclear localization with a characteristic 200 amino acid 
domain(173).  This family currently contains 6 genes termed ifi-202, ifi-203, ifi-204, ifi-
205, aim2 (absent in melanoma), and pyhin1 in mice, encoding the proteins p202, p203, 
p204, p205, AIM2, and Pyhin1 respectively.  Four human homologs have been identified 
including, ifi-16, aim2, mnda(myeloid nuclear differentiation antigen), and ifix, encoding 
the proteins IFI-16, AIM2, MNDA, and IFIX respectively (173).  These genes are all 
located on chromosome 1 in both mice and humans (173).  Notably, this region is found 
within the Nba2 (New Zealand Black autoimmunity 2) locus and is a known 
susceptibility site for SLE in mice (174).   
The conserved 200 amino acid domain of HIN200 proteins contains a conserved 
motif of MF/LHATVAT/S (173). This domain is important not only for self association 
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of p202 but also for its association with a p53 binding protein (175).  Two other 
conserved sequences are found in this family though their location differs in each protein.  
LXCXE is important for pRb-binding, and a CDK2 phosphorylation site is also found 
(176, 177).   The HIN-200 family also contains a conserved nuclear localization signal 
and a DNA-binding motif.  All but p202 also contain a PYRIN domain (178).  Proteins 
containing PYRIN domains are known to be involved in induction of apoptosis and 
processing of IL-1β, through their interaction with the inflammasome (179).  Thus, p202 
may be unique among the family members and may not induce pyroptosis or IL-1 
processing.  Our current understanding of these proteins is relegated to experiments 
investigating AIM2 and p202 which are described below.   
 
1.4a AIM2 expression and function 
 AIM2 is first described as one of a set of genes that was not expressed in 
malignant melanoma cell lines (180).  The gene aim2 encodes a 1456 base pair RNA 
sequence that is predicted to lead to a 485 amino acid protein (NCBI database).  AIM2 is 
expressed in spleen, small intestine and peripheral leukocytes (180).  Similar to all the 
other HIN-200 family members, it has been shown to be induced with IFN treatment 
(180).  AIM2 is localized to the cytoplasm in overexpressing cells (181).  Overexpression 
of AIM2 also suppresses proliferation in a variety of cell types (181, 182).   
 More recently, AIM2 functions as a major binder of cytoplasmic dsDNA.   
Sensing of cytoplasmic dsDNA is important for identification of viral pathogens as well 
host DNA that has escaped regulated compartments.  Three different groups 
simultaneously published that AIM2 can bind dsDNA (183-185).  Burckstummer and 
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colleges use a genomic screen approach in which dsDNA known to be interferon 
stimulatory is immobilized and used to affinity purify nucleic acid-binding proteins from 
RAW264.7, L929, and NIH3T3 cell lines (183).  Separately, they use the same cell lines 
to screen for genes regulated by IFNβ by microarray.  These screens pull out a total of 7 
proteins including Trex1 which is known to remove retroviral DNA.  Among the 6 other 
proteins are three HIN-200 family members, p204, p205, and AIM2 (183).  However, 
since only AIM2 is predicted to be localized to the cytoplasm, this group focused on 
AIM2.  They reconfirm the ability of AIM2 to bind dsDNA, and went on to show that 
AIM2 can associate with apoptotic spec-associated protein containing a card 
domain(ASC) to activate the inflammasome leading to IL-1β cleavage (183).    
 A second group, Fernandes-Alnemri and colleges, identifies the HIN-200 family 
using a NCBI database screen for proteins that contained a PYRIN domain as well as an 
oligonucleotide binding domain (184).  This group narrows the HIN-200 family down to 
AIM2 by over-expressing the human HIN-200 family proteins and finding only AIM2 
could activate caspase cleavage.  This group also finds that overexpressing AIM2 could 
to lead to pyroptosome formation even greater than the known inducer PYRIN (184).  
Pyroptosomes are visual specs found when ASC aggregates in the cytoplasm.  They also 
show that addition of dsDNA to the cytoplasm of cells can cause pyroptosome formation 
in an AIM2 dependent manner.  In addition, they show that both AIM2 and ASC 
oligomerize in pyroptosomes containing dsDNA (184). 
 A third group, Hornung et. al., identifies the HIN-200 family using the PFAM 
database again screening for proteins containing PYRIN domains and known DNA-
binding domains (185).  They find that of the human HIN-200 proteins, only AIM2 is 
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primarily located in the cytosol, and overlaps microscopically with ASC in co-
overexpression of fluorescently-tagged proteins.  In addition, the pyroptosome formation 
is greatest with AIM2 overexpression, and immunoprecipitation for ASC could only pull 
down AIM2.  Cell viability is also monitored and knockdown of AIM2 results in less 
dsDNA-induced cell death, using vaccinia virus (a dsDNA virus) and poly dA:dT 
transfection (185).  Finally, they show that AIM2 uses its HIN domain to bind dsDNA 
(185).  Taken together these studies provide overwhelming evidence that AIM2 is critical 
for detecting cytoplasmic dsDNA and inducing inflammasome and pyroptosome 
formation, caspase-mediated cell death, and primed IL-1β cleavage.  
 
1.4b p202 expression and function 
 p202 was first described as a protein that was upregulated after IFN stimulation 
(186).  The gene encoding p202, ifi-202, is about 1338 base pairs long and encodes a 
protein of 445 amino acids (NCBI database).  By Northern blot analysis, p202 is 
expressed in heart, brain, spleen, liver, skeletal muscle, and kidney, but is absent from 
lung and testes (187).  p202 is also expressed in fibroblast cell lines, MФ, and DC (188-
190).  As with all of the HIN-200 family members, p202 is upregulated by IFN; however 
it has also been shown in various types of cells to be upregulated with IL-6 and LPS (190, 
191).  
Interestingly, serum growth factors appear to negatively regulate p202 expression 
(188).  When in reduced serum conditions, cells upregulated p202, arrest the in G1 phase, 
and activation of the transcription factor AP-1 is increased.  As there is an AP-1 binding 
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site in the p202 promoter, thus, it makes sense that reduced serum growth factors would 
upregulate p202.   
 In addition to AP-1, two other putative binding domains have been identified in 
the p202 promoter.  These include Stat3 and E2F1 binding sites.  IL-6 is a known 
activator of Stat3 phosphorylation and subsequent translocation to the nucleus (192).  
Binding of Stat3 to the ifi-202 promoter is increased upon IL-6 stimulation, and mutation 
of this site resulted in a decrease in ifi-202 promoter induced luciferase expression (191).  
E2F1 is identified as a transcriptional regulator of ifi-202 as p202 is found to be elevated 
in E2F1 knock-out mouse embryonic fibroblasts (193).  Interestingly, E2F1 appears to be 
negatively regulated by p202 because increased expression of p202 results in decreased 
expression of E2F1 and its target genes (193).   
 Like all of the HIN-200 family members, p202 has a DNA-binding domain. 
Although, direct binding of p202 to promoters has not been established, p202 modulates 
a number of transcription factors (194, 195).  For example, p202 binds AP1, cFos and 
cJun and inhibits their transcriptional activity (195).  In addition to its interaction with 
AP-1 transcription factors, p202 binds NF-κB p65 and p50 and inhibits transcriptional 
activity of NF-κB (195).  Two subsequent studies investigate the modulation of NF-κB 
activity by p202.  Using fibroblasts overexpressing p202, p202 inhibits the 
transactivation complex of p65/p50 NF-κB binding while enhancing inhibitory p50/p50 
NF-κB binding to DNA (194).  A subsequent study investigates p202 in DC from the 
SLE mouse model NZB/W F1.  This study shows that expression of p202 correlated to 
enhanced LPS stimulated IL-12, IL-6, IL-10, and TNFα production (190).  In addition, 
knock down of p202 in a MФ cell line showed decreased expression of these cytokines 
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(190).  Taken together these studies show that p202 has transcriptional modulation 
capabilities that may be cell type-specific.   
 In addition to its ability to bind and modulate transcription factors, p202 also 
modulates cell cycle and cell death (188, 189, 196, 197).  The first identified binding 
partner of p202 was the retinoblastoma protein(pRb)(176).  p202 has a pRb consensus-
binding sequence of LXCXE and p202 can bind pRb at two distinct locations.  As pRb 
negatively controls cell cycle and proliferation, the authors hypothesize that p202 may be 
binding pRb to modulate cell cycle (176).  Another cell cycle control protein that binds to 
p202 was the p53 binding protein 1(53BP1).  This study uses yeast two-hybrid 
technology to identify p202 and 53BP1 as binding partners and shows that this binding 
was dependent on a histidine in the conserved 200 amino acid region found in a HIN-200 
proteins(187).  As its name states, 53BP1 binds to p53 and thus it is not surprising that 
overexpression of p202 would modulate expression of p53 dependent genes (187).   
 Subsequently, p202 binds to p53’s proline rich region using its C-terminal 
conserved 200 amino acid region (197).  Interestingly UV treatment increases p202 
expression in multiple cell types (196, 197).  Because UV-induced apoptosis is mediated 
by p53, and p202 can bind p53, it is likely that cells expressing high levels of p202 would 
be more resistant to UV-induced apoptosis (196, 197).  
 In addition to the role of p202 in the suppression of p53-mediated apoptosis, a 
recent study implicates p202 in suppression of intracellular dsDNA-induced apoptosis.  
Roberts et. al. first demonstrates that intracellular dsDNA could induce apoptosis in a 
concentration and fragment size dependent manner.  p202 binds and co-localizes to 
dsDNA in a manner that was dependent on DNA fragments being larger than 100 bp.   In 
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addition, using siRNA knock-down of p202, they show that p202 could prevent the 
activation of the inflammasome, thus preventing caspase1 and 3 cleavage(189).  This 
study also shows that p202 co-localizes with dsDNA in the cytoplasm in small aggregates 
unlike the large specs(pyroptosomes) formed by dsDNA and AIM2 (183-185, 189).  In 
addition, when p202 is highly expressed as in NZB MФ, there is less caspase1 and 3 
cleavage (a measure of cell death) as compared to C57BL/6 MФ which  p202 expression 
is low (189).  Taken together, the studies provide a model in which the ratio of p202 and 
AIM2 in a cell dictates whether the cell will live or die in response to intracellular 
dsDNA.   
 
Summary 
 The literature presented above provides a detailed introduction to the TAM 
family, responses to infectious agents and apoptotic cells, as well as SLE.  Since Mertk is 
expressed on APC and mice lacking Mertk manifest an SLE-like autoimmune disease, 
these mice provide a unique opportunity to investigate SLE disease in a model in which 
only one gene is mutated, mertk, and that gene is not normally expressed on T or B cells.  
Subsequent chapters of this dissertation investigate 1) the role of the TAM family in the 
phagocytosis and killing of bacteria, 2) the increased peritoneal cells found in mice 
lacking Mertk, and 3) the ability of Mertk to regulate cytoplasmic dsDNA-induced cell 
death through the p202.  The overall hypothesis is that Mertk regulates innate immune 
responses by MФ.  Application of knowledge gained from this dissertation may provide 
novel insights towards mechanisms of autoimmunity and may advance treatments for 
SLE.   
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Abstract 
 Many receptors that are employed for the engulfment of apoptotic cells are also 
used for the recognition and phagocytosis of bacteria.  Tyro3, Axl, and Mertk (TAM) are 
important in the phagocytosis of apoptotic cells by macrophages.   Animals lacking these 
receptors are hypersensitive to bacterial products.  In this report, we examine whether the 
TAM receptors are involved in the phagocytosis of bacteria.  We found that macrophages 
lacking Mertk, Axl, Tyro3 or all three receptors were equally efficient in the 
phagocytosis of Gram-negative E. coli.  Similarly, the phagocytosis of E. coli and Gram-
positive S. aureus bioparticles by macrophages lacking TAM receptors was equal to 
wild-type.  In addition, we found that Mertk did not play a role in killing of extracellular 
E. coli or the replication status of intracellular F. tularensis.  Thus, while TAM receptors 
may regulate signal transduction to bacterial components, they are not essential for the 
phagocytosis and killing of bacteria.   
 
Keywords: Macrophage, E. coli, Mertk, Axl, Tyro3, phagocytosis 
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Introduction 
During the course of a bacterial infection, innate immune cells such as neutrophils 
and macrophages sense bacteria and bacterial products via pathogen-associated molecular 
patterns (PAMPS) such as lipopolysaccharide (LPS) or peptidoglycan.   PAMPs are 
recognized by several pattern recognition receptors on innate immune cells, including the 
Toll-like receptors (TLR)(57).  Following recognition, the resident cells release pro-
inflammatory cytokines and chemokines to recruit neutrophils and additional 
macrophages to the lesion.  These responding neutrophils and monocytes arrive equipped 
as professional phagocytes to quickly ingest and kill the invading bacteria.  This rapid 
immune response and phagocytosis of bacteria is critical to the resolution of a bacterial 
infection.    
Many other receptors are implicated in the recognition and phagocytosis of 
bacteria including: Scavenger receptor A, Mannose receptor, TLRs, integrins, as well as 
Fc receptors and complement receptors(70, 72). Upon binding of bacteria, these receptors 
signal a rearrangement of the actin cytoskeleton that is mediated by the Rho family of 
GTPases, Rac, Rho, and Cdc42, ultimately leading to engulfment of the bacteria(63).  
One indication of the importance of these molecules is evident in that some bacteria 
attempt to evade phagocytosis by producing molecules that modulate the signaling to and 
from the Rho GTPases (198, 199).   
 Phagocytosis is not only important for controlling infection, it is also key in 
down-regulating inflammation and limiting tissue damage by returning the infected area 
to proper homeostasis.  This is partly accomplished by the phagocytosis of apoptotic 
cells.  As bacteria grow and/or infect cells, these cells often succumb to the infection and 
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die, either indirectly by toxic bacterial by-products or directly by intracellular pathogens.  
For example, neutrophils have been shown to become apoptotic after treatment with E. 
coli(200).   Apoptosis is a form of cell death that has been well characterized and 
includes exposure of phosphatidylserine from the inner membrane to the outer surface of 
the dying cell.  Subsequently, these apoptotic cells are cleared from the infected area 
typically by macrophages.  Interestingly, many of the same receptors that facilitate 
phagocytosis of bacteria are also important for the phagocytosis of apoptotic cells 
including CD14, Scavenger receptor A, Fc Receptor, complement, and integrins(74, 75).   
The Tyro3/Axl/Mertk (TAM) receptors have been shown to be required for 
efficient phagocytosis of apoptotic cells (18, 28).  All three receptors are expressed by 
macrophage and dendritic cells(DC), however, Mertk is also expressed by NK cells, but 
is not expressed on neutrophils or non-malignant lymphocytes(7, 18, 201).  These 
proteins are receptor tyrosine kinases that are similar in structure and function.  Each 
family member has two Ig-like and two fibronectin III-like extracellular domains, as well 
as a characteristic KWAIAES sequence in the intracellular domain(7, 8).  In 
macrophages, Mertk is essential for rapid ingestion of apoptotic cells(28); though Axl 
and Tyro3 are partly involved(18).  In contrast, Axl and Tyro3 appear to function in DC 
and Mertk has no role in phagocytosis although the process is much slower(18, 
29).Knock-out mice have been generated for all three family members(35, 39).  The 
inability to properly clear apoptotic cells in these knock-out mice results in the 
development of a lupus-like autoimmunity characterized by autoantibody production as 
well as splenomegaly(28, 29, 43).  Gas6, a ligand for the TAM family members, binds 
these receptors with a relative affinity of Axl>Tyro3>>Mertk(20). Gas6 is produced by 
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several cell types including macrophages, DC and apoptotic thymocytes(18, 19).  
Another ligand for the family member Tyro3 is the serum protein, Protein S (15).  Both 
Gas6 and Protein S bind phosphatidylserine on apoptotic cells and it is through this 
molecular bridging interaction that the TAM family members bind apoptotic cells(202).   
In addition, to their role in phagocytosis of apoptotic cells, the TAM family 
members have also been shown to have a role in the innate immune response.  Mice 
lacking functional Mertk (mertk-/-) are hypersensitive to Gram-negative bacterial LPS and 
are susceptible to endotoxic shock that is mediated by prolonged NF-κB activity resulting 
in over production of TNFα(35).  This regulation of NF-κB by Mertk shown in 
macrophages has been corroborated in DC and the phagocytosis of apoptotic cells by DC 
appears to be important for self tolerance in a model of diabetes(36)   Furthermore, 
knock-out mice lacking all three TAM family members (TAM-/-) mice also displayed an 
increase in serum TNFα levels following LPS injection(43) and DC from TAM-/- mice 
have been shown to have hyper-immune responses to TLR ligands(40).    Interestingly 
Axl and Interferon receptor appear to cooperate to modulate STAT inhibiting the innate 
immune response to TLR mediated activation by the induction of SOCS1(40).   However 
in these studies, the response to whole bacteria and importantly, phagocytosis of bacteria 
was not thoroughly examined.   
Previous studies that have investigated the involvement of TAM receptors in 
phagocytosis of bacteria have provided conflicting results(28, 43).  Macrophages isolated 
from mertk-/- mice were shown to phagocytize the Gram-positive bacterium L. 
monocytogenes similarly to wild-type(28).  However, the TAM-/- macrophages displayed 
an increased ability to phagocytize Gram-negative E. coli(43).    
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Based on the importance of TLRs for phagocytosis, the ability of the Mertk to 
regulate LPS signaling, and the increase in phagocytosis of E. coli by the TAM-/- 
macrophages, we sought to determine whether Mertk regulated phagocytosis of the 
Gram-negative bacterium, E. coli.  In this study we demonstrate, by multiple methods, 
that individually or collectively the TAM family members are not essential for 
phagocytosis of E. coli by thioglycollate-elicited macrophages.  In addition, we show that 
individual TAM receptors are also not important for phagocytosis of bacteria by resident 
and bone marrow-derived macrophages.  Complementary to the lack of a role in 
phagocytosis, we show that Mertk is not essential for killing of E. coli or modulation of 
growth of the intracellular pathogen F. tularensis.   
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Materials and Methods 
Animals 
 Mice were housed in a specific pathogen-free facility and maintained according to 
the UNC-Chapel Hill Institutional Animal Use and Care Committee guidelines.  mertk-/- 
mice were developed here at UNC. mertk-/- is the updated nomenclature which was 
described previously as merkd or mertkkd(18, 28).  Although the cytoplasmic kinase 
domain was targeted, the lack of protein expression makes these mice null for Mertk.  
axl-/-, and tyro3-/- mice were kindly provided by Dr. Stephen P. Goff  (Columbia 
University, New York) and Dr. Greg Lemke (Salk Institute for Biological Studies, San 
Diego) respectively.  TAM-/- mice were generated by breeding of backcrossed single 
knock-outs.  All genotypes were backcrossed at least 6 generations to the C57BL/6J 
background.  Male mice 8-12 weeks old were used in all studies.  Wild-type mice used 
were strain C57BL/6J.     
Macrophages 
 Thioglycollate-elicited macrophages were obtained as previously described(28).  
Briefly, 3 mL of 3% thioglycollate was injected intraperitoneally (I.P.) 3 days prior to 
harvest by peritoneal wash in PBS.  Cells were washed 3 times in PBS and allowed to 
adhere for 3 hours in media (RPMI 1640 (Gibco) supplemented with 5% fetal bovine 
serum, 1 mM sodium pyruvate, 2 x 10-5 2-ME, 10 mM HEPES, 50 units penicillin G and 
50 µg/mL streptomycin sulphate).  Non-adherent cells were washed off and fresh media 
was added.  In order to eliminate activity due to stimulation by thioglycollate, 
macrophages were allowed to rest at 37°C 5% CO2 for seven days prior to experimental 
use.   
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Resident peritoneal macrophages were obtained by 60 seconds of gentle 
peritoneal lavage in Versene.  Cells were removed, washed and allowed to adhere onto 
glass coverslips in 24 well plates or plastic tissue culture dishes.  Non-adherent cells were 
washed off which resulted in a highly enriched population of resident macrophages.   
 Bone marrow-derived macrophages were obtained by harvesting bone marrow 
from mouse femurs.  Cells were flushed from femurs, washed and incubated overnight in 
DMEM-H (Gibco) supplemented with 50 units penicillin G, 50 µg/mL streptomycin 
sulphate and 10 mM HEPES.  Non-adherent cells were removed and plated in media 
containing 10 ng/mL recombinant mouse M-CSF (Peprotech).  Fresh media was added 
on day 4.  Macrophages were harvested on day 8 and re-plated at appropriate density for 
experimental use on day 9.  Bone marrow-derived macrophages were confirmed to be 
100% CD11b-positive and 100% CD11c-negative by flow cytometry (data not shown).   
Phagocytosis Assays 
 Phagocytosis assays were preformed using a MOI of 10 E. coli 0111:B4 (ATCC) 
transformed with green fluorescent protein plasmid (pEGFP; Clontech).  Green 
fluorescent protein (GFP)-containing E. coli (E. coli O111:B4-GFP) were added to 
antibiotic-free, serum-free media and aliquoted into wells containing macrophages on 
glass coverslips.  Macrophages were allowed to phagocytize bacteria for the indicated 
time periods.  Macrophages were then washed 5 times in PBS and 0.2% trypan blue was 
added to wells to quench fluorescence from extracellular bacteria.  Cells were then fixed 
in 2% paraformaldehyde and coverslips were mounted on slides with Vectamount 
mounting media for fluorescence (Vector). Phagocytosis was determined by overlays of 
bright field and GFP images captured using an Olympus fluorescent microscope 
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equipped with a DP70 digital camera and Image Pro Plus software (Opelco).  At least 100 
macrophages were counted per time point with triplicate samples per genotype.   
 Fluorimetric phagocytosis assays were also preformed.  Briefly, cells were 
plated in 96 well plates and a MOI of 10 bacteria in serum-free and antibiotic-free media 
was added to each well.  After indicated time periods, cells were washed as described 
above and trypan blue was added to quench any extracellular fluorescence.  Plates were 
then read on a Fluoroskan Ascent FL fluorimeter (Thermo Labsystems) according to 
manufacturers instructions.  E. coli and S. aureus Bioparticles used for fluorimetric 
assays were obtained from Molecular Probes.  Normalized fluorescent intensity was 
calculated by obtaining a ratio of fluorescent cell tracker green-labeled wild-type 
macrophages to mertk-/- macrophages (measured in separate wells) and multiplying this 
ratio to the ingested bacterial bioparticle fluorescence.   
 In addition, phagocytosis assays were performed and analyzed by flow cytometry.  
For these experiments, cells were plated in 60 mM dishes and a MOI of 10 bacteria in 
serum-free, antibiotic-free media was added for indicated time periods.  Cells were then 
washed and trypan blue was added as previously described.  Cells were then fixed and 
analyzed using a BD FACScan flow cytometer.   
Apoptotic Cells 
 Apoptotic cells were harvested as previously described (18).  Briefly, thymi from 
4-6 week old wild-type mice were harvested and tissues were mechanically dissociated 
using forceps.  Cells were then washed and incubated in media containing 2 µM 
Dexamethasone.  After 5 hours, Cell tracker Orange (Molecular Probes) was added to 
thymocytes for 30 minutes according to manufacturer’s instructions.  Cells were then 
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washed in 1x PBS and then allowed to incubate in media for 30 minutes prior to 
experimentation.    
Bactericidal Assays 
 Thioglycollate-elicited macrophages were plated and rested as described above.  
Cells were washed 3 times with PBS to remove media containing antibiotics.  MOI of 10 
E. coli O111:B4-GFP was added to wells.  After 30 minutes 5 µg/mL gentamicin was 
added to each well to kill extracellular bacteria.  After the allotted times, cells were 
harvested by scraping in PBS and plated in serial dilutions on LB agar containing 
ampicillin to select only E. coli O111:B4-GFP. 
Gentamicin protection assays 
All Francisella tularensis Live Vaccine Strain (LVS) gentamicin protection 
assays were performed under appropriate bio safety precautions.  Approximately 105 
bone marrow-derived macrophages were plated per well in a 96-well tissue culture dish.  
Bacteria were added at a multiplicity of infection of 10:1 or 100:1 in a volume of 100 μL 
per well.  Supernatants were aspirated and replaced with media containing gentamicin 
(25 μg/mL) to kill extracellular bacteria at 4 hours post-inoculation. Six and 24 hours 
post-inoculation, cells were rinsed with 1x PBS and scraped from the wells with sterile 
wooden applicator sticks, vortexed, diluted, and plated onto chocolate agar for bacterial 
recovery.  All gentamicin protection experiments were performed in triplicate and the 
mean and standard deviations were calculated. 
Statistics 
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 Statistics were performed using Graph Pad Prism Software.  Where appropriate 
students t-test or 2-way ANOVA with Bonferroni’s post-tests were performed.  A p value 
of less than 0.05 was considered significant.    
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Results 
 While a role for the TAM receptors in phagocytosis of apoptotic cells has been 
well documented(18, 28), their participation in phagocytosis of bacteria remains 
controversial.  To determine if the TAM receptors play a role in the phagocytosis of 
bacteria, thioglycollate-elicited macrophages were harvested from wild-type, mertk-/-, axl-
/-, tyro3-/-, axl-/-/tyro3-/- double knock-outs and TAM-/- triple knock-out mice and exposed 
to E. coli O111:B4-GFP for one hour.  No significant differences were found in terms of 
the number of cells that had phagocytized at least one bacterium (percent phagocytosis, 
Figure 2.1A).   In contrast, macrophages from mertk-/- and axl-/-/tyro3-/- mice harvested at 
the same time were deficient in phagocytosis of apoptotic cells similar to previous 
publications, and documented for the first time, this deficiency was most apparent when 
all three receptors were lacking (Figure 2.1B).  To determine whether one strain was 
phagocytizing more bacteria on a per cell basis, we also performed a phagocytic index.  
The phagocytic index was calculated as the total number of bacteria ingested by 100 
cells.  In corroboration of the percent phagocytosis results, the total number of bacteria 
ingested was similar between strains tested across the time course (Figure 2.1C).  Thus, 
despite the importance of Mertk, and to a lesser extent Axl and Tyro3, in the 
phagocytosis of apoptotic cells, neither Mertk nor the other family members appear to 
play a prominent role in bacterial engulfment.   
To determine whether Mertk could affect phagocytosis of E. coli at earlier time 
points, we preformed a similar experiment using wild-type and mertk-/- thioglycollate-
elicited macrophages and bone marrow-derived macrophages (BMMΦ) from 15 minutes 
to 1 hour.   While phagocytosis proceeded in a time dependent manner for both types of 
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macrophages, there were no statistically significant differences between wild-type and 
mertk-/- strains in percent phagocytosis (Figure 2.2A) or phagocytic index (Figure 2.2B).    
Interestingly, though independent of genotype, the thioglycollate-elicited macrophages 
were found to be significantly more active in phagocytosis of bacteria compared to 
BMMΦ by 2- way ANOVA in percent phagocytosis and phagocytic index (Figure 2.2A 
and B).   
 Since the macrophages used in the previous study were either thioglycollate-
elicited or derived in vitro with cytokines, we wanted to confirm our results using 
resident peritoneal macrophages.  Unlike BMMΦ, resident peritoneal macrophages 
phagocytize similarly to thioglycollate-elicited macrophages.  However, there still 
remained no differences in phagocytosis of E. coli between wild-type and mertk-/- 
macrophages.  In addition to mertk-/-, macrophages from axl-/- and tyro3-/- single knock-
out mice also showed no statistical differences in percent phagocytosis when compared to 
wild-type resident macrophages (Figure 2.3).   
 To confirm that phagocytosis was indeed similar between wild-type and mertk-/- 
macrophages, we also assessed the phagocytosis of E. coli O111:B4 GFP by 
thioglycollate-elicited macrophages using a flow cytometry-based approach.  This 
approach allows for a large scale analysis of the amount of phagocytosis that is taking 
place.  As the cells phagocytize bacteria, they accumulate GFP, become fluorescent and 
are therefore detectable by flow cytometry.  As shown in Figure 2.4, the number of 
fluorescent thioglycollate-elicited macrophages increased rapidly with time; however, 
similar to our previous findings, wild-type, mertk-/-, and TAM-/- macrophages showed 
similar numbers of cells containing fluorescence at all time points tested.  In addition, 
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even at 120 minutes a few cells did not become fluorescent indicating that not all 
macrophages will phagocytize a bacterium (Figure 2.4).   
E. coli O111:B4 is known to be an extracellular bacteria that deliberately prevents 
phagocytosis and forms pedestals on the gut epithelial cells which it normally 
encounters(203).  To rule out a role for this process and lack of an effect by Mertk on 
phagocytosis of bacteria, we performed a phagocytosis assay using E. coli bioparticles.  
Bioparticles are chemically or heat-killed bacteria that are fluorescently labeled and thus 
easily detected by a fluorimeter.  E. coli bioparticles were phagocytized similarly by both 
wild-type and mertk-/- thioglycollate-elicited macrophages (Figure 2.5A).  Thus, 
regardless of whether the E. coli were alive or dead; their phagocytosis was unimpaired 
in wild-type or mertk-/- macrophages.  Since components of Gram-positive and Gram-
negative bacteria are recognized by different TLRs, we wanted to demonstrate that our 
results were not specific to Gram-negative bacteria.  Therefore, we performed the same 
phagocytosis assay using Gram-positive S. aureus bioparticles.  As with the E. coli, wild-
type and mertk-/- macrophages phagocytized S. aureus bioparticles equally (Figure 2.5B).  
Therefore, Mertk is not essential for phagocytosis of bacterial bioparticles regardless of 
Gram status.   
Previous reports indicate mertk-/- macrophages produce greater amounts of TNFα 
in response to E. coli LPS(35).  Thus, we hypothesized that after phagocytosis these 
hyper-activated macrophages may be more efficient at bacterial killing than wild-type.  
To determine if the lack of Mertk affected the ability of the macrophages to kill bacteria, 
we performed a bactericidal assay using the naturally extracellular E. coli O111:B4 GFP 
used in previous experiments.  As shown in Figure 2.6A, mertk-/- macrophages ingested 
 53
and killed the bacteria equally to wild-type macrophages over a 6 hour period.  Thus, 
Mertk does not inhibit or enhance the ability of the macrophage to kill this strain of 
bacteria.   
We further examined whether the presence or absence of Mertk would affect the 
killing of intracellular pathogens that replicate in the cytoplasm.   Francisella tularensis 
is a Gram-negative facultative bacterium that is able to escape the phagolysosome and 
replicates in the cytosol of the host cells such as macrophages(204).   F. tularensis is able 
to down-regulate phagocytosis and TLR signaling and inhibits apoptosis of macrophages 
which appears to provide an advantage in propagation of the bacterium.  As shown in 
Figure 2.6B and C, F. tularensis Live Vaccine Strain (LVS) had similar replication 
kinetics in mertk-/- and wild-type macrophages at two different MOIs.  These data suggest 
that Mertk  does not affect the ability of the macrophage to slow intracellular replication 
or kill bacteria.   
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Discussion 
 Many receptors including CD14, scavenger receptor, integrins, complement 
receptors and Fc receptors recognize and participate in the phagocytosis of apoptotic cells 
as well as bacteria(72-74).  The Tyro3, Axl, and Mertk (TAM) family of receptors has 
been shown to be important for the phagocytosis of apoptotic cells(18, 28).  Previous 
studies have found conflicting evidence for the role of the TAM receptors in the 
phagocytosis of bacteria(28, 43).  Our past findings suggested that the Mertk receptor did 
not play a critical role in the phagocytosis of the Gram-positive bacteria L. 
monocytogenes by macrophages(28).  This study used live L. monocytogenes and this 
intracellular bacteria  can invade host cells independent of phagocytosis(205).  As such, it 
is possible that the results from this study were merely a consequence of the bacteria 
being equally able to invade cells in the presence or absence Mertk.  A second study used 
only the TAM triple knock-out macrophages and examined phagocytosis of the Gram-
negative bacteria E. coli (43).  In this study, the investigators found that phagocytosis of 
bacteria was increased over 3-fold in the TAM-/- cells; however, these cells were derived 
from mice with a heterogeneous background of founder genes that may have influenced 
the phenotype.   
In this report, we find that macrophages from mertk-/-, axl-/-, tyro3-/-, axl-/-/tyro3-/- 
double knock-outs and TAM-/- triple knock-out mice on the C57BL/6 background ingest 
E. coli bacteria equally to wild-type macrophages (Figure 2.1, 2.2, 2.3, 2.4).  Our current 
findings that TAM family members do not play a role in phagocytosis of E. coli is in 
contrast to a previously published report(43).  Furthermore, we examined the 
phagocytosis of S. Aureus and found Mertk does not affect the engulfment of Gram-
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positive bacteria, corroborating our past finding with L. monocytogenes(28).  
Interestingly prior exposure of macrophages to apoptotic cells significantly reduced the 
phagocytosis of bacteria; however this process too was independent of the TAM family 
members as knock out macrophages also could not ingest bacteria after treatment with 
apoptotic cells (data not shown).  It is plausible that apoptotic cells bind multiple 
receptors that share recognition of bacterial components such as complement receptors, 
Scavenger Receptor or CD14 and these could be acting as competitive ligands that 
prevent macrophages from recognizing the bacteria.  Nonetheless, our results strongly 
suggest that Mertk and the family members, Axl and Tyro3 are not essential for the 
engulfment of Gram-positive or Gram-negative bacteria.  It is likely that other receptors 
present on macrophages that recognize microbial molecular components may compensate 
for the lack of TAM receptors.    
 We also examined the role of Mertk on three populations of macrophages in the 
event that different populations might use the TAM receptors preferentially. We show 
fewer bone marrow-derived macrophages (BMMФ) were phagocytic for bacteria 
compared to thioglycollate-elicited macrophages (Figure 2.2).  Even though the 
thioglycollate-elicited macrophages were rested prior to phagocytosis for 7 days, the data 
suggests that they phagocytize in greater numbers than BMMФ.  For example, at the one 
hour time point, about 65% of wild-type thioglycollate-elicited macrophages had 
engulfed at least one bacterium as compared to only about 45% of the wild-type BMMΦ 
(Figure 2.2).  Interestingly resident unstimulated macrophages ingest E. coli similar to 
thioglycollate macrophages (Figure 2.3).  These results point to the possibility that 
different macrophage inducing agents produce different phagocytic activities among 
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macrophages.  Those collected after thioglycollate exposure tend to be more phagocytic 
whereas BMMФ may be more differentiated and less phagocytic.   
Since mertk-/- macrophages produce elevated TNFα in response to LPS (8), we 
hypothesized that macrophages from these mice may be able to kill bacteria more 
efficiently.  As we showed in Figure 2.6A, the lack of Mertk had no effect on the ability 
of the macrophage to kill the naturally extracellular pathogen E. coli.  In addition, we 
examined a similar scenario using an intracellular pathogen, F. tularensis LVS.  F. 
tularensis is Gram-negative bacterium that is able to escape the phagolysosome and 
replicate in the cytosol of macrophages (204).  We examined the ability of the 
macrophages lacking Mertk to inhibit this replication.  As with the E. coli, we saw no 
difference in the replication of F. tularensis LVS between the mertk-/- and wild-type 
macrophages (Figure 2.6B and C).  Thus, Mertk also does not play an essential role in 
inhibition of replication or killing of bacteria.   
In summary, while previously published data document a role for TAM receptors 
in response to bacterial by products, we demonstrate that Mertk, Axl, and Tyro3 appear 
to have no essential role in the phagocytosis of Gram-negative or Gram-positive bacteria 
or in the killing of extracellular or intracellular bacteria.  This is in contrast to our 
previous understanding of TAM receptors in bacterial clearance.   
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 Figure 2.1. TAM receptors are not required for the phagocytosis of E. coli O111:B4 
GFP by macrophages.  A, Phagocytosis assay using MOI of 10 E. coli O111:B4 GFP by 
thioglycollate-elicited macrophages from wild-type (WT), mertk-/-(M-/-), axl-/-(A-/-), and 
tyro3-/-(T-/-), axl-/-/tyro3-/-(AT-/-), and TAM-/- mice. B, In vitro phagocytosis assay of 
apoptotic cells 10:1 to thioglycollate-elicited macrophages from wild-type (WT), mertk-/-
(M-/-), axl-/-/tyro3-/-(AT-/-), and TAM-/- mice. C, Phagocytic index calculated as number of 
bacteria phagocytized by 100 cells from samples in 1A.  Figures are mean and standard 
error, n=3 and representative of at least 2 separate experiments.  * p<0.01 by students t 
test vs. wild-type.  A and C are not statistically significant by one-way ANOVA or post 
test. 
 
Figure 2.2.  Phagocytosis of E. coli O111:B4 is time dependent and Mertk independent 
in thioglycollate-elicited and bone marrow-derived macrophages 
A, In vitro phagocytosis assay using a MOI of 10 E. coli O111:B4 GFP by thioglycollate 
and BMMΦ from wild-type and mertk-/- mice, over a time course of 15 to 60 minutes.  B, 
Phagocytic index was calculated as number of bacteria phagocytized by 100 cells from 
samples in A.   Figures are mean and standard error, n=3 and representative of at least 2 
separate experiments.  No statistically significant differences were found between 
genotypes of either cell type by 2 way ANOVA for both panel A and panel B.   
Statistically significant differences were found between BMMΦ and thioglycollate-
elicited macrophages by 2 way ANOVA in both genotypes p<0.0001 for 2. 2A.  
Bonferroni’s post tests also show significance between wild type BMMΦ and 
thioglycollate-elicited macrophages at 30, 45, and 60 minutes p<0.01 for figure 2.2A.  
 59
Statistical significance was also found by Bonferroni’s post test between mertk-/- BMMΦ 
and thioglycollate-elicited macrophages at 30 and 60 mins p<0.05 and 0.001 respectively 
for Figure 2.2A.   For Figure 2.2B statistically significant differences were found between 
BMMΦ and thioglycollate-elicited macrophages by 2-way ANOVA in wild-type and 
mertk-/- p<0.0001, p<0.05 respectively.  Post tests indicate significance at the 45 and 60 
minute time points for wild-type, p<0.001.   
 
Figure 2.3 Phagocytosis of E. coli O111:B4 is similar in thioglycollate and resident 
peritoneal macrophages.  In vitro phagocytosis assay of MOI of 10 E. coli O111:B4 GFP 
and thioglycollate (□) and resident peritoneal (■) macrophages from wild-type (WT), 
mertk-/-(M-/-), axl-/-(A-/-), and tyro3-/-(T-/-). Figures are mean and standard error, n=3 and 
representative of at least 2 separate experiments.  No statistically significant differences 
found between genotypes or cell types by one-way ANOVA.   
 
Figure 2.4. In vitro phagocytosis assay by flow cytometry.  A time course of 30 to 120 
minutes was used to examine the phagocytosis of MOI of 10 E. coli O111:B4 GFP by 
wild-type, mertk-/-, and TAM-/-  thioglycollate-elicited macrophages.  Data is 
representative of 2 separate experiments  
 
Figure 2.5.  Lack of affect in mertk-/- macrophages is not dependent on Gram status.  In 
vitro phagocytosis assay of E. coli (A) and S. aureus (B) bioparticles at a ratio of 10:1 by 
wild-type (□) and mertk-/- (■) thioglycollate-elicited macrophages.  Bioparticles were 
incubated over a time course of 15-120 minutes.  Groups at each time point are mean and 
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standard error of n=4, and is representative of 3 experiments.  No statistically significant 
differences were found between genotypes by 2-way ANOVA. 
 
Figure 2.6.  Killing and replication of bacteria are not Mertk dependent.  A, In vitro 
bactericidal assay of E. coli O111:B4 GFP by thioglycollate-elicited wild-type (■) and 
mertk-/- (▲) macrophages was conducted over a 6 hour time course and at a MOI of 10:1.  
B and C, In vitro gentamicin protection assay was used to examine the killing of the 
intracellular pathogen F. tularensis at a MOI of 10 (B) or MOI of 100 (C) by wild-type 
(□) and mertk-/- (■) BMMΦ. Each bar is the mean and standard deviation of triplicate 
wells, n=3 and is representative of 3 separate experiments.  No statistically significant 
differences were between genotypes found by 2-way ANOVA.  
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Abstract 
The peritoneal cavity is recognized as an important site for autoreactive B cells 
prior to their transit to other immune tissues; however, little is known of the genes that 
may regulate this process.  Mice lacking the receptor tyrosine kinase Mertk display a 
lupus-like autoimmune phenotype with splenomegaly and high autoantibodies titers.  
Here, we investigate whether Mertk regulates the composition of peritoneal cells that 
favor an autoimmune phenotype.  We found an increase in the number of macrophages, 
DC, plasmacytoid DC, T cells and B cells in the peritoneal cavity of mertk-/- mice when 
compared to wild type mice. This disparity in cell numbers was not due to changes in cell 
proliferation or cell death.  In adoptive transfer experiments, we showed an increase in 
migration of labeled donor cells into the mertk-/- peritoneal cavity.  In addition, bone 
marrow chimeric mice showed hematopoietic-derived factors were also critical for T cell 
migration.  Consistent with this migration and the increase in the number of cells, we 
identified elevated expression of CXCL9, its receptor CXCR3, and IL-7 receptor on 
peritoneal cells from mertk-/- mice.   This control of peritoneal cells numbers correlated 
with autoantibody production and was exclusively attributed to Mertk since mice lacking 
other family members, Axl or Tyro 3, did not display dysregulation in peritoneal cell 
numbers or the autoimmune phenotype.  
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Introduction 
The peritoneal cavity is a site of leukocyte colonization in which the development 
and regulation of immune cells is poorly understood.  The peritoneal cavity is similar to a 
lymph node in that some cells reside in the cavity while others are transient, passing 
through enroute to other targeted tissues.  Immune cells found in the peritoneal cavity 
include, macrophages, T cells, B cells, NK cells, mast cells and dendritic cells (DC)(206, 
207).  This heterogeneous population of cells is involved in both innate and adaptive 
immunity.  While macrophages may be the predominant cell type of the peritoneal cavity, 
the B1-B cell is the largest lymphocyte population in this location.  Peritoneal B1-B cells 
are the primary secretor of serum IgM, which targets pathogen associated molecular 
patterns (PAMPs)(167, 208).  B1-B cells can also produce low affinity autoantibody and 
their development and regulation has been the focus of autoimmune disease models (167, 
209).  Increases in B1-B cells are found in human autoimmune diseases as well as the 
NZB/NZW mouse model of lupus (167, 210).    
More recently, an additional murine model of autoantibody production and lupus 
is found in the mertk-/- mice.  Mice lacking Mertk as well as mice lacking all three 
receptor family members, Tyro3, Axl, and Mertk, (TAM-/-) display a lupus-like 
autoimmune phenotype characterized by splenomegaly and dysregulated lymphocyte 
activation as well as high auto-antibody titers to dsDNA, ssDNA, nucelosomes, 
chromatin and Smith antigen (Sm) (28, 29, 37, 43).  Also, 2-12H/mertk-/- transgenic mice 
display increased numbers of peritoneal B1-B cells as compared to 2-12H transgenic 
mice with wild-type Mertk (172).  Furthermore, Sm-specific B cells injected into the 
peritoneal cavity of mertk-/- mice become activated, and are selectively lost.  This loss is 
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most likely due to differentiation and migration to the lamina propria and mesenteric 
lymph node (172).  Lastly, ablation of peritoneal B-1 cells abrogated autoantibodies in 
autoimmune-prone mice (168).  These studies suggest the peritoneal cavity is an 
important transit site as autoreactive B cells migrate through prior to entering terminal 
immune sites.   
Mertk is a receptor tyrosine kinase found on macrophages, DCs, and natural killer 
cells as well as other non-hematopoietic cells, however T and B lymphocytes lack 
expression under normal conditions (1, 7, 23, 201).  Mertk is a member of the 
Tyro3/Axl/Mertk (TAM) family of receptors.  This family of receptors is characterized 
by an extracellular domain containing two Ig like and two fibronectin III like motifs and 
by an intracellular kinase domain with a characteristic KWIAIES motif (7, 8).  Gas6 is a 
ligand for all three family members with a relative binding affinity of 
Tyro3>Axl>>Mertk (20).  Gas6 is produced by macrophages and can also be found pre-
bound to apoptotic thymocytes (18, 19).  In addition to Gas6, Protein S, has also been 
identified as a ligand for this family (15, 18).  These ligands bind phosphatidylserine 
which is exposed on the outer-membrane of apoptotic cells and provide a molecular 
bridge to the TAM family members.  This subsequently triggers the phagocytosis of 
apoptotic cells by macrophages and dendritic cells, presumably through integrin-
mediated, Rac1-activated signaling (18, 28, 32).   
In addition to a defect in phagocytosis of apoptotic cells, macrophages and DCs 
lacking Mertk are hypersensitive to LPS stimulation, resulting in hyper-activation of NF-
κB and subsequent over-production of TNF-α (35, 36, 43).  Recently, Rothlin et. al. 
presented a mechanism by which the TAM family members cooperate with the type I 
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IFN receptor to induce expression of the suppressor of cytokine signaling 1(SOCS1), 
which regulates TLR signaling and cytokine production (40).  The TNF-α family member 
BAFF is also produced in greater amounts by DCs lacking Mertk or all three TAM 
receptors (37, 40).  This is of particular interest to the autoimmune phenotype of the 
mertk-/- mice as excess BAFF can lead to an increased number of B cells and a propensity 
for autoimmune disease (211-213).  However, DC from mertk-/- mice expressing high 
levels of BAFF did not increase survival of B cells, indicating other factors may be 
contributing (37).   
There has been much speculation as to the reason for the autoimmune phenotype 
of mice lacking the TAM receptors.  It is presumed that the lack of ability to phagocytize 
apoptotic cells results in higher availability of self-antigen and greater priming of 
autoreactive B cells.  However, as in humans, it appears that the autoimmunity in these 
animals is more likely a multi-factorial development of molecular and cellular events that 
lead to a break in tolerance. 
In this report, we hypothesized that the cell populations in the peritoneal cavity 
maybe different in the autoimmune prone mertk-/- mice.  We characterized peritoneal 
exudate cells (PEC) in both wild-type and mertk-/- mice, and found an increase in all 
immune cell types in mertk-/- mice.  We also characterize the activation status of the B 
cell population as well as the subpopulations of the T cells.  We determined that the 
increase in cells was not due to aberrant division or defects in apoptosis, but rather an 
increased propensity for cells to migrate to the peritoneal cavity.  We also determined 
that this migration was independent of cellular development in the mertk-/- mouse and 
show that neither hematopoietic nor non-hematopoietic factors exclusively contribute to 
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this recruitment/migration.  However, T cells are recruited by hematopoietic factors.  We 
identify one chemokine and two receptors that are elevated in the mertk-/- peritoneal cells 
and they may contribute to increases in the migration of cells.  Finally, we show that mice 
lacking Mertk family members, axl-/-, tyro3-/- and axl-/-/tyro3-/- showed no differences in 
resident peritoneal cell numbers compared to wild-type.  Correspondingly, splenomegaly 
and autoantibody production were found only in mertk-/- mice and not other mutant mice. 
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Materials and Methods 
Animals 
 All animals were housed in Specific Pathogen Free facilities according to the 
guidelines of the UNC-Chapel Hill Institutional Animal Use and Care Committee.  mertk-
/- (also known as merkd or mertkkd mice) were generated as previously described(35).  axl-
/- and tyro3-/- were generously provided by Dr. Stephen P. Goff  (Columbia U., New 
York) and Dr. Greg Lemke (Salk Institute for Biological Studies, San Diego) 
respectively.  axl-/-/tyro3-/- mice were bred by crossing axl-/- and tyro3-/- mice.  All 
animals are backcrossed at least 6 generations to C57BL/6J which serves as wild-type in 
all experiments.  Three month old male mice were used unless otherwise indicated.  
Actin-green fluorescent protein (GFP) C57BL/6 transgenic mice were purchased from 
Jackson Labs.  
Resident Peritoneal Exudate Cells (PEC) 
 Mice at indicated ages were euthanized with isofluorane.  Mice were injected i.p. 
with 3mL of Versene, after 60 seconds of peritoneal massage cells were harvested.  Cells 
were washed three times with 1X PBS prior to experimentation.  Total number of cells 
was counted using a hemocytometer and Trypan Blue.   
Flow Cytometry 
 Before antibody labeling, cells were incubated with Fc Block (anti-CD16/CD32) 
from BD biosciences.  Cells were then stained for surface expression using the following 
antibodies, anti-CD19-PE-Cy5, anti-CD5-PE, anti-B220-PE, anti-CD11b-PE-Cy5, anti-
PDCA-1-FITC, anti-CD44-APC, anti-CD62L-PE, and anti-IL7R-PE antibodies are from 
ebioscience.  Anti-CD8-PE, anti-CD11b-FITC, and anti-CD4-FITC are from Caltag.   
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Anti-CD11c-PE or PE-Cy7, anti-CD3-FITC, and anti-I-Ab-FITC are from 
BD/Pharmingen.  Anti-F480-PE-Cy5 was obtained from Serotec.  Anti-CXCR3 antibody 
was obtained from Zymed.  Secondary antibody to detect primary anti-CXCR3 antibody 
was anti-Rabbit-Alexa 405 obtained from Invitrogen.  All washes and staining were done 
with 2% FCS in PBS and samples were analyzed using a Dako-Cyan and Summit 4.3 
software.  At least 15,000 cells were analyzed from each sample.  Total number was 
calculated using percent cells positive for each stain.   
Migration to Peritoneal Cavity 
 Resident PECs were obtained as described previously.  Cells were washed with 
PBS and stained with Cell-Tracker green (Molecular Probes) according to manufacturers 
instructions.  Three million cells were injected in 0.5mL 1X PBS via tail vein of naïve 
recipient mice.  24 hours after injection, cells were harvested from the peritoneal cavity 
using Versene to lavage out cells.  PECs were analyzed by flow cytometry to identify 
percent of Cell Tracker green-positive cells in the collected.  Number of cells migrated 
was then calculated by multiplying the percent Cell Tracker green-positive cells by total 
number harvested.     
Bone Marrow Transplant Chimeras 
 Recipient male mice at 4 weeks of age were lethally irradiated with 800 rads 
using either 137Cs gamma irradiator or X-ray irradiator.  Twenty-four hours post 
irradiation, bone marrow cells were obtained from femurs and tibia of donor mice.  Bone 
marrow cells were treated with red blood cell lysis buffer to remove red cells and 8 x 106 
white cells were injected i.v. into irradiated recipient mice.  Each irradiation experiment 
contained at least one actin-driven eGFP control donor mouse to assess hematopoietic 
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reconstitution of chimeric mice.  Percent reconstitution of chimeric mice at three months 
of age was assessed by quantifying the % GFP+ cells from the bone marrow and the  
peritoneum using flow cytometry.  Reconstitution of chimeric mice with GFP+ cells was 
approximately 90% as expected.   
BrdU Injection and Staining 
 Mice at the indicated ages were injected 24 and 48 hrs prior to harvest with 
0.75mL of 10mg/mL BrdU (Sigma) in 0.9% NaCl to quantify proliferating cells.  Cells 
were harvested and identified by staining with antibodies against cell surface markers.  
Cells were then permabilized using Cytofix/Cytoperm buffer system (BD) and DNase 
treated to expose the BrdU.  BrdU incorporation was visualized by using anti-BrdU-FITC 
antibody from BD.  Cells were analyzed by flow cytometry using a Dako-Cyan and 
Summit 4.3 software. 
Cell Death analysis 
 Resident PECs were harvested as described.  Apoptosis was detected using TACS 
AnnexinV-FITC/PI Apoptosis Detection Kit (Trevigen) according to manufacturer’s 
instructions.  For VAD-FMK staining, VAD-FMK-FITC (Promega) was diluted 1:1000 
in PBS and 0.5mL was injected intraperitoneally 1 hour prior to harvest of resident PEC.  
Both assays were analyzed by flow cytometry using a Dako-Cyan and Summit 4.3 
software. 
Real-Time PCR 
Resident PEC from at least 4 mice of each genotype were pooled and RNA was 
purified according to manufacturer’s instructions using the RNeasy Mini Plus Kit 
(Qiagen).  RNA was quantified and equal amounts were converted to cDNA using 
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Superscript II reverse transcriptase (Invitrogen) using random hexamer primers.  Equal 
amounts of cDNA were used for the Real-Time PCR reaction in 2x Sybr Green buffer 
(Applied Biosystems).  Reactions were conducted in 96 well plates and were performed 
on the ABI 7500 Realtime PCR machine in the UNC Neuroscience Center Expression 
Profiling and SNP Genotyping Core Facilty.  Primers were designed using FASTA 
sequences and primer express software3.0 (Applied Biosystems).  GAPDH was used as 
the internal control.  Primers set used are as follows:  GAPDH, Forward  
TGTGTCCGTCGTGGATCTGA, Reverse CCTGCTTCACCACCTTCTTGA  IL-5, 
Forward AGCACAGTGGTGAAAGAGACCTT, Reverse 
CATCGTCTCATTGCTTGTCAACA. IL-6, Forward CCACGGCCTTCCCTACTTC, 
Reverse TTGGGAGTGGTATCCTCTGTGA.  IL-7, Forward 
GCCATGCCTTCTTGCTTCTC, 
Reverse AGCTATCTGTACCACTGAGTAGAGCATT.  IL-9, Forward 
TTGCCTCTGTTTTGCTCTTCAG, Reverse CCCCATGTGGTGCTGCAT.  IL-10, 
Forward GATGCCCCAGGCAGAGAA, Reverse CACCCAGGGAATTCAAATGC.  
BAFF, Forward CCCAAAACACTGCCCAACA, Reverse 
CTCATCTCCTTCTTCCAGCCTC.  CXCL9, Forward 
AAGTCGTCGTCGTTCAAGGAA, Reverse AAGATTCAGGGTGCTTGTTGGT.  
CXCL13, Forward CCATCATGAGGTGGTGCAAAG, Reverse 
GGACTGTTTCCCCCAGGAA.  CXCL14, Forward GGCCCAAGATCCGCTACA, 
Reverse CAGGCATTGTACCACTTGATGAAG.  LFA, Forward 
CCTGAGGGTGGGCTGGAT, 
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Reverse GCCAATTTCCTCCGGACAT.  PECAM, Forward 
TGACCCAGCAACATTCACAGAT, Reverse CCGCTCTGCACTGGTATTCC.  L-
Selectin, Forward TGACGCCTGTCACAAACGA, Reverse 
GGCTGGCAAGAGGCTGTGT.  CXCR5, Forward CCTTCGCTGGCGTAAAGTTC, 
Reverse CAGCCCAGCTTGGTCAGAA. CXCR3, Forward 
TCGGACTTTGCCTTTCTTCTG, Reverse CTCTCGTTTTCCCCATAATCGT.  IL-7 
Receptor, Forward GCCGCTGTACACAGTGCAA, Reverse 
AACTGTTTCTGGTGGGCTGACT.   
Anti-nucleosome ELISA 
 ELISA plates (Dynatech) coated with 100µL of 40µg/mL histones 
(Immunovision) were incubated overnight at 4°C.  Plates were then washed with boric-
acid buffered saline (BBS) and wells were coated with 100µL of 10µg/mL dsDNA 
(Sigma) in BBS with 0.5%BSA and 0.4% Tween for 3 hrs at room temperature. Wells 
were then washed with BBS.  Samples and standards were loaded and incubated 
overnight at 4°C.  Samples were detected with anti-mouse Ig-alkaline phosphatase and 
developed with p-nitrophenyl phosphate (Sigma).  Wells were read at 405 nM.   
Statistical analysis 
 Statistical analysis was performed using Graph Pad Prism software.  Statistical 
tests used were one way or two-way ANOVA with Bonferroni’s post-tests, or Students t-
test.  The appropriate test was applied to each data set, and the particular test used is 
indicated in the figure legends.
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Results 
In mertk-/- mice, there is an age-related increase in the production of auto-
antibodies.  In addition, activated B1-B cells are known to migrate more quickly out of 
the mertk-/- peritoneal cavity to become antibody secreting cells in the lamina propria and 
mesenteric lymph nodes (28, 29, 37, 43, 172).  As cells from the peritoneal cavity are 
important for autoantibody production in other autoimmune mouse models (168), we first 
assessed whether the absence of Mertk affected the overall resident peritoneal cell 
population.  We harvested cells from the peritoneal cavity, and found an increase in the 
total peritoneal cells(PEC) found in the mertk-/- mice as compared to wild-type mice 
(Figure 3.1A) at 1.5, 3, and 6 months of age.  Flow cytometry identified the different cell 
types as F4/80+ macrophages, CD19+ B cells, and CD3+ T cells which were all found to 
have statistically significant increases when comparing the mertk-/- mice to wild-type 
mice across a time course of 1.5 to 6 months of age (Figure 3.1B, C, D).   
Because the increase in immune cells occurs most abundantly at 3 months of age, 
our subsequent experiments focus on that time point.  Our previous analysis of the spleen 
found an increase in the number of CD11c+ DC (37).  We examined whether there is a 
similar increase in these cells in the peritoneal cavity of the mertk-/- mice.  Indeed, we did 
find a statistically significant increase in the number of CD11c+ DC found in the 
peritoneal cavity of the mertk-/- mice (Figure 3.2A).  Similarly, the number of 
plasmacytoid DCs, as identified by positive staining for CD11c, B220, and PDCA1, were 
also statistically increased in the peritoneum of mertk-/- mice as compared to wild-type 
mice (Figure 3.2B).  The abundance of these cell types suggests the environment is 
conducive for the activation of the B1-B cells. 
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The increase in peritoneal lymphocyte populations shown in Figure 3.1 is 
particularly interesting because Mertk is not known to be expressed on either of the cell 
types under normal conditions.  In addition, the increase in these lymphoid cell types was 
not found in other lymphatic organs (37).  Therefore, we characterized these lymphocytes 
further to determine whether one subpopulation could account for the increase in total 
number of cells.  As shown in Figure 3.2C, both CD4+ and CD8+ T cells were present in 
higher numbers in the peritoneal cavity of mertk-/- mice compared wild-type mice.  We 
then used CD44 and CD62L staining to determine the activation state of the T cells from 
the peritoneal cavity of both wild-type and mertk-/- mice.  We found that there were 
statistically significant increases in effector (CD62L lo, CD44 hi), naive (CD62L hi, CD44 
lo), and central memory T (CD62L hi, CD44 hi) cells.  The largest increase was in the 
naive T cell population (Figure 3.2D).  Thus, the absence of Mertk prevents proper 
regulation of the T cell population within the peritoneal cavity. 
We next analyzed the B cell populations which were also expanded in the mertk-/- 
mice (Figure 3.1C).  Since the peritoneal cavity is known to contain a large number of 
B1-B cells, we used CD19, CD11b, and CD5 staining to analyze the B1a (Cd19+, 
CD11b+, CD5+) and B1b (CD19+, CD11b+, CD5-) subsets of the B1 (Cd19+, CD11b+) 
cells.  As shown in Figure 3.3A, we found a statistically significant three-fold increase in 
the overall B1 population.  Furthermore, in the absence of Mertk, there were over a four-
fold increase in the number of B1b cells and about a three-fold increase in the B1a cell 
population.  Thus, the increase in B1-B cells was due to an increase in both populations 
with a greater fold increase in B1b B cells.  The number of CD19+ Cd11b- B2 cells was 
negligible in comparison to the number of B1 cells; nonetheless, there was an increase of 
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B2 cells in mertk-/- mice compared to wild-type mice (Data not shown).  Furthermore, we 
wanted to determine whether the absence of Mertk affected the activation of the B cell 
population in the peritoneal cavity.  Using the activation markers, MHC II, CD80, and 
CD86, we found that there were statistically significant decreases in the mean fluorescent 
intensity of MHC II and CD80 on CD19+ cells from mertk-/- mice (Figure 3.3B, C, D, E).  
Thus, while there was an increase in the number of B cells in the peritoneal cavity of 
mertk-/- mice, the B cells were less activated than those of wild-type mice.   
We hypothesized three reasons that could account for the increase in the number 
of cells in the peritoneal cavity of the mertk-/- mice.  These included an increase in cell 
division, a decrease in cell death, and an increase in migration of cells into the peritoneal 
cavity of the mertk-/- mice.  We first used BrdU incorporation to delineate cells 
undergoing proliferation within the peritoneal cavity of the mertk-/- mice.  As shown in 
Figure 3.4A, an overall statistically significant decrease in the percent of dividing cells is 
evident when comparing cells collected from mertk-/- to wild-type mice at three different 
ages.  However, the total number of cells dividing was not different when comparing the 
genotypes (Figure 3.4B).  To assess whether excessive division was occurring elsewhere, 
we examined the bone marrow and found that there was no difference in cell division in 
the bone marrow (Figure 3.4C).  While the spleen is a location for division of 
lymphocytes and leukocytes upon infection, we observed very few dividing cells in the 
spleen of both genotypes of mice under unstimulated conditions (unpublished 
observations).  Thus, the large number of cells in the peritoneal cavity of mertk-/- mice 
was not due to local proliferation. 
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We next examined the possibility that the large number of cells in the peritoneal 
cavity of mertk-/- mice was attributed to decreased in cell death   We used several 
methods for measuring cell death at different stages, to provide a comprehensive profile.  
We first used VAD-FMK to analyze the number and percent of cells that were 
undergoing apoptosis.  VAD-FMK-FITC binds to active caspase 3, a key component for 
the induction of apoptosis.  We found the percent of cells that were VAD-FMK-FITC-
positive were not statistically different (Figure 3.5A).  However, while not reaching 
statistical significance, we found a trend toward an increase in the number of VAD-
FMK+ cells in the peritoneal cavity of mertk-/- mice (Figure 3.5B).  In addition to VAD-
FMK-FITC staining, we also used Annexin V and PI staining to identify cells that were 
undergoing early apoptosis (Annexin V+) as well as those cells that were already in late 
apoptosis (PI+).  We found no statistically significant differences in the percentage of 
cells that were undergoing apoptosis via Annexin V/PI staining (Figure 3.5C).  However, 
there was a significant increase in the number of cells undergoing cell death at all stages 
of apoptosis in the peritoneal cavity of the mertk-/- mice (Figure 3.5D).  We speculate this 
increase is likely due to an increase in total number of cells found in the peritoneal cavity 
of the mertk-/- mice.  Taken together, these data suggest that a difference in cell death 
could not explain the increase in peritoneal cells found in the mertk-/- mice.   
Our third hypothesis for the large number of cells was an increase in migration of 
cells into the peritoneal cavity mertk-/- mice.  To investigate this hypothesis, we labeled 
resident PEC from mertk-/- mice and adoptively transferred them into wild-type mice as 
well as in reciprocal combination to track migration into the peritoneal cavity.  As 
controls, we injected wild-type PEC into wild-type mice and mertk-/- PEC into mertk-/- 
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mice.  We found that there was indeed an increase in the number of labeled cells 
recovered from the peritoneal cavity of mertk-/- mice (Figure 3.6).  Interestingly the origin 
of the donor cells was not a factor since wild-type and mertk-/- donor cells migrated 
similarly to the peritoneal cavity of wild-type mice.  Correspondingly, both donors 
migrated similarly to the mertk-/- peritoneal cavity.  This data not only suggests that an 
increase in migration is the reason for the increase in cells found in the peritoneal cavity 
of the mertk-/- mice; but also that the environment of the mertk-/- mice influences the 
migration of cells.   
In order to differentiate between hematopoietic and non-hematopoietic sources for 
the increase in cells migrating to the peritoneal cavity of mertk-/- mice, we performed 
bone marrow transplants of mertk-/- bone marrow into wild-type mice and visa versa.  If 
the hematopoietic cells from mertk-/- mice were responsible for the greater migration, we 
would expect that the wild-type mice reconstituted with mertk-/- bone marrow would have 
an increase in PEC.  Conversely, we would expect that the mertk-/- mice reconstituted 
with bone marrow from wild-type mice would show a decrease in PEC.  Control mertk-/- 
recipients reconstituted with bone marrow from mertk-/- donors showed the expected 
increase in numbers of cells in the peritoneal cavity compared to control wild-type mice 
reconstituted with wild-type bone marrow (Figure 3.7A).  However wild-type and mertk-/- 
mice reconstituted with heterologous bone marrow showed similar number of peritoneal 
cells.  This indicates that factors from the immune cells and the host environment may be 
influencing migration into the peritoneal cavity.    
We next analyzed the composition of the peritoneal cells and found no significant 
increases in F4/80+ macrophages, CD11c+ DCs, or CD19+ B cells (Figure 3.7 B, C, D).  
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However, a significant increase was found in CD3+ T cell number when wild-type 
recipients were given bone marrow from mertk-/- mice as compared to donor wild-type 
mice (Figure 3.7E).  Correspondingly, there was a significant decrease in the number of T 
cells recovered from the peritoneal cavity of mertk-/- mice receiving wild-type donor cells 
as compared to the peritoneal cavity of mertk-/- mice receiving mertk-/- bone marrow.  
Concurrent with previously published data, the number of B cells recovered from the 
peritoneal cavity after bone marrow transplantation was dramatically reduced most likely 
due to the lack of B1 cells (167).  B1 cells are not able to repopulate because their 
precursors are only available from fetal tissue and not adult bone marrow (167).  Taken 
together, these data suggest that neither hematopoietic nor non-hematopoietic cells 
contribute solely to the overall increase in cells in found in the peritoneum of the mertk-/- 
mice.  However, the increase in T cells is most likely due to signals exclusively from the 
hematopoietic compartment.   
The increase in migration of immune cells into the mertk-/- peritoneal cavity may 
be due to several candidate chemokines and cytokines.  We hypothesized that the 
chemokine CXCL13 would be increased in mertk-/- cells since this chemokine is required 
for migration of B1-B cells to the peritoneal cavity (154).  However as shown in Figure 
3.8A, real-time PCR of mRNA for CXCL13 was similar in both the mertk-/- and wild-
type resident PEC.  Likewise, IL-5, IL-6, IL-7, IL-9, IL-10, and BAFF were not different 
between the strains (Figure 3.8A or data not shown).  However, a marginal increase in 
mRNA of the chemokine CXCL14 and a 3 fold increase in CXCL9 were observed in the 
mertk-/- population.  In addition to the soluble factors, we also examined receptors present 
on migrating cells to determine if a certain receptor was up-regulated and contributing to 
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the increase in number of cells found in the peritoneal cavity of mertk-/- mice (Figure 
3.8B).  We found the migration-associated receptors LFA, PECAM, and L-selectin were 
expressed similarly in cells from both genotypes (data not shown).  Also, mRNA for 
CXCR5, the receptor for CXCL13, was similar in mertk-/- and wild-type cells (Figure 
3.8B).  Therefore this combination of ligand-receptor pairing is unlikely to explain the 
large numbers of cells in the peritoneal cavity of mertk-/- mice.  
The receptor for CXCL9, CXCR3 is important to lymphocyte development and 
homing of T cells and B cells and its upregulation would be consistent with the increase 
of T and B cells within the peritoneal cavity of mertk-/- mice.  In fact, the CXCR3 
transcript was increased greater than 2-fold in cells from mertk-/- mice (Figure 3.8B).  In 
addition to CXCR3, IL-7 receptor mRNA was also found to be expressed over 4-fold 
greater in the cells harvested from mertk-/- mice. This increase in mRNA for CXCR3 and 
IL7R was confirmed by flow cytometry (Figure 3.8C and F).  Most of the expression of 
CXCR3 was on the cell surface of lymphocytes with the largest population on T cells in 
both wild-type and mertk-/- mice (Figure 3.8C).  However, there was a significantly 
greater number of B cells (two-fold) and T cells (nearly four-fold) expressing CXCR3 in 
the peritoneal cavity from mertk-/- mice.  Representative analysis of CXCR3 on wild-type 
and mertk-/- T cells demonstrates similar high expression levels (Figure 3.8D).  
Interestingly, percent of B cells that express CXCR3 are similar on wild-type and mertk-/- 
cells; however, the expression is very low (Figure 3.8E).  Thus, the greater numbers of 
lymphocyte subpopulations found in mertk-/- mice is not explained by expression levels 
of CXCR3.  Furthermore, a similar trend was observed for the number of B and T cells 
expressing IL-7R, however only T cells were significantly increased (Figure 3.8F).  
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Similar to CXCR3, T cells from wild-type and mertk-/- mice showed similar expression 
levels of IL-7R (Figure 3.8G).  There were very few macrophages expressing either 
CXCR3 or IL-7R receptor (Figure 3.8C and F).   Thus, we have identified potential 
ligands and receptors that appear to mark lymphocytes that are in greater numbers in 
mertk-/- mice. 
After finding the absence of Mertk led to an increase in PECs, we wanted to 
determine if knock out mice lacking the other TAM family members, Axl or Tyro3, had a 
similar increase in PEC number.  Interestingly, we found that there were no statistically 
significant differences in the total number of cells collected from the peritoneal cavity of 
the other knock-out mice when compared to wild-type mice (Figure 3.9A).  Along these 
lines, there were no differences compared to wild-type mice in the number of CD19+ B 
cells, CD3+ T cells, or F4/80+ macrophages found in the axl-/-, tyro3-/- and axl-/-/tyro3-/- 
double knock-out mice (Figure 3.9B). Previously, we and others have shown mertk-/- 
mice produce autoantibodies to several self-antigens including dsDNA and nucleosomes 
(28, 29, 37, 43).  Since the peritoneal cavity is an important reservoir for the B1-B cell 
population which is known to play a role in autoantibody formation, we assessed anti-
nucleosome antibody production of these mice.  Although autoantibodies had been 
attributed to the absence of all three family members(43), mertk-/- mice were the only 
mutant strain to show elevated levels of anti-nucleosome antibody (Figure 3.9C).  In 
addition, increased splenic weights were only associated with mertk-/- mice whereas axl-/- 
and tyro3-/- mice were similar to wild-type mice (Figure 3.9D).  This suggests that Mertk 
is the critical TAM family receptor that dictates the composition of cells in the peritoneal 
cavity and is important in regulating the production of autoantibody.   
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Discussion 
 Mice lacking Mertk manifest a lupus like syndrome including splenomegaly, 
nephropathy, and autoantibody production to many different auto-antigens (28, 29, 37, 
43, 172).  Autoimmune diseases in mouse models are often correlated with enlarged 
lymphocyte compartments.  We previously demonstrated that splenic weight was 
increased in mertk-/- mice, however only the DC populations were significantly 
elevated(37).  In this study, we characterized an increase in total cell number found in the 
peritoneal cavity of mertk-/- mice, and found this increase to be in multiple cell types 
including cells involved in both innate and adaptive immunity.  Our analyses demonstrate 
that only Mertk regulated the peritoneal cell numbers and the other family members Axl 
or Tyro3 were not important.  This increase in peritoneal immune cells correlated well 
with the increased production of autoantibodies since only mertk-/- showed excessive 
levels.  Our data suggests that in the absence of Mertk, migration of cells into the 
peritoneal cavity is dysregulated and this may be due to an elevation of specific 
chemokines and receptors associated with leukocyte homing and survival.  These 
findings provide insights for the propensity of mertk-/- mice to develop a lupus like 
syndrome highlighted by the inability to clear apoptotic cells normally and by the 
increased production of auto-antibodies.   
 Interestingly, we found that mertk-/- mice had an age dependent increase in PECs.  
This difference between wild-type and mertk-/- mice was most evident at 3 months of age 
(Figure 3.1).  In the absence of Mertk, we found an increase in the lymphocyte 
compartment of both B cells and T cells from the peritoneal cavity (Figure 3.1).  In the 
mertk-/- lymphocyte population, CD19+ B cells were over 5-fold greater in number than 
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wild-type, and CD3+ T cells were over 6-fold greater (Figure 3.1).  Further analyses 
indicated that the B1-B cells, the B1a and B1b cells were elevated compared to wild type 
mice (Figure 3.3).  An increase in B1 cell number was also found in the peritoneal cavity 
of the 2-12H-mertk-/- mice (172).  In the T cell population, the CD4+ and CD8+ T cell 
compartments were elevated in the mertk-/- mice although at equal ratios to that of wild-
type mice (Figure 3.2C).  The largest T cell increase was found in the naive T cells, 
shown in Figure 3.2D.  Lastly, there were elevated numbers of effector and memory T 
cells as indicated by the distribution of CD44 and CD62L (Figure 3.2D).  Thus, it appears 
in the absence of Mertk, T lymphocytes accumulate in greater numbers in the peritoneal 
cavity and this accumulation appears to be dependent on hematopoietic derived factors 
(Figure 3.7).  It is plausible that the increase in T cells may increase the frequency that a 
T cell may aid antigen activation of B cells.    
 While the peritoneum acts as a lymphoid organ, it lacks the architecture similar to 
that of a lymph node or spleen, thus presenting unconventional possibilities for antigen 
presentation and subsequent lymphocyte activation.  This may be particularly true for an 
animal with an increased lymphocyte population and greater numbers of antigen-
presenting cells with in the peritoneal cavity.  Although B1-B cells normally produce T 
independent, low-affinity auto antibodies (167); the mertk-/- mice present a unique 
scenario with increased levels of B1-B cells as well as T cells in the peritoneum (Figure 
3.1, 3.2, 3.3), thus creating an environment with greater likelihood that these B cells 
would receive T cell help, class switch and begin producing higher affinity auto 
antibodies.   
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 B1-B cells are critical for the autoimmune hemolytic anemia found in the NZB 
and NZB/W mice, as hypotonic ablation of peritoneal B1-B cells decreases autoantibody 
titers and prevents disease development in aged animals (168).  Interestingly these and 
other autoimmune mice display increased B1 cell levels in the peritoneal cavity prior to 
disease development (210, 214, 215)..  Previously published data from our lab and others 
indicates that autoimmune disease in the mertk-/- mice is not manifested until greater than 
3 months of age(29, 37, 43).  Similar to the NZB mice, we have found a dramatic 
elevation of peritoneal B cells by 3 months of age in mertk-/- mice (Figure 3.1C) prior to 
an age when auto-antibodies are prevalent (Figure 3.9C)(28, 29, 37, 43).  The influence 
of Mertk on the lymphocyte populations may be indirect as T cells normally do not 
express Mertk (1) and our analysis of the LPS-stimulated and unstimulated B cell 
population found no detectable expression of Mertk by flow cytometry (data not shown).  
Thus, the peritoneal cavity is an important site for autoreactive cells and it would be 
interesting to investigate if the B1-B cells were critical for autoantibody production in the 
mertk-/- mice similar to the NZB strain. 
 At 3 months of age mertk-/- mice have nearly four times the number of B1 cells 
compared to their wild-type counterparts (Figure 3.3A).  Using the 2-12H Tg model to 
track anti-Sm B cells on the mertk-/- background, the 2-12H auto-reactive B cells are 
antigen-activated in the peritoneum and migrate out to the lamina propria and mesenteric 
lymph nodes to become antibody-secreting cells, but not to the spleen or bone marrow 
(172).  Thus, the peritoneal cavity appears to be a recruitment area for the migration of T 
and B cells, DC, and macrophages that optimizes the priming of auto-reactive B1-B cells.  
In the absence of Mertk, it is plausible that the presence of apoptotic cells may not be 
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adequately cleared by the Mertk-deficient macrophages (28), resulting in exposure of  B 
cells and T cells to self antigens.  Over time this constant activation of auto-reactive B 
cells accumulates and may contribute to the increasing proportion of autoantibody-
secreting cells and the escalation of autoantibody titers associated with the Mertk defect 
(29, 37). 
 The large number of cells in the peritoneal cavity of mertk-/- mice is likely due to 
an increase in migration (Figure 3.6) of leukocytes rather than an increase in local 
proliferation (Figure 3.4) or an inhibition of cell death (Figure 3.5).  In support of this, we 
examined a list of candidate cytokines and chemokines as well as receptors known to be 
involved in homing and migration of cells.  While most of the molecules investigated did 
not show differences, we identified the chemokine CXCL14 as having a marginal 
increase in the mertk-/- mice (Figure 3.8A).  CXCL14 is a chemokine responsible for 
migration of macrophages to adipose tissue and also affects insulin uptake (216).  This is 
particularly interesting because the mertk-/- mice have a larger peritoneal fat pad as 
compared to wild-type mice (unpublished observations).   
However, we identified a more dramatic over-expression of the chemokine 
CXCL9 in the PECs of the mertk-/- mice which coincided with an increased expression of 
the cognate receptor CXCR3 (Figure 3.8A, B).  CXCL9 is a chemokine that can act as a 
chemoattractant for CXCR3 expressing T cells, B cells and plasmacytoid DCs 
(pDC)(163-165).   Type I IFNs are known to induce CXCL9 expression (164) and one 
common finding in patients diagnosed with systemic lupus erythematosus is increased in 
production of type I IFN which maybe a result of DNA/immune complexes activating 
pDC (217, 218).  Thus, it is plausible that the greater numbers of pDC (Figure 3.2B), T 
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cells and B cells (Figure 3.1, 3.2, 3.3) found in the peritoneal cavity of the mertk-/- mice 
are a consequence of greater amounts of CXCL9.  This amplification could result in 
greater expression of CXCL9, thus leading to an increase in CXCR3-expressing cells 
migrating to the peritoneal cavity.  In fact, we found there are more T cells and B cells 
that express CXCR3 in mertk-/- mice than in wild type mice (Figure 3.8C).  It would be of 
interest to determine if the mertk-/- pDC produce greater amounts of type I IFN in 
response to DNA/immune complexes, thereby leading to greater expression of CXCL9 
and a subsequent increase in migration of cells.  Clearly the role of Mertk on pDC 
warrants further investigation with regards to a role in autoimmune disease.   
 The other receptor that was notably increased in the mertk-/- PEC was the IL-7 
receptor.  Mice lacking the IL-7 receptor have low peritoneal B cell levels (219); 
however mice lacking the ligand,  IL-7, have normal numbers of peritoneal B cell 
suggesting the importance of another ligand for the IL-7 receptor in the peritoneal B cell 
population (220).  In addition, the chemokine critical for B cell homing to the peritoneal 
cavity, CXCL13, has been shown to act synergistically with the IL-7 receptor in 
development of lymph nodes, particularly the mesenteric lymph node (221).  This is of 
interest because while we did not find differences in expression levels of CXCL13, we 
did find an increase in expression of IL-7 receptor (Figure 3.8B and D), presenting the 
potential for the synergy of CXCL13 and IL-7 receptor in establishing the peritoneal 
cavity lymph system as well.  Thus, although we have not detected Mertk on B cells (data 
not shown), Mertk may be indirectly influencing the B cell populations through the IL-7 
receptor and perhaps account for the increase in total B cell and B1 cell numbers in the 
peritoneal cavity. 
 91
Equally intriguing is the expression of IL-7 receptor on T cells and we found a 
four-fold greater number in the absence of Mertk (Figure 3.8D).  It is plausible that IL-7R 
may allow greater immigration of T cells into the peritoneal cavity similar to B cells, 
increase the survival of T cells within the peritoneal cavity or dampen their egress.  This 
appears to be particularly true in the naïve T cell population since they show the greatest 
representation (Figure 3.2D).  Furthermore, IL-7 receptor has been associated with an 
increase in survival of CD8+ effector T cells that convert to memory T cells (222) and 
indeed, we find elevated numbers of effector T cells and central memory T cells in the 
peritoneal cavity of mertk-/- mice compared to wile-type mice (Figure 3.2C).  Taken 
together, this data indicates that Mertk has a profound affect on the regulation of T cell 
populations within the peritoneal cavity. 
Although Mertk is not normally expressed on lymphocytes, we observed 
increased numbers of T and B cells.  We deduce that typically, Mertk-expressing cells 
may be regulating the expression of chemoattractants and cytokines to prevent excessive 
accumulation of peritoneal cells that may promote autoimmune disease.  Work presented 
here identifies an increase in the cellular populations found in the peritoneal cavity of 
mertk-/- mice.  We show that this increase is not due to one particular cell type but rather 
all cell types investigated.  We also determined this increase in B cells, T cells and 
antigen-presenting cells is due to enhanced migration/recruitment into the peritoneal 
cavity, not a change in local proliferation or death of cells.  Our data suggest that Mertk 
may be increasing the accumulation of immune cells by upregulating CXCL9 and its 
receptor CXCR3 as well as IL-7R.  Consequently, by establishing an abnormally large 
number of these immune cells in the peritoneal cavity, the likelihood of interaction and 
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support of autoreactive B1-B cells is favored.  We find only Mertk to be critical for the 
regulation of peritoneal cell recruitment as mice lacking Axl and Tyro3 do not show a 
similar increase (Figure 3.9).  This is consistent with our current findings that the onset of 
high autoantibody titers was found only in mertk-/- mice and not axl-/- and tyro3-/- mice.  
Our report provides a platform to study additional mechanisms that are controlled by 
Mertk and it appears that Mertk is a primary regulator driving the autoimmune 
phenotype.   
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Figure 3.1.  Increase in peritoneal cellular populations in the mertk-/- mouse.  PEC were 
harvested from male mice at indicated ages and quantified by flow cytometry.  A) Total 
number of PEC from wild-type (■) and mertk-/- (▲) mice were counted. B) The total 
number of F4/80+ macrophages, C) The total number of CD19+ B cells, and D) The total 
number of CD3+ T cells were also examined. *** p<0.0001 by 2-way ANOVA 
comparing wild-type to mertk-/- mice.  n>6 ** p<0.001 by 2-way ANOVA comparing 
wild-type to mertk-/- mice.  
 
Figure 3.2. Increase in DC, pDC, and T cells by subset in mertk-/- peritoneal cavity. Cells 
were stained and quantified by flow cytometry.  A)PECwere stained for CD11c+ DC or 
B) CD11c+ B220+ PDCA1+ plasmacytoid DC. C) PEC were stained for CD4+ T cells and 
CD8+ T cells.  D) PEC were stained for Effector T cells (CD44hi CD62Llo), Naïve T cells 
(CD44lo CD62Lhi), and Central Memory T cells (CD44hi CD62Lhi) T cells (CD3+). The 
sample number is n >4.  Statistical significance was analyzed by Students t-test 
comparing samples from wild-type and mertk-/- mice.  p-values are: *p<0.05; **p<0.005; 
and ***p<0.0001.  
 
Figure 3.3. Increase in B1 cell populations and lower B cell maturation status in mertk-/- 
peritoneal cavity. A) PEC were stained for B1a (CD19+ CD11b+ CD5+) and B1b (CD19+ 
CD11b+ CD5-) cells.  B) PEC were stained with CD19 to identify B cells and then double 
labeled with MHC II, CD80 and CD86. The Mean Fluorescence Intensity on CD19+ cells 
was graphed.   The number of samples is n ≥4.  Statistical significance by Students t-test 
was *p<0.05 and **p<0.005.   
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 Figure 3.4.  Increase in cells is not due to proliferation.  Proliferating PEC were 
identified by their incorporation of BrdU.  PEC were collected after injection of BrdU i.p. 
and stained with anti-BrdU antibody.  (A) Percent and (B) total number of BrdU+ cells 
across aged mice from 1.5 months to 6 months were examined. n>6.  C) Bone marrow 
cells from wild-type (WT) or mertk-/- (M-/-) mice were stained for BrdU incorporation and 
the data is expressed as the percent of BrdU+ cells, n > 3 and representative of at least 2 
separate experiments.  Statistical significance is * p<0.05 by 2-way ANOVA.  * p<0.05 
by Bonferroni’s post-test.   
 
Figure 3.5. Increase in cells is not due to cell death.  3 month old mice were injected 
with VAD-FMK-FITC 1 hour prior to PEC harvest to detect caspase-positive cells.  Cells 
were analyzed by flow cytometry. (A)The percent VAD-FMK+ cells. (B) The total 
number of VAD-FMK+ cells were examined.  PEC were harvested from 3 month old 
mice, stained with Annexin V-FITC and PI, and subsequently analyzed by flow 
cytometry.  Data is expressed as (C) percent or (D) total number of Annexin-V+ or PI+ 
PEC. n ≥ 4.  Statistical significance comparing samples from wild-type and mertk-/- mice 
is *** p<0.0001 by 2-way ANOVA.  (**) p<0.001 by Bonnferoni’s post-test.  * p<0.05 
by Bonnferoni’s post-test.  
 
Figure 3.6.  Enhanced migration to mertk-/- peritoneal cavity.  Indicated donor PECs 
were harvested, stained with cell tracker green and injected via tail vein into recipient 
mice.  PEC were harvested from 24 hrs after injection and analyzed by flow cytometry.  
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Data is expressed as number of cell tracker green positive cells recovered from recipient 
peritoneum.  n ≥ 10.  Statistical significance is * p<0.01 by Students t-test.   
 
Figure 3.7. Both hematopoietic and non-hematopoietic sources are required for cellular 
increase in mertk-/- peritoneal cavity.  Recipient 4 week old mice were lethally irradiated 
and given indicated donor bone marrow 1 day later. At 3 months of age PEC were 
collected and (A) total cell number was counted.  Cells were then stained for (B) F4/80+ 
macrophage, (C) CD11c+ DC, (D) CD19+ B cells, and (E) CD3+ T cells. WT = wild-type 
M-/- = mertk-/- mice.  Statistical significance using the Student’s t-test * p< 0.05 and ** 
p<0.0005.   
 
Figure 3.8.  Expression of chemokines, cytokines, and migration receptors in PEC.  PEC 
were pooled from at least 4 three month old male mice.  RNA was harvested and reverse 
transcribed to cDNA. A) Real-time PCR was performed for soluble molecules, IL-7, 
BAFF, CXCL9, CXCL13, and CXCL14.  B) Real-time PCR was performed for 
receptors, CXCR5, CXCR3, and IL-7R.  C) PEC from wild-type and mertk-/- mice were 
double-stained for CD3, CD19, or F480 and CXCR3.  Representative histograms of 
CXCR3 expression gated on CD3+(D) or CD19+(E).   F) PEC from wild-type and mertk-
/- mice were double stained for CD3, CD19, or F480 and IL-7R.  G) Representative 
histograms of IL-7R expression CD3+ cells. Mean and standard deviation are graphed.  n 
> 3.  Statistical significance are indicated, *p<0.01, **p<0.005 by the Student’s t test 
when comparing wild-type vs mertk-/- mice.   
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Figure 3.9. Increase in peritoneal cells and autoantibody production is due to Mertk and 
not Axl or Tyro3.  PEC were harvested from 3 month old male mice from wild-type 
(WT), mertk-/- (M-/-), axl-/- (A-/-), tyro3-/- (T-/-), axl-/-/tyro3-/- (AT-/-).  A) Total cells were 
counted and stained for B) F4/80+ macrophage, CD19+ B cells and CD3+ T cells. C) Anti-
nucleosome antibody titers were determined by ELISA. From serum of mice 6 months of 
age or older D) Splenic weight was measured of mice 6 months of age or older.  n > 6   
No statistically significant differences were found by ANOVA with post-tests between 
WT, A-/-, T-/- and AT-/- peritoneal cells.  Statistical significance is indicated in 
comparisons with samples from wild type and mertk-/- mice, *p<.01 **p<.001 by 
ANOVA post-test.   
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Chapter 4: 
 
Mertk on macrophages is a critical regulator of p202 and DNA-induced 
cell death 
 
Abstract 
The regulation of cell death by cytoplasmic double-stranded DNA is governed by 
the HIN-200 family proteins AIM2 and p202 (183-185, 189).  These proteins are known 
to be associated with Systemic Lupus Erythematosus (148, 174).  However, the etiology 
of this multi-factorial disease is currently unknown.  There is mounting evidence for a 
viral infection as a potential initiation point for autoimmunity (89, 223, 224).  Here we 
show that Mertk regulates cytoplasmic DNA-induced cell death by controlling the 
expression of p202.  We found cleavage of caspase 1 and 3, and cell death due to 
cytoplasmic DNA was greatly reduced in cells lacking Mertk.  We screened each of the 
HIN-200 family members and found p202, which can bind DNA, to be upregulated in 
macrophages and dendritic cells lacking Mertk.  The HIN-200 family member AIM2 
which senses dsDNA and can trigger caspase cleavage was expressed at similar levels in 
wild type macrophages and mertk-/- macrophages suggesting variations in p202 
expression may be critical for preventing AIM2-mediated cell death.  This upregulation 
of p202 was not affected by Axl or Tyro3 which, the other members of the 
Tyro3/Axl/Mertk family of receptors.  We also showed that type I IFN dramatically 
upregulated ifi-202 mRNA and p202 protein expression in mertk-/- macrophages and this 
was correlated to reduced caspase cleavage induced by cytoplasmic dsDNA.  Our results 
indicate that Mertk is a critical regulator of cytoplasmic DNA-induced cell death and 
high levels of p202 found in mertk-/- and other lupus-prone mice may allow greater 
survival of antigen-presenting cells which in turn may contribute to the hyperactive 
immune phenotype associated with autoimmunity.     
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Introduction 
 Mertk is a receptor tyrosine kinase belonging to the Tyro3/Axl/Mertk (TAM) 
family of receptors.  The TAM receptors are characterized by two extracellular 
fibronectin III like domains and two extracellular Ig like domains as well as an 
intracellular kinase domain containing a signature KWIAIES sequence (7, 8).  These 
receptors are expressed on many cell types; however, Mertk is restricted primarily to cells 
of myeloid, epithelial and reproductive origin and is not detected on normal lymphocytes 
or neutrophils (7, 18).   
Different combinations of these receptors have been shown to be required for 
efficient phagocytosis of apoptotic cells by macrophages(MФ) and dendritic 
cells(DC)(18, 28).  The serum proteins Gas 6 and Protein S are two ligands that have 
been identified for the TAM receptors.  These ligands can bind phosphatidylserine on 
apoptotic cells and it is through this molecular bridging to the receptors that triggers the 
phagocytosis apoptotic cells.  The inability to adequately clear apoptotic cells and to 
maintain B cell anergy are two common features associated with autoimmune disease.  
Mice lacking these receptors are deficient in phagocytosis of apoptotic cells and they 
display a lupus-like autoimmune disease characterized by autoantibody production and 
splenomegaly (28, 29, 37, 43).  Furthermore, these receptors affect signal transduction, 
cell activation, and cell maturation pathways which regulate the function of antigen-
presenting cells (APC).  Hence, these mice lacking TAM receptors provide an 
opportunity to explore mechanisms that may link these receptors to dysregulation of 
APCs and lymphocytes.    
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Systemic Lupus Erythematosus (SLE) is a multifactoral autoimmune disease that 
is characterized by multiple clinical symptoms, including malar rash, lupus nephritis, oral 
ulcers, and high titers of autoantibodies.  These autoantibodies are usually directed 
against double-stranded DNA (dsDNA), Smith antigen (Sm), as well as other nuclear 
antigens (42).  The autoantibodies form immune complexes with self antigens and their 
deposition in blood vessels and various tissues promote autoimmunity and facilitate 
pathologies (42).   
This debilitating disease is believed to be cause by both genetic and 
environmental components (42).  Genetic correlations to SLE include polymorphisms 
that control expression of critical genes or mutations that affect cell function including 
phagocytosis of apoptotic cells, regulation of B cells, and production of type I interferon 
(IFN)(42).  One current theory for an environmental cause is viruses that possess nucleic 
acids or proteins that act in molecular mimicry as self antigens.  Furthermore, viral 
infection can trigger type I IFN or alter cell function and tolerance which may also be a 
potential initiation of SLE.  In support of this notion, many diagnosed SLE patients have 
high Epstein Barr Virus (EBV) titers (88).  Interestingly, one of the major EBV peptides 
that antibodies are raised against, Epstein Barr Virus Nuclear antigen-1, has the potential 
to induce autoantibodies to Ro and Sm through molecular mimicry (89).  Furthermore, 
increased in serum levels of type I IFN is correlated both with viral infection and SLE 
(56, 225-227).   
One family of IFN-inducible genes, the HIN-200 family, has been previously 
correlated with SLE (186).  In particular, p202 has been found to be overexpressed in 
many mouse models of SLE including, MRLlpr/lpr, NZB, and B6Nba.2 (148).  This family 
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of proteins is characterized by a conserved 200 amino acid sequence containing the 
highly conserved peptide motifs, MFHATVAT, proposed to be involved in protein-
protein interactions and a pRb-binding motif, LXCXE (173).  These genes are clustered 
in the q23 region of chromosome 1 in both mice and humans (148).   In addition, most of 
the HIN-200 family members also posses a PYRIN domain known to be important for 
inflammasome caspase activation that mediates IL-1β cleavage and cell death (173, 178, 
179).  However, p202 is the sole family member that does not contain a PYRIN domain.   
Recent publications have identified Absent in melanoma 2 (AIM2) and p202 of 
the HIN-200 family as important regulators of dsDNA-induced cell death (183-185, 189).  
These groups demonstrated that AIM2 can bind dsDNA as well as the inflammasome 
component apoptosis-associated speck-like protein containing a CARD (ASC) (183-185).  
This interaction between dsDNA, AIM2 and ASC results in cleavage of caspase 1 and 3 
and subsequent cell death by apoptosis or pyroptosis.  It is believed that this AIM2-
mediated mechanism may be critical in sensing DNA from intracellular pathogens and it 
may be a means to remove infected cells that may harbor pathogens.  However, p202 
appears to compete with AIM2 for the binding of dsDNA and this balance between the 
two cytoplasmic molecules controls cell susceptibility to DNA-induced death (189).  
Because p202 cannot associate with ASC and cannot activate caspases, the high levels of 
p202 found in lupus-prone cells may prevent proper disposal of key APCs and 
autoreactive B cells.  Therefore, it is plausible that high levels of p202 associated with 
lupus-prone mice prevent proper execution of virally-infected APCs or autoreactive B 
cells.     
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The fact that SLE maybe triggered by viral infections and that APCs such as MФs 
and DCs are important for T cell-dependent autoantibody production, we hypothesized 
that MФs lacking Mertk were less susceptible to a model of viral dsDNA-induced cell 
death.    In this report, we show that cells from the mertk-/- mouse are less susceptible to 
cytoplasmic dsDNA-induced caspase 1 and 3 cleavage and subsequent cell death.  Of the 
HIN-200 family of IFN-inducible proteins, we found p202 is negatively regulated by 
Mertk under resting or stimulated conditions in MФs and DCs.  More importantly, we 
also found that Mertk is the only TAM family member that negatively regulates p202.  
Interestingly, Stat3, a known ifi-202 promoter element, is hyperactivated in cells lacking 
Mertk.  Finally, we provide evidence that the stimulation of mertk-/- MФs with IFN 
increased p202 expression and subsequently further decreased cleavage of caspase 1 and 
3.   
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Materials and Methods 
Animals 
All animals were housed in Specific Pathogen-Free Facilities according to the University 
of North Carolina Institutional Animal use and Care committee (IACUC).  mertk-/- mice 
were generated as previously described(35).  axl-/- and tyro3-/- were generously provided 
by Dr. Stephen P. Goff (Columbia U., New York) and Dr. Greg Lemke (Salk Institute for 
Biological Studies, San Diego) respectively.  All congenic strains were backcrossed at 
least 6 generations on the C57BL6/J background.  axl-/-/tyro3-/- and TAM-/- triple knock 
out mice lacking all three receptors were derived by crossing congenic mutant mice.  
Male mice 8-12 weeks of age were used in experiments.  C57BL6/J strain was used as a 
wild-type control to compare individual mutant mice above.   
Antibodies 
Anti-Caspase 1, Anti-IFI-202(p202) antibodies were obtained from Santa Cruz.  Anti-
Caspase 3 antibody was obtained from Cell Signaling.  Anti-actin antibody was obtained 
from Millipore.   
Electroporation of Thioglycollate-Elicited Peritoneal Exudate Cells (Thio-PEC) 
Thio-PEC were obtained as previously described(228).  Cells were plated 2x106 in 6 well 
plates and washed after 3 hrs to remove non-adherent cells.  The remaining cells were 
greater than 95% MФs.  At least 1 day after washing wells, cells were electroporated with 
Calf Thymus DNA (Sigma) or poly dA:dT (Sigma) at indicated doses.  Electroporation 
was carried out using petri-pulser (BTX) and ECM 830 (BTX) with conditions of 2 
pulses of 100V for 10msec each.  Brightfield pictures were taken 3 days post 
electroporation.  For Cy3+ cell death counts, poly dA:dT was labeled with Cy3 using the 
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LabelIT DNA-labeling kit(Mirus) according to manufacturer’s instructions.  The 
membrane impermeable nuclear dye Sytox green(Invitrogen) was used as a vital dye 
marker.  Pictures were obtained using an inverted fluorescent microscope (Leica 
DMIRE2) and Metamorph 5.0 software(Universal Imaging Corp).  Overlays of pictures 
were compiled using IMAGE J, and cell counts were obtained using Image Pro Plus 
software.  Caspase cleavage was detected by Western blots using whole cell lysates that 
were obtained 30 minutes after electroporation.  Where indicated, cells were treated with 
1000U/mL of IFN for 3 days prior to electroporation.   
Real-Time PCR 
Cells were plated and left untreated or treated for indicated time periods with either 1000 
U/mL IFN (PBL), 200ng/mL LPS (Invivogen), 20ug/mL Poly I:C (Invivogen) or 150nM 
Gas6 (R and D Systems).  After treatment, cells were harvested in RLT Plus lysis buffer 
(Qiagen) and subjected to clean up with RNeasy Plus kit (Qiagen) according to 
manufacturers instructions.  RNA was quantified and converted to cDNA using 
Superscript II reverse transcriptase (Invitrogen) with random hexamers.  Gene-specific 
primers were designed with primer express software (Applied Biosystems).  Real-time 
PCR was carried-out using 2x Sybr Green (Applied Biosystems) solution and run in an 
ABI 7500 real-time PCR machine that is housed in the UNC Neuroscience Center 
Expression Profiling and SNP Genotyping Core.   Primers used are the following.  
AIM2-Forward: CACTGAGGGTATAAGTATGGCAGGAT  
Reverse: CAGGCGTCTCTCCGACAAG 
Pyhin1-Forward: GAGGTAAATGATGGCGAACCA 
Reverse: TGTTCGATTGGCACTTTTCCT 
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IFI 202 Forward: TCTGCCTTGTTGGAGATCTAGGA  
Reverse: CTTCAAGCCAACTTCTTC 
IFI203 Forward: TGGCAACCTCAACACTTCCTT  
Reverse: CTGGGCTCTGTTTTTGGAGACT 
IFI 204 Forward: GGCTGCTCCTGACCAAATGA  
Reverse: GCTGGCATTTGCATTTCTGA 
IFI205 Forward: GCATCCTGGAGATCAATGAGACT  
Reverse: TGGGCACTTCAATCATTTGTTT 
GAPDH Forward: TGTGTCCGTCGTGGATCTGA  
Reverse CCTGCTTCACCACCTTCTTGA   
Bone Marrow-derived DCs 
Bone marrow-derived DCs were obtained as previously described(37).  Cells were 
harvested from low culture dishes on day 7 counted and re-plated at 2x106 per well for 
treatment with IFN 1000U/mL at indicated time periods starting on day 9.   
Statistics 
 Statistics were performed using Graph Pad Prism Software.  Where indicated, 
Students t-test were performed.  A p value of less than 0.05 was considered significant.    
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Results 
 We first investigated whether MФs lacking Mertk were more susceptible to 
cytoplasmic dsDNA-induced cell death.  Shown in Figure 4.1A, MФs lacking Mertk 
were less susceptible to electroporated dsDNA-induced cell death when compared to 
wild-type MФs.  There are many fewer phase bright cells 3 days post electroporation in 
the wild-type well that received DNA (top left panel Figure 4.1A) as compared to mertk-/- 
MФs (bottom left panel).  This cell death was not due to electroporation alone as cells not 
receiving DNA remained healthy and phase bright (right two panels).  This reduction in 
cell death was confirmed for mertk-/- MФs by MTT Assay (data not shown).   
Some wild type MФs did not undergo cell death after electroporation which may 
be reflective of a lack of dsDNA. To more accurately correlate dsDNA with MФ cell 
death, we used Cy3-labeled DNA and the vital dye Sytox green to determine which cells 
received dsDNA and were dead.  While similar numbers of wild-type and mertk-/- cells 
were transfected with the Cy3-labeled DNA, almost all of the wild-type cells that were 
Cy3-positive were also vital dye-positive cells, indicating that their membranes were 
compromised and they were dying.  In contrast, very few of the mertk-/- cells that 
received dsDNA were also positive for the Sytox green vital dye (Figure 4.1B).  These 
data are quantified as a percent of Cy3-positive cells that are dead (vital dye-positive) in 
Figure 4.1C; where greater than 90% of wild-type cells that received DNA are dead as 
compared to less that 15% of mertk-/- cells.  Furthermore, caspase 3 and 1 cleavage in 
response to electroporated DNA was dramatically reduced in the mertk-/- cells as 
compared to their wild-type counter parts (Figure 4.1D). 
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 Given that the cells lacking Mertk were less susceptible to dsDNA-induced cell 
death, we hypothesized that HIN-200 family members may be dysregulated in the mertk-/- 
cells.  Since these molecules are known to be induced with type I IFN, we examined the 
HIN-200 family members by real-time PCR over a time course of 3 and 24 hours of IFN 
treatment in wild-type and mertk-/- MФs.  We found a 900-fold overexpression of ifi-202 
RNA in unstimulated mertk-/- cells as compared to wild-type MФs, with a greater 
difference after 3 and 24 hours of IFN stimulation (Figure 4.2 top left panel).  Upon 
stimulation with IFN, mertk-/- macrophages dramatically upregulated ifi-202 RNA by 
over 7000-fold which is in stark contrast to wild-type macrophages.  While RNA for the 
other HIN-200 family members (ifi-203, ifi-204, ifi-205, aim2, pyhin-1) increased after 
stimulation with IFN, only ifi-203 had a difference greater than 3 fold.  We found that ifi-
203 showed a greater than 20-fold decrease comparing mertk-/- MФs to wild-type (Figure 
4.2, top middle panel).  Unfortunately, little is known about the function of this family 
member.  In addition, mertk-/- cells show up to 3-fold less RNA for ifi-205 compared to 
wild-type cells after 24 hour stimulation (Figure 4.2, lower left panel).  RNA for AIM2 
showed a slight reduction in mertk-/- MФs compared to wild-type MФs (Figure 4.2 
bottom middle panel). 
 We focused on ifi-202(p202) because of extremely high expression in mertk-/- 
MФs and the recent publications regarding p202 in the regulation of cytoplasmic 
dsDNA-induced cell death.  Previous reports indicated that LPS and IL-6 could activate 
p202.  We also wanted to examine whether Gas6, a ligand for Mertk, and Poly I:C, an 
RNA analog, could induce ifi-202 expression.  As shown in 4.3A, in addition to IFN 
stimulation, ifi-202 RNA increased upon stimulation with LPS, Gas6, and Poly I:C.  
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However, IFN was the strongest inducer of ifi-202 expression in the mertk-/- cells.  We 
corroborated the RNA data with protein expression and found p202 was over-expressed 
as early as 12 hours after IFN stimulation (data not shown).  Subsequent time points 
revealed even greater p202 expression after 48, 72, and 96 hours of IFN stimulation 
(Figure 4.3B).  p202 expression was occasionally detectible in mertk-/- cells under 
unstimulated conditions (data not shown); however p202 was undetectable in all wild-
type samples tested.  This suggested that Mertk is dominant in restricting p202 expression 
and that this repression is tightly controlled.  In addition, we could detect p202 protein in 
mertk-/- MФs with as little as 250U/mL of IFN after 6 days of treatment (data not shown).  
Interestingly we also found that electroporated dsDNA could induce p202 protein 
expression in mertk-/- MФs (Figure 4.3C).   
 After confirming over-expression of p202 by protein, we sought to determine if 
the other TAM family members would regulate ifi-202 similarly to Mertk.  However, we 
found that after IFN stimulation, MФs lacking Axl (axl-/-) singly, or cells lacking Axl and 
Tyro3 (axl-/-/tyro3-/-), or cells lacking all three receptors, TAM-/-, did not show over-
expression of ifi-202 compared to wild-type (Figure 4.4A).  In fact, we found MФs from 
the TAM triple knock-out mice have lower ifi-202 expression than mertk-/- MФs, 
indicating that Axl and Tyro3 may be providing a positive signal for IFN-induced 
stimulation of ifi-202 gene expression.  This lack of over-expression of RNA by cells 
lacking Axl or Tyro3 singly, Axl and Tyro3, or all three family members was confirmed 
at the protein level as well (Figure 4.4B).    
 After ruling out Axl and Tyro3 receptors as being involved in suppression of ifi-
202 at the RNA level and p202 at the protein level, we wanted to determine if other cells 
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that normally express Mertk were regulating p202 similarly.  While DCs also express 
Mertk, the role of this receptor is different from its role on MФs.  For example, DCs 
lacking Mertk are equally efficient at phagocytosis of apoptotic cells when compared to 
wild-type DCs (18, 29).  We found that unstimulated bone marrow-derived DCs from 
mertk-/- mice had greater than 500-fold more ifi-202 RNA by real-time PCR (Figure 
4.5A).  Upon type I IFN stimulation, this difference increased to greater than 20,000-fold 
as compared to wild-type DCs (Figure 4.5A).  In addition, LPS stimulation also resulted 
in an upregulation of ifi-202 in mertk-/- DCs similarly to IFN; however, IL-6 stimulation 
did not increase ifi-202 above unstimulated in mertk-/- DCs (Figure 4.5B).  IL-6 had been 
previously shown to induce p202 over-expression in another lupus mouse model (191).  
We again confirmed the RNA over-expression of ifi-202 by assessing p202 protein 
expression using Western blot.  In corroboration of the ifi-202 RNA findings, we found 
p202 protein in mertk-/- bone marrow-derived DC after 48 hours of 1000U/mL of IFN; in 
contrast, p202 was undetectable in wild-type DC (Figure 4.5C).  
 We next wanted to determine the mechanism by which Mertk was regulating 
p202 expression.  Since there is a known Stat3-binding element in the ifi-202 promoter 
region (191), we first investigated whether activation of Stat3 was different in MФs 
lacking Mertk compared to wild-type MФs.  We found that mertk-/- MФs had greater 
IFN-stimulated phosophorylation of Stat3 compared to wild-type after 15 and 30 minutes 
(Figure 4.6A).  Interestingly, pStat3 was detectible as early as 5 minutes after stimulation 
but was dramatically reduced by 60 minutes in both mertk-/- and wild-type MФs (Figure 
4.6A and data not shown).  We also found this increase in phosphorylation to be dose 
dependent (Figure 4.6B).  Since Stat1 had previously been shown to be regulated by the 
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TAM family member Axl (40), and to be sure that this regulation was specific to Stat3, 
we also investigated the phosphorylation of Stat1.  We found that IFN-stimulated pStat1 
was similar in both mertk-/- and wild-type MФs (Figure 4.6C).  Thus, Mertk appears to 
negatively regulate IFN-induced Stat3 phosphorylation.   
After establishing that p202 was dramatically upregulated in mertk-/- cells after 
IFN stimulation, we wanted to demonstrate that these high p202 levels had functional 
consequences regarding caspase activation.  IFN-stimulated or unstimulated MФs from 
wild-type and mertk-/- mice were transfected with dsDNA and then harvested for protein 
lysates.  As shown in Figure 4.7A, IFN treatment decreased the cleavage of both caspase 
1 and 3 to almost undetectable levels in response to dsDNA in mertk-/- MФs (Figure 
4.6A).  In addition, the wild-type MФs had slightly more cleavage of caspase 1 or 3 after 
IFN treatment, which was anticipated given the increase in aim2 expression and lack of 
increase in ifi-202 expression shown in Figure 4.2.  Figure 4.7B depicts lysates from 
Figure 4.7A showing an increase in p202 in mertk-/- MФs that correlated to the decrease 
in caspase cleavage.  Taken together these data suggest that the lack of dsDNA-induced 
cell death in mertk-/- cells is correlated to p202 over-expression.  With IFN treatment, a 
further increase in p202 expression resulted in even less caspase cleavage in mertk-/- cells.   
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Discussion 
The data presented in this chapter provide a unique mechanism by which Mertk 
regulates dsDNA-induced cell death through the stringent regulation of p202.  We have 
shown that intracellular dsDNA rapidly induces caspase cleavage and cell death in wild-
type MФs.  This caspase cleavage and cell death was reduced in MФs lacking Mertk 
(Figure 4.1).  We subsequently identified the HIN-200 family member, ifi-202, as 
upregulated over 900-fold in unstimulated cells lacking Mertk and this upregulation can 
be dramatically increased to over 7000-fold following IFN stimulation (Figure 4.2).  The 
restriction of p202 by Mertk is not a function of Axl nor Tyro3; however, Axl or Tyro3 
may cooperate with the IFN receptor to induce ifi-202 in the presence of IFN.  Lastly, 
aim2 expression did not differ dramatically, suggesting the varied levels of p202 may be 
effectively competing for dsDNA binding away from AIM2 and dictating protection from 
caspase 1 and 3-mediated cell death.  Please see Figure 4.8 for a schematic description.     
While nearly all HIN-200 family members were found to be upregulated by wild-
type and mertk-/- MФs, p202 is the only family member increased in mertk-/- MФs (Figure 
4.2).  In contrast, ifi-203 is regulated in a reciprocal fashion to ifi-202 and is found to 
have 50-fold lower expression in MФs lacking Mertk.  Unfortunately, the literature is 
lacking with regard to p203 function.  It contains a PYRIN domain similar to AIM2 and 
characteristic 200 amino acid domain found in all HIN-200 family members.  However, 
ifi-203 has been shown to have a similar reciprocal expression pattern in DBA/2 mice 
compared to C57BL/6J(229).  While it is likely that p203 does bind DNA, the DNA-
binding screens which identified AIM2 and p202 as regulators of dsDNA-induced cell 
death did not detect p203.  However, one of these screens did identify p204 and p205, 
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and did not identify p203 (183).  The predicted localization of p203 to the nucleus also 
suggests that p203 may regulate transcription and is unlikely to play a role in the cell 
death induced by intracellular dsDNA.   
ifi-202 expression was found to be induced by several pathways other than IFN 
stimulation.  We found that stimulation with LPS, Gas6, and Poly I:C could induce ifi-
202 expression at least 200-fold in the absence of Mertk compared to wild-type MФs.  
p202 protein was occasionally detectible by Western blot in unstimulated mertk-/- MФs 
and upon IFN stimulation, p202 showed a dose and time-dependent increase in 
expression (Figure 4.3B).  However, p202 protein levels were never detectible by 
Western blot in wild-type cells.  This suggests that Mertk is able to repress p202 despite 
leverage from positive stimulants. 
Interestingly, electroporated calf thymus (CT) DNA was also able to induce p202 
protein expression in mertk-/- MФs (Figure 4.3C).  It is possible that intracellular CT 
DNA is activating the cells to produce IFN and not directly activating the p202 
production; however, the levels of CT DNA-induced p202 were higher than the IFN-
induced levels.  If CT DNA was inducing IFN, CT DNA would have to induce IFN at 
levels greater than 1000U/mL.  It is also possible that CT DNA may be binding p202 and 
inducing p202 to trigger signal transduction or act as a transcription factor for its own 
expression in a positive feedback loop.  It makes sense that a cell surviving a viral insult 
would want to produce more of the protein that allows it to survive.  
We also found that p202 levels were only dramatically upregulated in the absence 
of Mertk.  In contrast, ifi-202 expression was not up-regulated in the absences of the 
other TAM family members Axl or Tyro3.  However, cells lacking all three receptors 
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were more similar to wild-type than mertk-/- MФs in ifi-202 expression (Figure 4.4A).  
This suggests that while Mertk is clearly a negative regulator of p202 expression, Axl 
and/or Tyro3 may be acting as positive regulators of IFN-induced ifi-202 expression.  In 
fact Axl has been shown previously to interact with the IFN receptor in DC upon Gas6 
stimulation (40).  It is plausible that Axl-IFNR may be mediating p202 induction upon 
IFN stimulation, yet this induction does not override the overwhelming dominant 
repression imparted by an intact Mertk. 
The observation that Mertk may be repressing p202 expression is novel; however, 
the mechanism mediating the suppression is unknown.  Stat family of transcription 
factors are well known to be activated after IFN stimulation.  In addition, there is a Stat3 
binding site in the ifi-202 promoter region (191).  We have shown that Stat3 but not Stat1 
is hyper-phosphorylated in mertk-/- MФs (Figure 4.6).   In support of our findings, an 
over-expression system of constitutively active mutated Mertk led to hyper-activation of 
Stat3 as compared to wild-type Mertk (230).  Conversely, in DCs, Stat3 has been shown 
to be activated by apoptotic cells and Gas6 (86).  We did not find Stat3 activation by 
Gas6 in MФs (data not shown).   It is possible that similar to the differential roles of 
Mertk in phagocytosis of apoptotic cells by MФs versus DCs, Mertk may be regulating 
Stat3 differently in different cell types.    
We also show that in mertk-/- MФs, IFN stimulation, which produces increased 
phosphorylation of Stat3 and increased expression of p202, also leads to a decrease in 
intracellular dsDNA-induced caspase 1 and 3 cleavage (Figure 4.7).  Stat3 expression has 
been associated with cell survival in other cell types and is a concern with oncogenesis 
(231).  Our data suggest that the high levels of activated Stat3 may be assisting activation 
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of ifi-202 and this correlates Stat3 function to our observations here regarding cell 
survival.  Moreover, E2F1, which has been shown to inhibit p202 expression and is 
known to inhibit cell cycle and cell survival, is not over-expressed in mertk-/- MФs (193).  
The E2F1 expression in mertk-/- MФs is similar to wild-type MФs (data not shown).  
Therefore, the high amounts of Stat3 and the unremarkable expression of E2F1 is 
consistent with conditions that favor dominance of p202.     
Although p202 levels have been shown to be correlated with SLE-like disease is 
mouse models, the regulation of p202 expression in these SLE models is not understood.  
These mouse models include MRLlpr/lpr, NZB, and B6Nba.2 (148).  Because these models 
produce SLE-like disease due to multi-factoral genetic and environmental components, it 
would be difficult to determine the regulation of p202 expression.  Here we present an 
SLE mouse model were only Mertk is knocked out allowing for identification of all 
subsequent alterations to be traced back to Mertk.  These studies provide a link with 
Mertk, p202, and the autoimmune phenotype beyond the association of Mertk to 
phagocytosis of apoptotic cells.  Mertk is a receptor with multiple effector functions that 
may be critical for providing check points that prevent autoimmune disease.  
Furthermore, Mertk has been associated with cytokine regulation, such as TNFα, and 
BAFF, that may be inhibiting or promoting B cell activation (35, 37, 40); therefore, 
mertk-/- mice may be an excellent model to define downstream effects of p202 and 
consequences to autoimmunity.  Similarly, it may be interesting to determine if Mertk 
expression levels or function are altered in other SLE mouse models that show increased 
levels of p202.   
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This chapter also provides important insight into the autoimmune disease SLE.  
As SLE patients often have increased type I IFN levels and EBV titers, it is possible that 
Mertk on DC and MФs may be a regulator of cell death in response to dsDNA viruses 
through its control of p202.   Thus, a dsDNA virus may infect an APC and depending on 
the levels or functionality of Mertk and thus p202, the cell may die, or continue to live 
providing aberrant antigen presentation.  If the APC survives and is hyper-activated as 
indicated by high levels of p202 and other factors such as BAFF (37), then aberrant 
stimulation of autoreactive T cells or autoreactive B cells may break anergy.  Chronic 
presentation of antigens is especially important in a scenario in which molecular 
mimicking of self antigens by pathogens such as EBV infection or a scenario found in the 
mertk-/- mice where there is an abundance of autoantigens due to a defect in phagocytosis 
of apoptotic cells.  This hyperactivity and perhaps excessive presentation of self antigens 
or foreign nucleic acids has the potential to jump start autoimmune disease resulting in 
the autoantibody production found in the mertk-/- mice and other lupus-prone mice.   
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Figure 4.1.  MФs lacking Mertk are less susceptible to cytoplasmic DNA-induced cell 
death.  A) 3 days after calf thymus (CT) DNA electroporation, brightfield pictures were 
obtained of wild-type and mertk-/- MФs.  B) 4 hrs post electroporation, Cy3-labeled poly 
dA:dT and 30 Sytox Green-labeled cells were imaged and C) quantified.  D) 30 minutes 
post electroporation cells were harvested and whole cell lysates were examined by 
Western blot with the indicated antibodies.  Figures are representative of 3 independent 
experiments.  p<0.0001.   
 
Figure 4.2.  Mertk negatively regulates ifi-202 expression.  Real-time PCR was 
preformed on time course of IFN-treated wild-type and mertk-/- MФs.  Transcripts of 
genes analyzed were ifi-202, ifi-203, ifi204, ifi-205, aim2, and pyhin-1.  Graphs are 
representative of at least 2 independent experiments.   
 
Figure 4.3. Mertk negatively regulates ifi-202 mRNA and p202 protein expression in 
response to a variety of stimulants.  A) Quantitative Real-Time PCR was preformed for 
ifi-202 expression on wild-type and mertk-/- MФs stimulated with 150nM Gas6, 
1000UmL of IFN, 200ng/mL of LPS, and 20µg/mL Poly I:C for 3 hours. B) Whole cell 
lysates from wild-type and mertk-/- MФs stimulated with IFN for 48, 72, and 96 hours 
were subjected to Western blot analysis for indicated proteins.  C) Whole cell lysates 
from wild-type and mertk-/- MФs that were electroporated with 50µg Calf Thymus DNA 
were subjected to Western blot analysis for the indicated proteins.  Figures are 
representative of at least 2 separate experiments.   
 
 126
Figure 4.4. Axl and Tyro3 do not negatively regulate ifi-202 mRNA and p202 protein 
expression.  A) MФs from indicated genotypes were treated with 1000U/mL IFN for 
24hrs.  mRNA was obtained and subjected to quantitative Real-Time PCR for ifi-202 
expression.  B) Macropahges from the indicated TAM genotypes were treated with 
1000U/mL of IFN for 48 hours and whole cell lysates were obtained and subjected to 
Western blot analysisfor the indicated proteins.  Figures are representative of at least 2 
separate experiments.   
 
Figure 4.5.  Mertk regulates ifi-202 mRNA and p202 protein expression in bone marrow-
derived DC.  A) mRNA from wild-type and mertk-/- bone marrow-derived DC were 
treated with 1000U/mL of IFN for indicated time periods and subjected to quantitative 
Real-Time PCR for ifi-202 expression. B) mRNA from wild-type and mertk-/- bone 
marrow-derived DC were treated with 1000U/mL of IFN, 200ng/mL of LPS, or 10ng/mL 
of IL-6 and subjected to quantitative Real-Time PCR for ifi-202 expression. C) Whole 
cell lysates were obtained from wild-type and mertk-/- bone marrow-derived DC left 
untreated or treated with 1000U/mL of IFN for 48 hours.  Lysates were then subjected to 
Western blot analysis for indicated proteins.  Figures are representative of at least 2 
separate experiments.   
 
Figure 4.6. Mertk suppresses IFN-stimulated Stat3 phosphorylation.  A) MФs were 
treated with 1000U/mL of IFN for 15, 30 and 60 minutes.  Whole cell lysates were 
subjected to Western blot analysis for pStat3 and total Stat3.  B)  MФs were treated with 
500, 1000, or 2000U/mL of IFN for 30 minutes.  Whole cell lystates were subjected to 
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Western blot analyses for pStat3 and total Stat3.  C) Whole cell lystates treated as in A 
were subjected to Western blot analysis for pStat1 and total Stat1.  Blots are 
representative of at least 3 separate experiments. 
 
Figure 4.7.  IFN stimulation increases p202 expression and decreases response to 
cytoplasmic DNA in mertk-/- cells.  A) MФs were either treated with IFN for 72 hrs or left 
untreated prior to Calf Thymus (CT) or poly dAdT (AT) electroporation.  Whole cell 
lysates were obtained 30 minutes after electroportation and subject to Western blot 
analysis for the indicated proteins.  Note that different exposure times were required for 
uncleaved casapase 1 (p45) and cleaved caspase 1(p10).  B) Whole cell lysates from A 
were subjected to Western blot analysis for the indicated proteins.  Figures are 
representative of 5 separate experiments.   
 
Figure 4.8. Schematic of AIM2 and p202 function in the context of Mertk. A) In wild-
type cells AIM2 binds cytoplasmic dsDNA, interacts with ASC and forms the 
inflammasome to induce Caspase 1 and 3 mediated cell death.  p202 is at low levels, 
suppressed by an unknown mechanism.    B) In cells from autoimmune mice, p202 and 
AIM2 are present.  p202 competes for binding of cytoplasmic dsDNA with AIM2.  
Binding of p202 to dsDNA prevents inflammasome activation and subsequent cell death.  
C) In mertk-/- cells is absent, levels of p202 are increased via overactivation of Stat3.  
Thus dsDNA induced capsase cleavage and cell death are prevented.  The amount of 
p202 dictates the prevention of cell death.   
 128
Figure 4.1 
 
 
 
 
 129
Figure 4.2 
 
 
 
 
 130
Figure 4.3 
 
 
 
 
 131
Figure 4.4 
 
 
 
 
 132
Figure 4.5 
 
 
 
 
 133
Figure 4.6 
 
 
 
 
 134
Figure 4.7 
 
 
 
 
 135
Figure 4.8 
A 
 
 
B 
 
 
 
C 
 
 
 
 136
  
Chapter 5: 
 
Summary and Future Directions 
 The studies undertaken here have greatly expanded our understanding of the role 
of TAM receptors on innate immune cells.  This dissertation focuses on three major 
areas: innate immunity to bacteria, peritoneal cells in autoimmunity, and innate immune 
responses to viral cell death cues.  These multiple facets are partly tied together by the 
fact that autoimmune disease may be triggered by pathogens, that dysregulation of innate 
immune cells may be contributing to immune deviation in the peritoneal cavity, and that 
proper cell death may be important in restricting APC stimulation of autoreactive 
lymphocytes.  The hypothesis is that Mertk or Axl or Tyro3 may be central regulators in 
these processes and sought to answer these important questions.  Mertk is likely the 
critical negative regulator that restricts the autoimmune phenotype.   Thus, the studies 
here expand the role of TAM receptors in regulating immune populations and have 
provided insights to the autoimmune phenotype primarily controlled by Mertk. 
 
The function of TAM receptors with regards to bacterial infection. 
Previous reports regarding the role of TAM receptors in clearing bacteria are 
controversial (28, 43).  Scott et. al. do not see differences in ingestion of Gram-positive 
Listeria monocytogenes by macrophages from mertk-/- mice; however, Escherichia coli 
particles are phagocytized in greater numbers when TAM receptors are absent (28, 43).  
Chapter 2 conclusively demonstrates that phagocytosis and killing of Gram-negative and 
Gram-positive bacteria was not affected by the TAM family members.  This is observed 
using multiple experimental protocols and definitively shows that the TAM receptors are 
not involved in phagocytosis of bacteria.  
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 Although TAM receptors are not involved in phagocytosis or killing of bacteria, 
we speculate that they may be involved in clearance of systemic bacterial infections.  
Evidence to support this hypothesis includes both MФs and mice lacking Mertk produce 
excess pro-inflammatory cytokines in response to bacterial byproducts (35).  Thus, it 
would be interesting to determine if mertk-/- mice are less susceptible to bacterial 
infections due to the local and systemic increase in pro-inflammatory cytokines.  One 
way a systemic increase in pro-inflammatory cytokines and chemokines would result in 
better clearance of an infection is by recruiting more cells in response to the infection.  In 
addition to more cells in the area, pro-inflammatory cytokines can also induce other 
genes or anti-bacterial effects which may allow for better killing of cells.  For example, 
TNFα can prime neutrophils to produce NADPH-oxidase, a potent anti-bacterial response 
(232).  Perhaps NADPH-oxidase production by neutrophils in the mertk-/- mouse is 
elevated due to increased TNFα.   Since the absence of Mertk does not affect killing or 
division of Gram-negative bacteria, production of pro-inflammatory cytokines is 
independent of the MФ’s ability to kill bacteria.  Therefore, if mertk-/- mice are less 
susceptible to bacterial infection, it is most likely due to cooperation of the entire immune 
system rather than the ability of individual cells to kill bacteria.   
The increase in production of pro-inflammatory cytokines by the mertk-/- MФs 
may indirectly affect the ability of another cell, perhaps the neutrophil, to be better at 
killing bacteria.  This brings up the idea of the age old question of inflammation “friend 
or foe”?  A certain amount of inflammation in response to pathogens is necessary for a 
proper immune response (inflammation as a friend).  However under certain 
circumstances, the inflammatory response is actually more detrimental than the 
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pathogenic insult, which can result in exacerbated pathology or in more severe 
circumstances, endotoxic shock.  Furthermore, chronic stimulation of the immune cells 
may lead to inflammatory diseases or autoimmune disease (inflammation as a foe).  Our 
lab previously shows that mice lacking Mertk are more susceptible to LPS-induced 
endotoxic shock and that this is prevented by anti-TNFα antibody administration (35).  
Under physiologic conditions, the amount of LPS produced by an infectious agent is 
much lower than experimentally administrated levels. Therefore it is conceivable that the 
increased pro-inflammatory response by mertk-/- mice may actually aid in the systemic 
response as opposed causing the animal to go into shock.  Since Mertk is expressed on 
fibroblasts and other non-hematopoietic cells, the possibility of the resident infected cell 
also producing excess pro-inflammatory responses must also be considered in the 
resolution of infections.    
 Our lab also shows that mice lacking Mertk have increased intestinal 
inflammation upon LPS administration (35).  These mice do not have spontaneous 
intestinal inflammation, thus this is an example of how an improper inflammatory 
response could lead to inflammatory bowel disease.  Interestingly one of the top 
treatments for many patients with inflammatory bowel diseases such as Crohn’s disease 
and Ulcerative Colitis is a humanized mouse anti-human TNFα antibody, Infliximab (87).  
This antibody blocks TNFα in the serum and on the cell surface, and can leave patients in 
remission for up to a year.    
Another potential treatment for inflammatory diseases may be through the 
activation of Mertk to prevent pro-inflammatory cytokine production.  Since Mertk is 
known to suppress inflammation, perhaps the activation of this receptor with antibodies 
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or Gas6 would aid in resolution of excess inflammation.  In support of this, 
administration of apoptotic cells has been shown to protect mice from LPS-induced 
endotoxic shock (233).  However, the exact mechanism of this protection is not known.  
Apoptotic cells have been shown to have Gas6 pre-bound to phosphatidylserine on their 
surface (19).  Therefore, it is possible that the protection afforded by apoptotic cells 
maybe through the activation of Mertk.   
 
Insights regarding the role of TAM receptors in the peritoneal immune populations.     
 The role of the peritoneal cavity and innate immune cells in autoimmunity is not 
clear.   The TAM receptors are implicated in autoimmunity due to their role in clearing 
apoptotic cells and the production of autoantibodies (18, 28, 29, 37, 43).  In Chapter 3, 
we explore whether the TAM receptors dictated resident cells in the peritoneal cavity.  In 
summary, Chapter 3 provides data characterizing the MФ, T cell, B cell, and DC 
populations in both wild-type and mertk-/- mice.  While the total number of peritoneal 
cells increases over time in wild-type animals (Figure 3.1), the mertk-/- animals have the 
greatest number of peritoneal cells at 3 months of age.  At 3 months old, mertk-/- mice 
have 4-fold more cells in the peritoneal cavity than wild-type mice, and this is due to 
migration and not local division or cell death (Figure 3.4, 3.5, 3.6).  In addition the 
migration of the T cell populations appears to be due to hematopoietic-derived factors 
(Figure 3.7).  The overall increase in cells could be due to overproduction of CXCL9 by 
mertk-/- peritoneal cells or a greater number of cells expressing IL-7R or the receptor for 
CXCL9, CXCR3 (Figure3.8).  In addition, the increased number of cells in the peritoneal 
cavity was exclusive to mertk-/- mice, as axl-/-, tyro3-/-, or axl-/-/tyro3-/- mice had similar 
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numbers to wild-type mice (Figure 3.9).  This increase also correlates to autoantibody 
production later in life and again was only found in mertk-/- mice and not axl-/- or tyro3-/- 
mice.    
There are B1 B cells in the peritoneal cavity that contribute to natural immunity 
and an earlier study suggests the peritoneal cavity is critical for the induction of 
autoantibody formation (168).  Other studies that observe peritoneal B1 cells usually 
focus on their antibody production roles ex-vivo or in relationship to the marginal zone B 
cell characteristics.  However, studies regarding what cells are important in the induction 
of autoimmunity and how this occurs in the peritoneal cavity are sparse.  Our studies in 
Chapter 3 characterizing immune cells in the peritoneal cavity provide substantial 
insights on the dynamics of the resident peritoneal cell populations in lupus-prone mertk-/- 
mice versus normal wild-type mice.  To my knowledge, there has never been a thorough 
characterization of the cells found in the peritoneal cavity.  In relationship to SLE, 
virtually all of the publications describing cells in the peritoneal cavity focus on 
macrophages and B1 cells.   
The data presented in Chapter 3 poses many other questions to be answered with 
future experiments.  First, hypotonic ablation of B1 cells from the peritoneal cavity of 
NZB and NZB/W F1 lupus-prone mice resulted in less disease (168).  It would be 
extremely interesting to investigate if hypotonic ablation of B1 cells would decrease 
autoantibody production in the mertk-/- mice as well.  Given that both mertk-/- and NZB 
mice also have an increase in peritoneal cells prior to the onset of autoantibody 
production, it would not be surprising if hypotonic ablation of these cells leads to similar 
reduction in autoantibody formation in both strains (234).  Thus, if mertk-/- mice act 
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similarly to NZB, without the B1 cells, we expect a decrease in the amount of 
autoantibody produced and/or number of mice that were making detectible 
autoantibodies.  This also brings up an interesting option for treatment of SLE.  If it were 
possible to selectively delete the B1 population from the peritoneal cavity, it may also be 
possible to decrease human disease. 
It is also important to consider the role of B1 cells as APC.  Peritoneal B1 cells 
express MHC II and are more efficient than peritoneal MФ when acting as APC to T 
cells in response to CpG oligonucleotide stimulation (235).  This study shows that B1 
cells were efficient at processing and presenting antigen to T cells.  These B1 cells also 
produce IL-10 and possess high levels of CD86 and MHC II (235).  The idea of the B1 
cell acting as an APC is often overlooked.  However, given increases in B1 cells in 
murine models of SLE, it is possible that these cells may be acting as more than just low 
affinity autoantibody-producing cells.   This could be addressed using a transgenic cells, 
stimulating B1 cells with antigen (OVA or HEL) and determining activation response of 
T cells.  
With regard to macrophages, the previous studies usually remove the cells as a 
method of easily harvesting resident macrophages for ex-vivo experiments. There have 
been few reports examining the function of peritoneal macrophages in the context of 
inducing autoreactive B cells.  One could deplete macrophages from wild-type mice and 
mertk-/- mice and determine whether there is a shift in the cell populations within the 
peritoneal cavity and if autoreactive B cells are diminished.       
Surprisingly, the literature is particularly deficient in peritoneal T cell data, 
though it has been acknowledged that both B1 cells and T cells contribute to SLE, and 
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the peritoneal cavity is a location that harbors T cells and the majority of the B1 cells in 
the body.  Thus, the abundance of T cells in the peritoneal cavity of the mertk-/- mouse 
provides greater opportunity for T cell help to autoreative B cells.  Chapter 3 shows that 
T cells are being recruited to the peritoneal cavity by a hematopoietic-derived factor 
(Figure 3.7).  Interestingly, bone-marrow transplant has been used as a therapy for 
catastrophic cases of SLE (236), however, as the disease is not normally immediately life 
threatening, both doctors and patients are reluctant to pursue this option.   In addition, the 
majority of cells in the peritoneal cavity expressing CXCR3 and IL-7R were T cells.  In 
order to determine if peritoneal T cells play a role autoantibody production in the mertk-/- 
mice, it would be possible to remove T cells from the peritoneal cavity with repeated I.P. 
injections of anti-CD3 antibody and then measure autoantibody production.   
 Chapter 3 attempts to investigate the mechanism behind the increase in cells 
found in the mertk-/- peritoneal cavity by identifying increased CXCL9, CXCR3 and IL7-
R expression (Figure 3.8).  First, it would be interesting to determine if other SLE mouse 
models had increased expression of these molecules.  As NZB mice appear to follow a 
similar peritoneal infiltration and autoantibody time courses, investigation of these 
molecules would be especially interesting.  In addition, analysis of the mertk-/- peritoneal 
cavity after blockade of these molecules or crossing with knock out mice would 
determine definitively if these molecules are indeed involved in the increased migration 
to the peritoneal cavity. CXCR3-/- and IL-7R-/- mice are viable, however CXCL9-/- mice 
have not been produced.  In addition, antibodies to all of the molecules are available 
commercially,   
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The PCR-based screen of potential receptors expressed by peritoneal cells in 
Chapter 3 highlights IL-7R.  IL-7R knock-out mice have reduced peritoneal B cell 
numbers (219).  As shown in Figure 3.8, we find an increase in the number of IL-7R-
expressing peritoneal T cells as well as B cells; however, the number of peritoneal T cells 
found in the il-7r-/- mouse is not known.  It would be important to determine if the 
peritoneal T cell levels are also low in mice lacking the IL-7R.  A low level of T cells 
would suggest IL-7R maybe important in attracting or retaining T cells in the peritoneal 
cavity and if crossed to mertk-/- mice, autoantibody assessment might link these IL-7R+ T 
cells as important components.  Interestingly, mice lacking the known IL-7R ligand, IL-7, 
do not have decreased peritoneal B cell numbers (220).  Thus, there is most likely 
another, as yet unidentified, ligand for the IL-7R.  It is therefore possible that the 
unidentified ligand may be upregulated in the mertk-/- peritoneal cavity.  Although this 
ligand is currently unknown, it may be possible to identify it through yeast two-hybrid 
studies.  Currently, a role for IL-7R in SLE pathology has not been elucidated; however, 
our data suggests that elevated levels of IL7-R may correlate with disease.   
Mice lacking CXCR3 and CXCL9 have been generated; however, the 
composition of the peritoneal cavity of these mice has not been investigated.  
Interestingly, CXCL9 has been implicated in the progression of immune-mediated kidney 
disease (237).  Both CXCL9 and CXCL10, ligands for CXCR3, have been shown to be 
elevated in plasma from SLE patients and this correlated to disease index (152).  In 
addition, MRL/lpr mice lacking CXCR3 have reduced kidney pathology and decreased T 
cell recruitment to the site of injury (166).  It would be interesting to determine if these 
mice also had fewer cells in the peritoneal cavity and less autoantibody production.  
 145
Since, the CXCL9/CXCR3 chemokine-receptor combination is involved in recruitment of 
T cells and kidney pathology progression in SLE; it is possible that these molecules may 
also be involved in the migration of cells to the peritoneal cavity in SLE.  Either way, 
blockade CXCL9 and/or CXCR3 is an attractive target for SLE therapies, whether to 
prevent onset by preventing migration to the peritoneal cavity, or preventing subsequent 
kidney pathology.  Thus, a number of directions can be pursued based on work in this 
Chapter 3.  The most timely and urgent is to determine the function of these cells and 
whether elimination or inhibition of a particular cell type abrogates autoimmune disease. 
 
Role of Mertk and apoptosis of APCs  
 Lastly, we show that Mertk is central for MФs to ingest apoptotic cells; however, 
the death of these macrophages themselves is not known and studies show macrophages 
are critical in the formation of autoimmunity.  In summary, Chapter 4 presents a set of 
experiments showing MФ lacking Mertk are more susceptible to intracellular dsDNA-
induced cell death.  The mechanism behind this cell death appears to be due to an 
increase in p202 production (Figure 4.2, 4.3).  p202 can bind dsDNA and prevent 
activation of the inflammasome and thus prevents subsequent caspase cleavage and cell 
death (189).   MФ lacking Mertk upregulate p202 in response to a variety of stimulants 
(Figure 4.3).  DC lacking Mertk also produce greater amounts of p202 compared to wild-
type, and this suggests other cell types which express Mertk may also be affected 
similarly.  In addition, IFN stimulation to increase p202 levels decreases the amount of 
caspase cleavage found in MФ lacking Mertk (Figure 4.6). 
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 Chapter 4 exclusively uses electroporation as a method of transfecting the dsDNA 
into the cytoplasm.  It would be interesting to determine if a dsDNA virus would act 
similarly to the dsDNA electroporation.  Hornung et. al. showed using cells lacking 
AIM2 that were exposed vaccinia virus were less susceptible to cell death (185).  Given 
the AIM2/p202 relationship proposed by Roberts et. al., it makes sense that when AIM2, 
which normally activates the inflammasome, is removed, p202 will be the major binder 
of dsDNA and prevent inflammasome activation (189).  Thus, we would expect a similar 
outcome with the mertk-/- MФ, an infection with vaccinia virus would indeed be 
comparable to the electroporated dsDNA.  In fact, given that viruses induce type I IFN 
responses by MФ with more than just their nucleic acid, and IFN increases the amount of 
p202, it is possible that mertk-/- MФ treated with vaccinia virus are even less susceptible 
to cell death than dsDNA alone.   
Along these lines, it would be important to investigate the infection of mertk-/- 
mice with a dsDNA virus to examine systemic affects.  In this case, there are multiple 
possible outcomes.  Since the levels of p202 are dramatically higher in mertk-/- MФ, we 
would expect that mertk-/- mice would have a greater number of viable APCs during 
dsDNA virus infection.  The increased APC life span presents two scenarios.  First, 
increased APC viability could result in greater production of viral particles compared to 
wild-type macrophages.  In this case, the inability of the mertk-/- cell to induce apoptosis 
would be detrimental to the animal.  Second, an increase in APC life span would also 
result in greater antigen presentation to lymphocytes leading to greater activation of the 
adaptive immune response.   
Which scenario is more important would depend on the particular virus.   
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If a virus replicates preferentially in APCs, increased mertk-/- APCs would serve as viral 
production factories, increasing viral load and facilitating viral spread.  Thus, the virus 
would be more likely to kill the host, a clear disadvantage in host survival.  However, if 
the APC is not the preferred cell for viral replication, then the increase in live APC and 
activation of adaptive immune response would be an advantage for the host.   
 Another caveat to consider when predicting the outcome of a viral infection in the 
mertk-/- mice, is whether APCs and non-APCs have similar death responses to dsDNA.  
This would be particularly important if the virus preferred replication in a non-APC.  As 
the expression of p202 in mertk-/- non-APCs is not known, it is difficult to predict the 
outcome of an infection of non-APCs.  Thus, it would be important to investigate the 
expression of p202 on non-APCs, especially those cells which normally express Mertk, 
including those of the epithelial and reproductive tissues.     
The relationship of the HIN-200 family members to SLE is another exciting 
avenue of investigation.  The data in Chapter 4 reinforces the correlation between the 
expression of p202 and SLE mouse models.  It is also relevant that SLE patients have 
increased EBV titers (87, 88) and increased levels of the antiviral cytokine IFNα (142-
144), which is a known inducer of the HIN-200 family of proteins.  The serum levels of 
Type I IFNs in the mertk-/- mice have not been investigated.  However, we have 
preliminary data showing MФ from mertk-/- mice do not have elevated IFN under 
stimulated or unstimulated conditions.   Currently there is no human homologue 
identified for p202, thus in humans the AIM2/p202 ratio may not be a relevant 
explanation of intracellular dsDNA-induced cell death.  It would be quite interesting to 
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know if the levels of the HIN-200 family members are indeed altered in SLE patients and 
if this correlates to intracellular dsDNA-induced cell death.     
Further investigation into the signaling pathway activating and suppressing p202 
is also required.  Chapter 4 shows that in wild-type MФ, Mertk normally suppresses the 
expression of p202 (Figure 4.2, 4.3), thus allowing for intracellular dsDNA-induced cell 
death to proceed.  However, the exact mechanism of this suppression is not yet fully 
understood.  There is a known Stat3-binding element in the p202 promoter (191).  Data 
from our lab suggests that in MФ, Mertk may be normally suppressing Stat3 
phosphorylation and activation in response to IFN stimulation.  In contrast, the Tisch lab 
has shown that Mertk activates Stat3 in response to AC or Gas6 stimulation (86).  It has 
previously been shown that Mertk is used differently by different cell types (18), and thus 
it is possible that the use of Mertk to activate or suppress Stat3 may also be different in 
different cell types.      
The discovery of the AIM2/p202 dsDNA-binding paradigm is a relatively new 
addition to the literature.  Our current understanding is based on four recently published 
papers, three of which focus on AIM2 with no mention of p202, and one which focuses 
on p202 and peripherally investigates AIM2.  Some unanswered questions arise based on 
this literature and the work presented in Chapter 4.  First, the cleavage and activation of 
caspase 3 has not been attributed to the inflammasome.  Caspase 3 is known to be 
activated by caspase9 via a complex termed the apoptosome.  The apoptosome is 
comprised cytochrome c, APAF1 and caspase 9, which in turn cleaves caspase 3 (238).  
APAF contains a CARD domain, however there are no known PYRIN domains in the 
apoptosome complex.  None the less, perhaps AIM2 may also be binding and activating 
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the apoptosome through an adaptor molecule.  Another possibility is that activation of 
caspase 1 may be required for the activation of caspase 3.  It is known that the 
inflammasome comprised of ASC and one of a number PYRIN domain containing 
proteins activates caspase 1 through a cleavage event.  However, the method of dsDNA-
induced caspase 3 cleavage remains to be elucidated.  
The literature describes inflammasome and caspase 1-dependent cell death as 
pyroptosis.  Pyroptosis is unique from apoptosis and is thought of as an inflammatory 
host response, which is independent of caspase 3, 6, and 8 (239).  Loss of mitochondrial 
integrity and cytochrome c release which are characteristics of apoptosis also do not 
occur in pyroptosis (240, 241).  Pyroptosis is also characterized by loss of osmotic 
integrity resulting in cellular swelling and eventual plasma membrane rupture and 
spillage of inflammatory contents (239).  A similar swelling of the plasma membrane is 
observed shortly after dsDNA electroporation (unpublished observations).  The 
intracellular dsDNA-induced cell death appears has characteristics of both apoptosis 
(caspase 3 cleavage) and pyroptosis (caspase 1 cleavage).  Clearly more investigation 
into the differences and similarities of these two processes is warranted.   
 
Final thoughts 
 In conclusion, this work advances the understanding of the function of Mertk on 
innate immune cells and whether these processes can be tied to the autoimmune 
phenotype displayed by mice lacking Mertk.  We find here that Mertk is not essential for 
the phagocytosis of bacteria, but it appears to be central in regulation of peritoneal cell 
migration and autoantibody production, and Mertk is a critical regulator of intracellular 
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dsDNA-induced cell death.  The later two observations are novel and add to the growing 
list of processes associated with the multi-functional Mertk receptor.  While these topics 
are quite diverse, they each have valuable contributions to the role of Mertk.  This work 
provides evidence that a correlation between expression and function of Mertk in other 
lupus models and SLE patients is warranted and may allow for the identification of novel 
drug targets.   
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